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Abstract 
Neisseria meningitidis is a major cause of meningitis and septicaemia in 
infants and children. Disease caused by serogroup A, C, W-135 and Y strains is 
prevented by vaccination using capsular polysaccharide preparations. For serogroup B 
strains for which the capsular polysaccharide is poorly immunogenic, antigenic 
proteins on the bacterial surface are under investigation as promising vaccine 
candidates. Due to the variability in sequence of antigenic proteins, vaccine 
formulations containing combinations of proteins and protein variants are tested for 
broad protection against serogroup B isolates. 
In search for new members for inclusion in multi-protein vaccines, the surface 
proteome of N. meningitidis from MC58 strain was investigated using treatment of 
whole meningococci with proteases followed by quantitative differential in-gel 
electrophoresis (DIGE) of the meningococcal proteome. The majority of proteins 
identified included known surface antigens and other uncharacterised predicted 
surface proteins. Quantitative analysis also allowed the assessment of the extent of 
protease cleavage on the protein population and suggested proteins were either 
completely or partially digested. Additionally, differences in the protein content of 
outer membrane vesicles (OMVs) from H44/76 meningococci grown in rich or 
minimal culture media were assessed by DIGE. Differentially expressed proteins were 
related to differences in bactericidal activity detected between immune sera from mice 
immunised with the different OMV preparations. Of the proteins detected on the 
surface and OMVs, those able to induce an immune response in mice were identified 
by immunoproteome analysis.  
Four of the previously uncharacterised proteins identified by the proteomic 
analyses were assessed in immunological assays for their potential as vaccine 
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candidates. Recombinant forms of macrophage infectivity potentiator (NmMIP), type 
IV pili biogenesis proteins PilP and PilO and putative adhesin complex protein 
NMB2095 were produced in Escherichia coli, purified and used to immunise mice. 
Immune sera against NmMIP bound strongly to the surface of MC58 whilst exhibiting 
opsonophagocytic activity and facilitating deposition of complement factors on the 
surface of various meningococcal strains. The nucleotide sequence encoding NmMIP 
was assessed across a panel of 106 meningococcal isolates and found to be highly 
conserved and under negative selective pressure. 
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1. General Introduction 
1.1 Overview 
Bacterial meningitis has been recognised as a devastating disease for more 
than 200 years since its first description in 1804 (Stephens et al., 2007). 
Meningococcal disease is an important cause of morbidity and mortality with 
approximately 500,000 reported cases and 50,000 deaths annually worldwide and 
presents a major threat to the health system of both industrialised and developing 
countries (Maiden and Caugant, 2006). The bacterium N. meningitidis, also known as 
the meningococcus, colonises the human nasopharynx and is responsible for most of 
the cases of meningitis and septicemia. Systemic infection occurs when the bacterium 
crosses the epithelial barrier and enters the bloodstream. It can then multiply rapidly 
and spread to sites in the brain to cause meningitis whereas uncontrollable replication 
leads to the more serious septicaemia (Brandtzaeg, 2006; Steven and Wood, 1995; 
van Deuren et al., 2000). 
Though antibiotic treatment is effective and can reduce mortality (van Deuren 
et al., 2000), rapid development of the disease can lead to permanent neurological 
damage (Steven et al., 1995) and prevention through prophylactic vaccination is the 
only efficient way to fight the disease (Feavers, 2001). The meningococcus is divided 
into serogroups based on chemical and antigenic differences on the polysaccharide 
capsule surrounding the bacterium (Vedros, 1987). Serogroups A, B, C, W-135 and Y 
account for almost all disease cases and polysaccharide-based conjugate vaccines 
have been developed to provide protection against one or a combination of all but 
disease serogroup B (Harrison, 2006). In the case of infection based on serogroup B 
strains vaccine development has instead focused on outer membrane proteins (OMPs) 
which are directly involved in interaction with host cells and are able to induce an 
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immune response. Outer membrane vesicle vaccines including the repertoire of OMPs 
have been successfully developed and used to protect against outbreaks around the 
world (Nokleby et al., 2007; Poolman et al., 2002; Thornton et al., 2006). However, 
their specificity for the strain they are derived from has redirected studies towards the 
targeted identification of bacterial proteins that could elicit a cross-protective 
response. 
Studies on vaccine discovery and understanding of the biology behind the 
processes involved in pathogenicity and carriage have been greatly influenced by new 
technologies and availability of genome sequences. Since the publication of the 
genome sequence of two Neisseria strains in 2000 (Parkhill et al., 2000; Tettelin et 
al., 2000), functional genomics has been successfully used to provide a genome-wide 
picture of virulence factors involved in disease (Grifantini et al., 2003; Sun et al., 
2000) and protein antigens (Grifantini et al., 2002b; Pizza et al., 2000) which formed 
the basis for the first vaccine formulations against serogroup B-based meningococcal 
disease (menB) currently tested in clinical trials. Proteomics has also been used for 
the characterisation of the content of OMV vaccines (Wheeler et al., 2007) and 
demonstrated the need for protein-level analysis and the potential of this technology 
in the identification of vaccine candidates. 
 
1.2 Neisseria meningitidis 
1.2.1 Microbiology 
 Neisseria meningitidis is an aerobic Gram-negative diplococcus which strictly 
colonises the human nasopharynx in an asymptomatic manner. It has the typical 
structure of Gram-negative bacteria with the outer and inner membranes flanking the 
periplasmic space and the thin peptidoglycan layer. The outer membrane can be 
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surrounded by a polysaccharide capsule, a typical feature of pathogenic isolates that 
can cross the nasopharynx and enter the circulation. Unencapsulated strains are 
frequently isolated from the nasopharynx of asymptomatic carriers and rarely, if ever, 
cause disease (Claus et al., 2002; Harrison, 2006; Hoang et al., 2005). The cell wall 
also contains lipopolysaccharide (LPS), an abundant antigenic glycolipid, and a 
number of variable surface exposed proteins which either traverse the outer 
membrane or attach to it via lipid moieties (Figure 1.1). Many members of the 
meningococcal cell wall are involved in interactions with the host and determine 
processes required for establishment of colonisation and survival in the host including 
adhesion to host epithelial cells and uptake of essential nutrients.  
 
 
Figure 1.1 Schematic representation of meningococcal surface structures 
(adapted from Sadarangani and Pollard, 2010). 
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1.2.2 Carriage and disease 
Meningococci are spread through droplets and are carried in the human 
nasopharynx with no symptoms (Stephens et al., 2007) (Figure 1.2). Their attachment 
to nasopharyngeal epithelial cells is mediated by specific surface structures and their 
survival facilitated by acquisition of nutrients essential for bacterial growth. Carriage 
is a prerequisite of disease occurrence and is also considered to be required for 
transmission (Broome, 1986). How meningococci cross the epithelium and gain 
access to the circulation is still unclear. However, infection is expected to be an 
accidental event since host killing would prevent meningococcal spread. The 
magnitude and rate of bacterial growth in the bloodstream determines the severity of 
disease symptoms and fatality rate. The number of circulating meningococci rises 
gradually in patients with distinct meningitis and mild systemic infection whilst rapid 
multiplication occurs in the patients developing septic shock (Brandtzaeg, 2006) 
(Figure 1.2). Infants and children are at the greatest risk of developing meningococcal 
disease mainly due to immunological immaturity (Cartwright, 1995). The incidence 
rate is lower in adolescents and adults but can be increased by factors such as 
overcrowding (Baker et al., 2000) and poverty which favour carriage and 
transmission. Individuals suffering from complement deficiencies (Fijen et al., 1999; 
Figueroa et al., 1991), respiratory infections or hyposplenism are also more 
vulnerable to disease progression. 
 
1.2.3 Classification and epidemiology 
Knowledge of the nature and distribution of meningococcal isolates is 
essential for disease management and development of preventive treatments. Various  
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Figure 1.2 Life cycle of N. meningitidis. Images adapted from 
http://www.meningitis.org, http://www.mayoclinic.com and freely available internet 
content. The microscopic image of the N. meningitidis diplococcus was produced in 
this study. 
 
classification systems have been developed and used in surveillance studies. The first 
such method is the serological classification of meningococcal isolates and is based 
on phenotypic characteristics of variable surface structures probed with specific 
antibodies (Kuipers et al., 2001). The biochemical composition of the polysaccharide 
capsule defines an isolate’s serogroup. Neisseria meningitidis strains are classified 
into 12 distinct serogroups, of which serogroups A, B, C, W-135, Y and occasionally 
X are responsible for almost all cases of invasive disease (Harrison, 2006; Vedros, 
1987). Antigenic variation of the outer membrane porins PorB and PorA is used to 
assign the serotype and the serosubtype, respectively. The serosubtype is given by two 
numbers which correspond to two surface exposed loops of PorA (Frasch, 1987; 
Wedege et al., 1990). Meningococci are further classified into 12 immunotypes based 
on the LPS variability (Scholten et al., 1994). 
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Among other classification tools widely used to distinguish between closely 
related strains are multilocus enzyme electrophoresis (MLEE), multilocus sequence 
typing (MLST) and polymerase chain reaction (PCR)-based antigen sequencing. 
Multilocus enzyme electrophoresis uses starch gel electrophoresis of bacterial cell 
lysates to identify variations in the electrophoretic mobility of up to 25 metabolic 
enzymes which account for allelic variations of the corresponding housekeeping loci. 
Each electrophoretic profile is referred to as an electrophoretic type (ET) (Selander et 
al., 1986). Meningococcal strains with similar ETs are assigned to genetically related 
groups or “clonal complexes” of strains. The most invasive meningococcal isolates 
belong to ET-37, ET-5, cluster A4 and lineage III complexes (Caugant et al., 1987). 
Multilocus sequence typing is the DNA-based version of MLEE. It is based on 
nucleotide sequencing of 6 housekeeping genes following amplification of the genes 
by PCR (Maiden et al., 1998; Spratt, 1999). Each new sequence is assigned an allele 
and the combination of alleles from the 7 genes is assigned a sequence type (ST). 
Genetically closely related STs constitute central genotypes and can be categorized 
into clonal complexes with each complex including STs that match the central 
genotype at 4 or more loci. The ease of use, sensitivity and applicability of the method 
on every specimen render MLST advantageous over MLEE. Additionally, PorA and 
PorB PCR-based sequencing approaches have been implemented to provide finer 
resolution of the STs identified by MLST (Feavers et al., 1992; Suker et al., 1991). 
Sequencing is targeted to variable regions 1 and 2 and semi-variable region 3 of PorA 
which correspond to surface-exposed loops (Clarke et al., 2003; Russell et al., 2004). 
The number of variable loops in PorB is higher as almost all 8 surface-exposed loops 
show variability (Feavers et al., 1992). These PCR-based typing methods find 
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particular use on unencapsulated strains where serogroup cannot be determined or on 
culture-negative cases (Newcombe et al., 1997). 
Meningococcal disease is both endemic and epidemic. Attack rates range from 
1 to 5 cases per 100,000 population during endemics and can exceed 500 cases per 
100,000 during epidemic outbreaks. Serogroup A strains are the main cause of the 
cyclic epidemics occurring in sub-Saharan African countries in a zone called “the 
Meningitis belt”. In industrialised countries in Europe and the Americas serogroup B 
and C strains are the most prevalent. The incidence of serogroup Y disease accounts 
for 30% of cases in the USA (Maiden et al., 2006). The introduction of 
glycoconjugate vaccines against A, C, W-135 and Y has led to a rapid decrease in 
cases caused by these serogroups (Balmer et al., 2002; Fairley et al., 1996; Pace and 
Pollard, 2007) and has highlighted the extent and persistence of serogroup B disease. 
Recent serogroup B outbreaks in the Americas (Cuba, Brazil, Chile), Europe 
(Norway, Spain, Belgium) and New Zealand (Bjune et al., 1991; Martin et al., 1998; 
Sierra et al., 1991) have also served to heighten awareness of serogroup B disease. 
A small number of STs are persistent in the population whereas most STs are 
only observed once (Maiden et al., 2006). This structuring of meningococcal 
populations is mainly the result of immunoselective evolutionary pressures imposed 
by the host and explains the high prevalence of certain invasive complexes, also 
called hyperinvasive lineages (Jolley et al., 2005; Yazdankhah et al., 2004). Sequence 
types 1, 4 and 5 have been associated with serogroup A pandemics whereas ST-11 
(ET-37) complex was observed in B, C, W-135 and Y epidemics. Two other 
complexes, ST-32 (ET5) and ST-41/44 (lineage 3), are mainly associated with the 
recent serogroup B epidemics and triggered the development of OMV vaccines for 
population protection (Fredriksen et al., 1991; Oster et al., 2005; Sierra et al., 1991). 
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1.3 Surface structures and their significance in carriage and disease 
1.3.1 Capsule 
 Meningococci are surrounded by the capsule, a polysaccharide layer 
covalently attached to phospholipids in the cell envelope. It is found in almost all 
invasive strains and is considered a major virulent factor though it is highly unlikely 
that it is an evolution-acquired virulence determinant in an accidental pathogen like N. 
meningitidis. It has anti-bactericidal, anti-phagocytic and anti-opsonic properties 
which help meningococcus survive the host defense mechanisms and establish 
systemic disease. It also possesses anti-adherent properties allowing meningococcal 
transmission and spread (Stephens et al., 1993). The capsule is the basis for 
serogrouping of meningococci due to variations in the polysaccharide structure. The 
polysaccharide of most of the invasive serogroups (B, C, W-135 and Y) usually 
consists of a 5-N-acetyl-neuraminic acid (sialic acid) homopolymer (Bhattacharjee et 
al., 1975). Differentiation arises from the different linkage between sialic acid 
monomers, for example serogroups C and B exhibit α(2-9)and α(2-8) linked sialic 
acid, respectively. 
 
1.3.2 Lipopolysaccharide (LPS) 
The LPS is a glycolipid with a mass of 4.6 kDa and consists of two distinct 
regions, lipid A and the core oligosaccharide. Lipid A comprises a β-D-glucosaminyl-
(1’→6)-D-glucosamine disaccharide backbone and is attached to the outer membrane 
through fatty acids. The core oligosaccharide consists of an inner and an outer core 
region. Structural differences on the outer core region and the oligosaccharide chains 
define the 12 distinct immunotypes of LPS (Scholten et al., 1994). Among the genes 
involved in LPS biosynthesis, the lgt gene family encodes for glycosyl transferases 
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which are responsible for additions to the outer core region of the LPS and are 
subjected to phase variation. The LPS is known to have a significant role to the 
adherence functions mediated by pili and also contributes to serum resistance (Smith 
et al., 1995; Virji et al., 1996). The LPS is immunogenic and immunotypes L3, L7 
and L9 have been linked to pathogenicity. 
 
1.3.3 Outer membrane proteins (OMPs) 
Outer membrane proteins are of the main components to come in direct 
contact with epithelial cells and possess a variety of functions to facilitate adhesion, 
colonization and interaction with the human immune system to escape complement 
mediated killing and phagocytosis (Bourdoulous and Nassif, 2006; Schneider et al., 
2007). As part of the mechanisms for meningococcal adaptation and immune evasion 
OMPs also exhibit characteristic variation, mainly phase and antigenic. Outer 
membrane proteins have long been considered promising targets for vaccine 
development and an increasing number of studies are targeted to the identification and 
characterisation of proteins on the meningococcal surface (Pizza et al., 2000). Among 
well studied OMPs are the abundant porins PorA and PorB, RmpA, Opa/Opc 
adhesins, proteins of the type IV pili machinery and iron-regulated proteins (Derrick 
et al., 2006).  
1.3.3.1 Porins 
 Porins are common channels in the outer membrane of Gram-negative bacteria 
for passive transport of hydrophilic nutrients. Neisseria meningitidis possesses two 
porins, named PorA and PorB which together constitute approximately 60% of the 
outer membrane protein content. Meningococcal porins share structural similarity 
with Escherichia coli porins and consist of a high proportion of beta sheets which fold 
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into beta barrel structures and associate to form the native trimer (Blake and 
Gotschlich, 1987). 
PorA, also known as class 1 protein, has a varying molecular weight of 44-47 
kDa depending on the isolate and is predicted to expose 7 loops on the meningococcal 
surface. Sequencing of the porA gene from different isolates has revealed 2 
hypervariable regions VR1 and VR2, located on the tip of loops 1 and 4 and one less 
variable region in loop 5 (VR3) (McGuinness et al., 1990; van der Ley et al., 1991). 
Interestingly, these regions have also been shown to be the antigenic epitopes targeted 
by strain-specific antibodies (McGuinness et al., 1993).  
Two distinct PorB proteins are encoded by two alleles of the porB locus, 
PorB2 (40-42 kDa, also named class 2) and PorB3 (37-39 kDa, class 3) and are 
mutually exclusive between different isolates (Minetti et al., 1998; Tsai et al., 1981). 
They also consist of 8 surface-exposed loops with variable regions observed in loops 
1, 5, 6 and 7. Unlike PorA epitopes, PorB exhibits discontinuous epitopes formed 
when the molecule takes its native conformation and regions from different loops 
come in close proximity (Bash et al., 1995). Structural characterization of PorB 
revealed pathways for transportation of ions and uptake of sugars (Tanabe et al., 
2010). PorB was shown to have a role in protection of host cells from apoptosis by 
translocation into the mitochondria where it binds to voltage-dependent anionic 
channels and blocks activation of caspases (Massari et al., 2000; Massari et al., 2003). 
PorB has also demonstrated adjuvant activity by direct binding to TLR2 receptor and 
activation of B cells (Massari et al., 2006). Both PorA and PorB have been linked to 
other activities affecting immune cells including inhibition of neutrophil actin 
polymerisation, opsonin receptor expression and phagocytosis (Bjerknes et al., 1995). 
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1.3.3.2 Adhesins 
The first step for colonisation of the human epithelium and subsequent 
invasion involves adhesion of meningococci on the epithelial layer. As such, adhesion 
mechanisms have attracted considerable attention from many research groups. A 
number of surface-located meningococcal proteins are involved in the primary 
interactions with epithelial cells and the initiation of adhesion (Bourdoulous et al., 
2006). The most representative and well studied adhesins are OpcA, proteins of the 
Opa family and type IV pili. 
 At least three Opa proteins (also termed class 5 proteins) are encoded by a 
family of genes in N. meningitidis and exhibit high variability in their surface exposed 
domains (Aho et al., 1991; Malorny et al., 1998). Unlikely, OpcA is the product of a 
single gene sharing little homology with Opa genes and exhibits less variation (Seiler 
et al., 1996). However, it has common physicochemical properties with Opa proteins 
and was also considered to be a class 5 protein. OpcA expression varies significantly 
and can even be absent in some meningococcal strains (Achtman et al., 1988; 
Olyhoek et al., 1991; Seiler et al., 1996). Opa proteins are known to mediate adhesion 
via interaction with a family of receptors, known as carcinoembryonic antigen-related 
cell adhesion molecules, expressed on epithelial and endothelial cells (de Jonge et al., 
2003). Heparin and heparin sulfate proteoglycans have been shown to serve as 
additional ligands for both Opa and Opc protein families during adhesion (Hauck and 
Meyer, 2003; Merz and So, 2000). 
Neisseria species produce type IV pili (tfp) essential for bacterial movement 
as well as interaction and colonization of the host cells. Type IV pili are filament-type 
structures made of pilin PilE, a small protein of about 150 aa length assembled in a 
helical way to form pili (Strom and Lory, 1993; Pelicic, 2008). Other minor pilins 
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have been identified to be part of pili structures and their sequence is well conserved 
across meningococcal isolates (Brown et al., 2010; Cehovin et al., 2010). Several 
proteins are required in the various steps of tfp biogenesis and function including the 
secretin PilQ, responsible for pili emergence on the surface (Wolfgang et al., 2000) as 
well as PilP and PilW which help in PilQ oligomerisation and pilus stabilisation, 
respectively (Carbonnelle et al., 2005; Drake et al., 1997). Type IV pili coordinate 
bacterial movement, known as twitching motility, utilizing the function of PilT, a 
AAA ATPase. Most importantly for meningococcal disease, tfp are essential for 
initiation of bacterial attachment to epithelial cells and phase and antigenic variation 
of pilin are mechanisms used to modulate adherence (Marceau et al., 1995; Nassif et 
al., 1993). The receptor CD46 is considered to be the interacting partner for tfp in the 
human host cell (Källström et al., 1997; Rytkönen et al., 2001). 
1.3.3.3 Iron-regulated proteins and iron metabolism 
Iron is a cofactor involved in many metabolic processes and an essential 
nutrient for meningococcal pathogenesis. In the human nasopharynx, iron can be a 
limiting factor for the pathogen’s survival as it is found complexed to high affinity 
iron-binding proteins such as transferrin, lactoferrin and hemoglobin. Under iron-
restricted conditions, meningococci produce a repertoire of outer membrane receptors 
to directly acquire iron from these proteins (Schryvers and Stojiljkovic, 1999). The 
transferrin receptor is a complex of two proteins, trasferrin binding protein A (TbpA), 
a 80kDa, surface-exposed variable protein and TbpB, a 98kDa, highly conserved 
inner membrane protein (Irwin et al., 1993; Legrain et al., 1993). Similarly, the 
lactoferrin receptor also consists of two proteins, lactoferrin binding protein A (LbpA) 
which forms the channel for transport and LbpB (Pettersson et al., 1993; Pettersson et 
al., 1998). Finally, heme is another source of iron on the mucosal surfaces in the 
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human nasopharynx and meningococci recruit the hemoglobin receptor HmbR and the 
hemoglobin-haptoglobin utilization receptor Hpu (Lewis et al., 1997; Stojiljkovic et 
al., 1995). 
Transferrin and lactoferrin binding proteins and hemoglobin receptors are 
transcriptionally regulated by iron through the ferric uptake regulator protein Fur 
which dimerises with ferrous iron and inhibits transcription of the respective genes 
(Escolar et al., 1999). The energy required for iron transport through the cell 
membrane and to the cytoplasm is provided by the inner membrane protein TonB. 
Further to TbpA, LbpA, HpuB and HmpR, a number of other TonB-dependent 
receptors have also been suggested based on sequence homology and are assumed to 
be involved in recognition of siderophores present on the mucosal surfaces. One such 
example is the ferric enterobactin receptor, FetA which is predicted to expose several 
loops on the bacterial surface, one of which exhibits high sequence variability 
(Pettersson et al., 1995; Thompson et al., 2003). 
1.3.3.4 Other OMPs 
Other OMPs with important roles in virulence and bacterial survival include 
the reduction-modifiable protein (RmpM), Omp85, factor H binding protein (fHbp) 
and neisserial surface protein A (NspA). RmpM (also known as class 4 protein) 
participates in PorA-PorB complexes and associates with iron-regulated LbpA, TbpA 
and FetA (Prinz and Tommassen, 2000). RmpM is suggested to stabilise the 
oligomeric complexes of the outer membrane which it forms part. Omp85 is another 
protein involved in protein architecture in the outer membrane. Omp85 is a 85kDa 
protein which belongs to a family of highly conserved OMPs across bacteria. Its role 
in the assembly of barrel proteins makes Omp85 an essential protein for bacterial 
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viability (Voulhoux et al., 2003). In N. meningitidis, Omp85 was also shown to be 
involved in lipid export to the outer membrane (Genevrois et al., 2003). 
Factor H-binding protein was first identified through genome mining as 
protein GNA1870 (Pizza et al., 2000). It is a lipidated, surface-exposed protein which 
recruits factor H (fH), a negative regulator of the alternative complement pathway, to 
the meningococcal surface as a mechanism to evade complement-mediated killing 
(Madico et al., 2006; Schneider et al., 2006). Structural analysis of fHbp in complex 
with fH suggested that fHbp imitates interaction of carbohydrates with fH on human 
endothelial cells for recruitment of fH on the bacterial surface (Schneider et al., 
2009). Recently, NspA was reported as another ligand for fH (Lewis et al., 2010). 
NspA is also surface exposed although its accessibility varies depending on the 
amount of polysaccharide produced by individual isolates (Moe et al., 1999a).  
 
1.4 Vaccine development 
Surface structures are of great value in vaccine development as the antigenic 
source in vaccine preparations. Being exposed to the environment of the host, 
meningococcal surface components are in direct contact with the host’s immune 
system and are most likely to evoke an immune response. Serum bactericidal activity 
(SBA), the accepted surrogate of protection, is used to assess whether antibodies 
elicited by potential vaccine candidates can confer protection against meningococcal 
disease by complement-mediated bacterial killing. Licensed vaccines exist against 
invasive serogroups A, C, W-135 and Y and are based on capsular polysaccharide 
preparations. Outer membrane vesicle-based vaccines protecting against specific 
serogroup B outbreak strains have also been used over the years, whilst protein-based 
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preparations aiming to protect against the majority of invasive serogroup B strains are 
under development. 
 
1.4.1. Capsular polysaccharide-based vaccines 
The first vaccines against meningococcal disease used capsular polysaccharide 
as the antigenic source and were developed 30 years ago to tackle epidemics against 
serogroup A and C strains among US military recruits (Gotschlich et al., 1969). These 
vaccines demonstrated the capsule’s ability to elicit bactericidal antibodies and helped 
identify SBA as a correlate for protection against meningococci (Goldschneider et al., 
1969). The reciprocal of the antibody dilution conferring killing of more than half of 
the meningococcal population used in the assay was defined as the protective titre. 
For polysaccharide vaccines, an SBA titre of ≥ 4 in the presence of human 
complement was found to correlate with protection.  
First generation polysaccharide vaccines included bivalent (A, C), trivalent (A, 
C, W-135) and quadrivalent (A, C, W-135 and Y) formulations of purified, high 
molecular weight polysaccharides. Efficacy studies on the early monovalent 
preparations as well as the later multivalent polysaccharide vaccines showed an age-
dependent response with infants being poorly protected (Gold et al., 1979; Harrison, 
2006; Law et al., 1998). They also failed to induce immunological memory in people 
of any age. 
Next generation conjugate meningococcal vaccines were developed through 
conjugation of polysaccharide to an immunogenic carrier protein aimed at inducing 
immunologic memory. The conjugation concept was first demonstrated in a vaccine 
against Haemophilus influenza type b as a strategy for inducing T-cell dependent 
responses. Vaccine preparation involves the use of purified or chemically synthesized 
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saccharide which is activated in a random or targeted way and conjugated to a carrier 
protein such as diphtheria toxoid, tetanus toxoid and CRM197 (variant of diphtheria 
toxoid) (Ravenscroft and Feavers, 2006). The first monovalent group C conjugate 
vaccine was licensed in the UK in 1999. It was shown to be safe and immunogenic in 
all age groups and demonstrated immunological memory and higher bactericidal 
activity compared to the unconjugated equivalents (MacDonald et al., 1998; 
Richmond et al., 1999a; Richmond et al., 1999b). Tetravalent (A, C, W-135 and Y) 
conjugate preparations are also available in the US and Europe for administration to 
adolescents and adults (Campbell et al., 2002; Cooper et al., 2011). 
Although the introduction of conjugate vaccines has been successful, it has 
highlighted the lack of protection against serogroup B strains which are currently 
dominant in developed countries. The poor immunogenicity of the serogroup B 
capsule (Devi et al., 1997; Zollinger et al., 1997) together with the risk of producing 
autoimmune responses due to its structural identity with the polysialylated form of the 
human neural cell adhesion molecule (Finne et al., 1983) has rendered the 
development of a conjugate group B vaccine difficult. Attempts to chemically modify 
the polysaccharide by replacing natural N-acetyl groups with N-propionyl groups 
followed by conjugation to tetanus toxoid resulted in a safe but poorly immunogenic 
preparation when administered to humans (Bruge et al., 2004; Jennings et al., 1987; 
Jennings et al., 1986). A more recent approach involved the identification of peptide 
mimetics, peptides of polysaccharide epitopes that do not cross-react with human 
tissue (Granoff et al., 1998; Lo Passo et al., 2007; Moe et al., 2005). One such 
peptide, designated 9M, was shown to elicit strong bactericidal antibodies and is 
considered a promising vaccine candidate (Lo Passo et al., 2007). 
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1.4.2 Subcapsular protein-based vaccines 
Proteins of the outer membrane have been recognised as alternative sources of 
antigens for use in vaccines. For the past two decades, the design of protein-based 
meningococcal vaccines has focussed on the prevention of serogroup B disease and 
several potential antigens have been identified on the surface of the meningococcus 
(reviewed in Feavers and Pizza, 2009). A common feature of surface antigens is the 
sequence diversity of their epitopes which are targets of protective antibodies. This 
diversity, which is the result of the immunoselective pressure imposed to 
meningococci by the host, has important implications to vaccine design. For vaccines 
containing variable antigens, protection will depend on the sequence variant used and 
be limited to only those strains expressing the same variant. To account for this, 
several combinations of different protein antigens or protein variants have been 
developed over the past years and assessed for their potential to offer cross protection 
against hyperinvasive serogroup B strains. 
1.4.2.1 Outer membrane vesicle vaccines 
Outer membrane vesicles are membrane blebs naturally released by a variety 
of Gram-negative bacteria during growth. They contain a significant number of 
membrane proteins and high levels of LPS. Meningococcal OMVs are enriched in 
major OMPs PorA, PorB, Omp85 and OpcA and contain a repertoire of other minor 
protein antigens (Vipond et al., 2006). Their role in the life cycle of meningococci is 
still unknown though it is hypothesized that they contribute to adherence and DNA 
transfer. Release of OMVs might also have a role in diverting immune response 
during invasive disease by transporting and presenting LPS and outer membrane 
proteins into host cells (Alaniz et al., 2007). 
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Outer membrane vesicle vaccines have been used for the past 20 years to 
control epidemics caused by serogroup B meningococcal strains. They are made of 
OMVs extracted from bacteria by treatment with the detergent deoxycholate to reduce 
LPS levels and hence toxicity of the extract (Fredriksen et al., 1991). The first OMV 
vaccines were developed by the Finlay Institute in Cuba and the Norwegian Institute 
of Public Health against outbreak strains CU350 and H44/76, respectively, and were 
used to contain epidemics in Chile, Cuba, Brazil and Norway (Bjune et al., 1991; 
Boslego et al., 1995; de Moraes et al., 1992; Sierra et al., 1991). Recently, a tailor-
made OMV vaccine against 98/254 strain was used to contain an outbreak in New 
Zealand (Oster et al., 2005). The efficacy of these OMV vaccines varied between 50-
80% and the protection was strain specific since bactericidal responses were mainly 
targeted against the highly variable PorA (Rosenqvist et al., 1995; Wedege et al., 
2007). However, where no other vaccine against menB disease is available, OMV 
vaccines constitute an effective and well-established solution against disease 
outbreaks.  
1.4.2.2 Major porins 
Much of the information on the immunogenic properties of the major porins 
PorA and PorB has been gathered during clinical evaluation of OMVs. Additionally, 
independent studies on recombinant forms of PorA and PorB have been conducted. 
Both porins were shown to elicit a bactericidal response when incorporated into 
liposomes suggesting that a correct, near native conformation is vital for induction of 
functional antibodies (Arigita et al., 2003; Wright et al., 2002). With the aim of 
providing protection against a larger panel of isolates representative of the 
hypervirulent lineages, vaccine developers selected different PorA variants to be 
introduced simultaneously either in liposomes or OMV preparations. Tetravalent 
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PorA-liposome and hexa- and nonavalent PorA-OMV preparations were shown to 
elicit a varying, cross protective bactericidal response against homologous and 
heterologous strains (Humphries et al., 2005; van den Dobbelsteen et al., 2007; 
Vermont et al., 2003). In all cases, selection of variants was facilitated by 
epidemiological data which suggest that a limited number of variants circulating 
between hyperinvasive lineages would be sufficient to confer broad protection (Urwin 
et al., 2004). These studies also highlighted the need for constant monitoring of 
spread of these variants especially following the use of serosubtype-specific OMV 
vaccines against certain epidemics. 
1.4.2.3 Other antigens of known function 
Other immunogenically important proteins expressed on the meningococcal 
surface have been identified over the years and included in tests assessing their 
potential as vaccine candidates. Proteins involved in iron uptake attracted attention 
mostly due to their vital role in the survival of the meningococcus in the host. 
Transferrin-binding proteins A and B were both found to protect mice when 
challenged with meningococci and raise bactericidal antibodies (Ala'Aldeen and 
Borriello, 1996). However, bactericidal response against a TbpB formulation assessed 
in phase I clinical trials was poor (Danve et al., 1998). Lactoferrin-binding proteins 
were also immunogenic and elicited a bactericidal response with limited cross-
reactivity as a result of sequence variation (Pettersson et al., 2006). FetA, an iron-
regulated OMP present in OMVs elicits antibodies which are directed against a highly 
variable surface-exposed loop and are thus strain-specific (Pettersson et al., 1990). 
However, given the antigenic structuring of meningococci, a limited number of FetA 
variants was suggested to potentially protect against the majority of hypervirulent 
strains, a hypothesis that remains to be tested (Urwin et al., 2004). 
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Proteins involved in adhesion and colonisation of epithelial cells have also 
been shown to be immunogenic. Major adhesins OpcA and Opa family proteins are 
abundant on the surface of the meningococcus and antibodies against them have been 
found in convalescent sera and sera from humans immunised with OMV vaccines 
(Mandrell and Zollinger, 1989; Poolman et al., 1983; Wedege and Froholm, 1986). 
Although they are phase variable and antigenically diverse, Opa proteins exhibit 
conserved sequence combinations across hyperinvasive lineages (Callaghan et al., 
2006). Based on this genetic structuring, a combination of 6 Opa variants was recently 
shown to induce bactericidal antibodies in mice that could potentially protect against 
90% of the lineages circulating in the UK (Callaghan et al., 2011). Antibodies against 
recently characterised, surface-exposed adhesins App and NhhA were also involved 
in protection via serum bactericidal killing in mice (Hadi et al., 2001; Pizza et al., 
2000). App is an autotransporter protein with autolytic properties mediating adhesion 
to epithelial cells (Hadi et al., 2001; Serruto et al., 2003). NhhA is a trimeric 
autotransporter adhesin with roles in protection from phagocytocis and complement 
mediated bactericidal killing (Scarselli et al., 2006; Sjolinder et al., 2008). Antibodies 
against App and NhhA have been detected in sera from patients and healthy colonised 
individuals suggesting that both are expressed in vivo (Litt et al., 2004).  
1.4.2.4 Genome-derived protein antigens 
An important contribution of genomic revolution has been the ability to 
identify and assign a function to proteins that could not be previously revealed by 
conventional methods. The first Neisseria genomes to be sequenced were that of 
serogroup B MC58 and serogroup A Z2491 strains (Parkhill et al., 2000; Tettelin et 
al., 2000). Availability of genome sequences facilitated a number of genome-based 
approaches either for direct discovery of vaccine candidates, or for functional 
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characterisation of virulence factors with implications in vaccine development 
(Dietrich et al., 2003; Exley et al., 2009; Grifantini et al., 2002b; Sun et al., 2005). 
Based on the MC58 genome sequence, a novel genome-based approach, termed 
reverse vaccinology, was applied for the identification of novel vaccine candidates 
(Pizza et al., 2000). In this pioneering study, the 570 of 2158 predicted open reading 
frames (ORFs) were chosen in silico as potentially encoding surface-exposed proteins 
(i.e. lipoproteins, outer membrane proteins). These were amplified and cloned in E. 
coli with the aim of expressing and purifying the corresponding products. Purified 
proteins were then used to immunise mice and immune sera were tested for 
bactericidal antibodies. This study identified antigens including fHbp, neisserial 
adhesin protein A (NadA) and heparin binding protein A (HBPA, or  GNA2132).  
Factor H-binding protein is expressed in the majority of meningococcal 
strains, however expression levels are strain-dependent. Based on sequence variation, 
fHbp has been classified into 3 variant families which exhibit different prevalence 
across strains (Masignani et al., 2003). Although bactericidal activity of antibodies 
against fHbp is known to be variant specific, a vaccine combining variants from the 
different families in one formulation could in principle confer cross protection. One 
such formulation was developed using 2 fully lipidated fHbp variants and is currently 
undergoing clinical trials (Richmond et al., 2008). In a different approach, the most 
prevalent variant 1 of fHbp was combined with NadA and HBPA in a multi-
component vaccine termed 5CVMB (also known as 4CmenB) (Giuliani et al., 2006). 
Neisserial adhesin protein A is considered to have a role in adhesion and invasion of 
epithelial cells and is present in 3 conserved alleles which can elicit cross reactive 
bactericidal antibodies in both mice and humans (Capecchi et al., 2005; Comanducci 
et al., 2002). It is present in some, but not all, serogroup B isolates representing 
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hyperinvasive clonal complexes. Heparin binding protein A, a surface-exposed 
lipoprotein which binds to heparin, has also been independently shown to elicit 
bactericidal antibodies against some isolates in mice and confer protection against 
bacteremia in an infant rat model (Serruto et al., 2010; Welsch et al., 2003). The 
5CVMB formulation also contained antigens GNA2091 and GNA1030 from the 
reverse vaccinology study which were fused to fHbp and HBPA, respectively 
(Giuliani et al., 2006). In preclinical studies in mice, 5CVMB formulated with 
aluminum hydroxide was able to elicit cross-protective antibodies against 66 of 85 
strains tested (Giuliani et al., 2006). In phase II trials, 63-100% of infants immunised 
with 5CVMB administered together with OMVs from New Zealand strain 98/254 
elicited protective titres (1:4 or greater) against strains expressing at least one of the 
vaccine antigens (Snape et al., 2008). Regardless of the final formulation, vaccines 
containing fHbp might offer an additional advantage. Further to the induction of a 
bactericidal response, antibody binding to fHbp could inhibit the binding of fH on the 
meningococcal surface and hence enhance complement-mediated killing of bacteria. 
Recently, the design of OMV preparations from strains engineered to 
overexpress different fHbp variants and NadA was reported (Zollinger et al., 2010). 
Three strains were engineered to express increased levels of one of fHbp variant 1, 
fHbp variant 2 and NadA. Each strain was additionally manipulated to reduce toxicity 
of LPS, include a second heterologous PorA variant in addition to endogenous PorA 
and express consistent levels of OpcA. The resulting antigenic preparation combined 
the virtues of strong immunogens with the advantage of OMVs to present antigens in 
their native conformation. Selection of antigenic variants was also based on the 
rationale of providing broad protection against strains that express at least one of the 
vaccine antigens. Manipulations on the LPS background also allowed for native 
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OMVs to be safely used and detoxified LPS to serve as additional antigen. In phase I 
clinical trials, the vaccine was found to elicit bactericidal antibodies that were cross 
protective against a small panel of strains tested (Keiser et al., 2011). 
1.4.2.5 Hypothetical proteins 
Genome-wide screening and characterization of OMVs led to the discovery of 
a number of protein antigens with unknown function. Proteins designated GNA992, 
GNA1946, GNA1162 and GNA2001 were identified during the original reverse 
vaccinology study conducted by Pizza et al. in addition to the proteins included in the 
5CVMB vaccine (Pizza et al., 2000). From a more recent application of the genome 
screening approach, four more antigens were found, namely NMB0606, NMB0873, 
NMB1163 and NMB0938 (Pajon et al., 2009). Finally, NMB0088 and NMB0928, 
two proteins identified following proteomic characterization of the OMV protein 
content from the CU385 outbreak strain were also included in the list of potential 
vaccine candidates (Delgado et al., 2007; Sardinas et al., 2009). All of these 
uncharacterised proteins were shown to elicit a bactericidal response and/or confer 
protection in experimental animal challenge studies. 
 
1.5 Proteomics and meningococcal disease 
1.5.1 Proteomic technologies 
Proteomics is a dynamic and large-scale study of the total protein content in an 
organism, tissue or cell. It also deals with the differences in protein expression levels 
between different conditions as well as networks of protein interactions (Aebersold 
and Mann, 2003). Proteomics exploits a wide range of separation techniques, 
spectroscopic methods and available genome sequences to study complex protein 
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samples. A typical workflow of proteome-wide analysis includes sample preparation 
for isolation and separation of protein mixtures, digestion of proteins with a specific 
protease (e.g. trypsin) and mass spectrometric (MS) analysis of the generated peptides 
for protein identification (Domon and Aebersold, 2006). 
1.5.1.1 Protein isolation and separation 
Protein isolation and separation methods are selected on the basis of the nature 
of the sample and the aim of the analysis to facilitate downstream mass spectrometric 
identification. Isolation methods are used to prepare samples enriched in proteins of 
interest (Figure 1.3). These methods involve either chemical or physical treatment to 
extract proteins from certain cell compartments (membrane, cytoplasm), or bearing 
post-translational modifications (e.g. glycoproteins, phosphoproteins) (Stasyk and 
Huber, 2004). In the former case, detergents or partitioning solutions that can create 
different phases upon centrifugation are commonly used for extraction of proteins 
from organelles and cell compartments (Abdolzade-Bavil et al., 2004; Everberg et al., 
2008; Fialka et al., 1997; Wright et al., 2005). In the latter case, modified proteins are 
purified from whole-cell lysates by exploiting their affinity to certain chemical 
structures. Phosphorylated proteins are normally isolated by affinity of the phosphate 
group to chelating metal ions or titanium dioxide (Larsen et al., 2005; Salomon et al., 
2003). Enrichment of glycoproteins is instead achieved by lectin affinity 
chromatography or by covalent capture on hydrazide moieties (Bunkenborg et al., 
2004; Zhang et al., 2003). 
Separation techniques are applied to reduce complexity of the analysed protein 
samples prior to MS analysis. Proteins are separated based on physicochemical 
parameters including molecular weight (MW), isoelectric point (pI) and 
hydrophobicity. 
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Figure 1.3 Sample preparation for MS analysis. Following cell culture, proteins of 
interest are isolated by chemical and/or physical methods. Proteins are subsequently 
separated on one or two-dimensional polyacrilamide gels (2D-PAGE or SDS-PAGE) 
or using liquid chromatography. Proteins from gel spots / bands or chromatographic 
fractions are subjected to digestion with proteases and the peptides generated are 
analysed by MS. 
 
At this stage, modifications can also be introduced to allow comparative analysis of 
different protein fractions. The most commonly used separation technologies in 
proteomics include two-dimensional polyacrylamide gel electrophoresis (2D-PAGE), 
one-dimensional sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) and multidimensional liquid chromatography (MD-LC) (Figure 1.3) (Issaq et 
al., 2002).  
In 2D-PAGE, complex protein mixtures are first separated by their pI using 
isoelectric focusing (IEF) and subsequently separated by MW in SDS-PAGE. Proteins 
in 2-D gels are then excised, digested with trypsin and extracted peptides identified by 
MS (Görg et al., 2004). The main advantage of 2D-PAGE is the high resolving power 
which can be further enhanced by the use of large-format gels. Comparative analysis 
in 2D-PAGE can be achieved through differential in-gel electrophoresis (DIGE), a 
Cell / tissue culture
Protein isolation
Protein separation
membrane 
proteins
protein 
complexes
glycoproteins / 
phosphoproteins
2D-PAGE SDS-PAGE Liquid chromatography
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method that involves chemical labelling of protein samples with spectrally resolvable, 
fluorescent dyes of similar size (Unlü et al., 1997; Yan et al., 2002). The most 
common dyes used are cyanine derivatives containing a N-hydroxysuccinimide 
(NHS) ester group to react and covalently attach to the epsilon amino group of lysine 
residues in proteins. Under minimal labelling conditions, one molecule of dye is 
attached to one protein molecule and fluorescence intensity is proportional to protein 
abundance. Protein samples to be compared are labelled with different dyes, mixed 
and separated in the same 2-D gel. (Yan et al., 2002). Where protein patterns are 
identical between samples, differences in protein expression levels can be inferred 
from differences in fluorescence intensity between the different dyes. Alternatively, 
different samples can be labelled with the same dye and run in different gels together 
with a differently-labelled internal standard made by the pooling of all samples to be 
compared (Alban et al., 2003; Kondo et al., 2003). Following matching of the same 
spots between different gels, fluorescence intensities are compared and differences in 
protein abundance detected. This design allows for more samples to be compared 
simultaneously and prevents variation caused by the use of different dyes. Differential 
in-gel electrophoresis offers the most sensitive quantitation platform in gel-based 
approaches with differences of less than 20% in protein levels being detectable (Alban 
et al., 2003). 
As an alternative separation method, IEF can be omitted and samples 
solubilised in buffers containing SDS and separated by traditional SDS-PAGE 
followed by digestion of proteins in gel bands and MS analysis of peptides for protein 
identification (Taylor et al., 2003). Each gel band usually consists of a mixture of 
proteins which require further chromatographic separation either directly linked to 
MS analysis or carried out offline. This approach, which is also known as GeLC-MS, 
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can be used for whole-proteome identification analysis as well as for quantitation 
carried out at the MS stage (Gao et al., 2008). Although separation of proteins does 
not compare to 2D-PAGE, the use of SDS to solubilise proteins enhances the 
representation of more hydrophobic membrane proteins in the analysed sample.  
Multidimensional liquid chromatography (MD-LC) is a gel-free strategy for 
analysis of complex samples at the peptide level which involves digestion of a protein 
mixture and subsequent separation of peptides by multiple sequential LC runs 
(Wolters et al., 2001). The most common setup consists of a LC step using strong 
cation exchange (SCX) chromatography to separate proteins by charge followed by 
reversed-phase chromatography (RP-LC) for separation based on hydrophobicity. The 
RP-LC step is directly interfaced with the mass spectrometer and can also be used 
independently to process peptide samples generated from 2-D gel spots and 1-D gel 
bands, as described previously. In this so called LC-MS setup, LC offers an additional 
separation step for proteins already resolved by gel electrophoresis. The automation of 
LC together with the increased solubility of the resulting peptides has rendered MD-
LC a powerful approach for fast identification of proteomes (Washburn et al., 2001).  
Quantitation in SDS-PAGE and MD-LC setups can be performed by 
comparison of peptide ion intensities in mass spectra. Samples to be compared are 
labelled with different isotopes to introduce a mass difference between the same 
proteins/peptides from different samples (Ong and Mann, 2005). Differentially-
labelled samples are then pooled and separated and analysed as one sample. Relative 
abundance of same peptides from different samples is inferred from the relative 
intensities of the corresponding ion peaks in mass spectra. Stable isotopic labelling by 
amino acids in cell culture (SILAC) is a technology for protein tagging and relies on 
the in vivo metabolic incorporation of a ‘light’ and ‘heavy’ form of one or more 
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amino acids into proteins during cell culture (Ong et al., 2002). When dealing with 
non-culturable samples, lysates can be isotopically labelled with isotope-coded 
affinity tags (Gygi et al., 1999) and isotope-coded protein labels (Kellermann, 2008) 
which attach to cysteine residues and free amino groups, respectively. Chemical tags 
such as iTRAQ can also be introduced at the peptide level, i.e. after protein samples 
have been digested to peptides by trypsin (Ross et al., 2004). Fragmentation of the tag 
attached to each peptide generates a low molecular mass reporter ion that is unique to 
the tag used to label each of the digests. Measurement of the intensity of these 
reporter ions enables relative quantification of the peptides in each digest and hence 
the proteins they originate from. 
1.5.1.2 Mass spectrometry 
A mass spectrometer measures the mass-to-charge ratio (m/z) of ionised 
analytes and consists of an ion source, a mass analyser and a detector which records 
the number of ions at each m/z value. Two soft ionization techniques, electrospray 
ionisation (ESI) and matrix-assisted laser desorption ionisation (MALDI) are 
commonly used for peptide analysis (Ahmed, 2008). Electrospray ionisation is based 
on an evaporation-ionisation process of analytes in liquid phase and can be directly 
coupled to LC or capillary electrophoresis for the analysis of complex peptide 
mixtures. In MALDI analysis, samples are applied on an inert metal surface, dried and 
ionised under laser with the aid of an organic material (matrix). 
Two types of spectra can be acquired, a typical MS spectrum that includes the 
m/z of every peptide present in the sample and a tandem MS/MS spectrum which is 
created by fragmenting a peptide into smaller fragments and measuring the m/z of the 
peptide fragments (Figure 1.4) (Aebersold et al., 2003). Fragmentation is achieved by 
collision with gas and is a process called collision-induced dissociation (CID). 
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Fragment ion spectra are rich in information on each peptide’s amino-acid sequence 
and are applied in the identification and quantitation of peptides as well as the 
characterisation of protein post-translational modifications (Aebersold et al., 2003; 
Witze et al., 2009). Based on the types of spectra available, two bioinformatic-based 
methods for protein identification have been developed, namely, peptide mass 
fingerprinting (PMF) and MS/MS peptide sequencing (Figure 1.4). In PMF, the list of 
experimental peptide masses generated during acquisition of MS spectra is matched to 
theoretical peptide masses calculated for each entry in a protein database 
(www.matrixscience.com, 2011d). Since peptides from different proteins can have the 
same mass, PMF is particularly beneficial for simple protein samples and the 
identification is confirmed when a statistically significant number of peptides map to 
the same protein. Peptide sequencing takes advantage of the MS/MS spectra which 
are scanned against theoretical MS/MS spectra constructed from protein sequence 
databases. Cross-correlation of the predicted spectra with the measured spectra 
determines the best match, thus MS/MS sequence search offers more unambiguous 
protein identification (Steen and Mann, 2004). 
The quality of the mass spectra generated determines the success of 
downstream analysis including identification and quantitation of proteins. Spectral 
quality mainly depends on the performance of the mass analyser defined by 
parameters including resolution, mass accuracy, sensitivity and dynamic range. 
Resolution describes the ability of the analyser to distinguish between peptides of 
similar m/z value, whereas mass accuracy accounts for the accuracy in assigning the 
correct mass to every peptide and measures the error in this assignment 
(www.matrixscience.com, 2011c). Sensitivity and dynamic range are measures of the 
minimal protein concentrations that can be detected in a simple or complex sample, 
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respectively. Four main types of analysers are available, namely ion trap, time-of-
flight (TOF), quadrupole and Fourier transform ion cyclotron. These can be used 
alone or in tandem leading to a variety of MS systems with different capabilities. Ion 
trap analysers can acquire MS and MS/MS spectra and fragment ions are generated in 
the same trapping space where peptide ions are captured. In TOF analysers, peptides 
of different m/z are scanned as they fly with different speed out of the analyser. The 
combination of TOF with quadrupole analysers has led to the development of hybrid 
instruments where selection of certain peptides and their fragmentation is carried out 
in the quadrupole part and m/z is measured in the TOF (Ahmed, 2008). More recent 
advances in hybrid MS systems include the use of ion traps in tandem where one trap 
is used for generation and selection of fragment ions while the other acquires MS 
spectra of high resolution. An example of such system is shown in Figure 1.5. 
 
 
Figure 1.5 The Thermo LTQ-Orbitrap hybrid mass spectrometer (adapted from 
Makarov et al., 2006). A typical MS method for protein identification involves the use 
of the Orbitrap for acquisition of high resolution MS spectra and the linear ion trap for 
CID fragmentation and acquisition of MS/MS spectra. 
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1.5.2 Proteomics of N. meningitidis 
Sequencing of the N. meningitidis genome enabled the application of 
proteomic technology for the study of meningococcal disease at the protein level. 
Characterisation of the protein content of OMV preparations has dominated 
proteomics of N. meningitidis. Outer membrane vesicles used in vaccines against the 
Cuban CU385 and New Zealand 98/254 outbreak strain were the first to be analysed 
by proteomics (Uli et al., 2006; Vipond et al., 2006). 2D-PAGE separation of 
detergent extracted OMVs followed by MS identification of protein spots on gels 
confirmed the presence of major and minor OMPs, with PorA and PorB being the 
most abundant. These studies also revealed a more complex protein mixture than 
anticipated with many cytoplasmic proteins present in detergent-extracted 
preparations. Proteomic analysis of detergent extracted OMVs from other strains 
resulted in similar observations (Vaughan et al., 2006; Williams et al., 2007). 
Considerably fewer cytoplasmic proteins were found in naturally-released OMVs 
(nOMVs) prepared using a knockout strain missing a lytic transglycosylase encoded 
by gene gna33 (Ferrari et al., 2006). Analysis of nOMVs confirmed the contribution 
of detergent extraction to the presence of cytoplasmic proteins in the previous OMV 
vaccine preparations. It also suggested that nOMVs might be a better sample for 
OMV vaccine production since LPS levels were comparable to those from detergent-
extracted preparations. The use of OMVs from LPS deficient mutant strains has also 
been suggested as an alternative way to minimize the amount of LPS without the need 
for detergents. The protein content of such OMVs was analysed by proteomics and 
found comparable to OMVs from the wild-type strain (Williams et al., 2007). 
Other applications of proteomics included the construction of 2-D proteome 
maps from strains representative of serogroups A and B (Bernardini et al., 2004; 
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Mignogna et al., 2005). Such maps aimed at providing information on protein 
expression under laboratory growth conditions to better understand biological 
processes in the meningococcus. Comparative proteomics were also used in some 
cases to assess the effect of certain factors on meningococcal protein expression. 
Proteins whose expression depends on iron availability were identified following 
comparison of the proteomes of bacteria grown under iron-depleted and iron-replete 
conditions (Basler et al., 2006). There are also examples of comparative studies on the 
changes in protein expression induced by autoinducer AI-2, a molecule involved in 
quorum sensing (Schauder et al., 2005) and Hfq, a conserved protein that mediates 
sRNA regulation (Fantappiè et al., 2009). Assessment of protein content of OMV 
batches from different vaccine manufacturers by 2D-DIGE proteomic analysis was 
also documented as part of a study on the New Zealand 98/254 OMV vaccine 
(Vipond et al., 2006). 
 More recent proteomic studies focussed on the identification of protein targets 
of immune response using antibodies raised against specific proteins or sera from 
patients and healthy carriers. These studies used so called immunoproteomic analysis, 
which involves separation of protein antigens by 2D-PAGE followed by their transfer 
onto membranes and blotting with antibodies (Utt et al., 2002). Immunoproteomics 
was used in two cases to identify antigens that contribute to natural cross-protective 
immunity against meningococcal disease (Mendum et al., 2009; Williams et al., 
2009). Using the same approach and specific monoclonal antibodies, NMB1468, a 
lipoprotein of unknown function, was identified as a novel immunogen able to confer 
protection in mice (Hsu et al., 2008). 
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1.5.3 Proteomics in the analysis of bacterial surface proteomes for the 
identification of vaccine candidates 
Recently, proteomic strategies for profiling the surface proteome of bacteria 
have emerged as promising tools for vaccine discovery (Cordwell, 2006). Methods 
involving chemical or physical treatment have been developed aiming to isolate only 
those proteins that are targeted by the immune system of the host. One strategy uses 
proteolytic enzymes to ‘shave’ the bacterial surface and release peptides originating 
from the surface-exposed regions of outer membrane antigens (Bledi et al., 2003). 
Protease treatment is followed by MD-LC MS analysis of the released peptides or 
comparison between treated and non-treated cell lysates for the identification of the 
affected proteins (Rodriguez-Ortega et al., 2006; Sabarth et al., 2005). This method 
has been applied to Gram-positive bacteria including Streptococcus and Bacillus 
species and in some cases was specific for membrane proteins leading to the 
identification of potential vaccine candidates (Rodriguez-Ortega et al., 2006; 
Rodríguez-Ortega et al., 2008; Severin et al., 2007; Tjalsma et al., 2008).  
Other strategies involve the modification of surface proteins by the application 
of chemical, membrane impermeable reagents to intact cells. Chemical tags consist of 
a reactive group for labelling lysine residues and a fluorophore or biotin molecule to 
directly visualise or purify the modified proteins, respectively. Modified proteins can 
then be separated and identified by MS analysis. Unlike protease treatment methods, 
proteins are permanently modified and their isolation requires additional purification 
steps. This approach has already been applied to several pathogenic bacteria using 
2D-PAGE separation techniques (Anaya et al., 2007; Ge and Rikihisa, 2007b; Ge and 
Rikihisa, 2007a; Mayrhofer et al., 2006). In all studies using chemical modification, 
concerns about potential permeability of chemical tags through the bacterial 
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membrane were raised following the isolation and identification of numerous 
predicted cytoplasmic proteins.  
 
1.6 Aim of the thesis 
In the search for antigens for inclusion in meningococcal vaccines, proteins 
exposed on the bacterial cell surface pose as the most attractive candidates. Whilst 
many surface antigens have been characterised over the years, others might have been 
missed by the experimental methods used so far. Recent proteomic advances in the 
specific identification of bacterial surface proteomes offer a promising alternative and 
have not been fully exploited for the screening of the meningococcal surface. In this 
context, this study aimed to: 
• refine and apply proteomic methods for the identification of proteins on the 
meningococcal surface. 
• compare the proteome and immune responses of OMV vaccines from 
meningococci grown in different media for identification of protein antigens 
contributing to vaccine-induced immunity.  
• identify protein targets of the immune system in mice through the application of 
immunoproteomics. 
• assess the vaccine potential of proteins identified in the proteomic studies. 
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2. Materials and Methods 
2.1 Materials 
All chemicals, equipment and analysis software used for protein labelling, 
SDS-PAGE, electro-transfer and immunoblotting were supplied by GE Healthcare 
(Chalfont St Giles, UK), unless otherwise stated. Enzymes, protease inhibitors, 
chemicals for immunological assays and solvents for liquid chromatography were 
provided by Sigma-Aldrich (Dorset, UK). Cell culture media were from Oxoid 
(Basingstock, UK). Plasmid vectors, purification kits and E. coli competent cells were 
purchased from EMD Chemicals (Gibbstown, New Jersey, USA). Liquid 
chromatography separation columns and equipment were from Dionex (Surrey, UK). 
The distributors of other materials and equipment used throughout the study are 
provided in the Methods section. 
Monoclonal antibodies against PorA (P1.7), PorB (P3.5) and fHbp (variant 1) 
were produced at the National Institute for Biological Standards and Control 
(NIBSC). Murine immune sera against live N. meningitidis MC58 and OMVs from 
H44/76 strain were kindly provided by Dr Y. Li (CMMI, Imperial College London, 
London, UK) and Dr E. Wedege (Norwegian Institute of Public Health, Oslo, 
Norway), respectively. Nucleotide sequences of the gene coding for N. meningitidis 
macrophage infectivity potentiator (NmMIP) from 106 meningococcal isolates were 
kindly provided by Prof M. Maiden (University of Oxford, Oxford, UK).  
 
2.2 Meningococcal strains and culture conditions 
Neisseria meningitidis MC58 wild-type and ∆-siaD strains were used to 
generate protein extracts and as target strains in whole-cell ELISA and serum 
bactericidal assays and were obtained from the NIBSC strain collection. Target strains 
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in complement deposition and opsonophagocytosis assays were obtained from the 
HPA Meningococcal Reference Unit and included Norwegian and New Zealand 
vaccine strains H44/76 and NZ98/254, respectively, and representatives of the most 
prevalent UK serosubtypes (Table 2.1) (Findlow et al., 2006). Strains used in 
phylogenetic analysis of the gene encoding NmMIP are presented in Table A1 
(Appendix). 
Strains were grown from frozen bead stocks in Columbia blood agar or brain 
heart infusion (BHI) agar supplemented with defibrinated horse blood and incubated 
at 37oC in a humidified atmosphere of 5% CO2. For long term storage of strains, 
colonies were scraped from a blood agar plate, suspended onto beads (Technical 
Service Consultants Ltd, Heywood, UK) and stored at -80oC. For downstream 
applications requiring liquid cultures, bacteria were grown in Mueller-Hinton (MH) 
broth under aerobic conditions at 37oC with gentle shaking. Bacteria were collected at 
an optical density (O.D.) of 0.5–0.6 (late exponential phase) by centrifugation at 
10,000 x g for 10 min and washed twice with cold phosphate buffered saline (PBS) 
until further use. 
Table 2.1 Meningococcal isolates used in complement deposition and 
opshonophagocytosis assays. 
Isolate serogroup 
sequence 
type 
clonal 
complex 
serosubtype 
VR1 VR2 
MC58 B 74 32 7 16-2 
H44/76 B 32 32 7 16 
NZ 98/254 B 44 41/44 7-2 4 
M01-240101 B 1049 269 19-1 15-11 
M01-240013 B 275 269 22 9 
M01-240149 B 41 41/44 7-2 4 
M01-240185 B 11 11 5-1 10-8 
M01-240355 B 213 213 22 14 
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2.3 Proteinase K treatment 
Bacteria from MH cultures of the MC58 ∆-siaD strain were used for treatment 
with proteinase K. Cell pellets containing approximately 12 x 109 bacteria were 
resuspended in 1 mL of PBS pH 7.2, containing 5 mM dithiothreitol (DTT) and 
proteinase K at concentrations varying from 1.25 to 80.0 µg/mL per 109 cells. Cell 
suspensions were incubated for 45 min at 37oC in a shaking incubator. Proteinase K 
activity was terminated by the addition of 10 µL of protease inhibitors. Cells were 
subsequently washed twice in cold PBS, resuspended in 200 µL lysis buffer 
containing 30 mM Tris hydrochloride, pH 8.5, 7 M urea, 2 M thiourea and 2% (v/v) 
Triton X-100 and lysed by repeats of 30 sec vortexing followed by incubation on ice. 
Protein extracts (also referred to as cell extracts and protein lysates) were recovered 
by centrifugation at 10,000 x g for 20 min. Protein concentrations were determined 
using the Bradford assay (Bio-Rad, Hemel Hempstead, UK) (Bradford, 1976). Optical 
density measurements were performed using the Lambda 800 UV/VIS 
spectrophotometer (Perkin-Elmer, Waltham, MA, USA). 
 
2.4 Preparation of OMV lysates 
Outer membrane vesicles were prepared at the Division of Infectious Disease 
Control, Norwegian Institute of Public Health as described by Tsolakos et al. 
(available in the electronic copy of the thesis) (Tsolakos et al., 2010). The 
meningococcal vaccine strain H44/76 (B:15:P1.7,16; ST-32) was cultured in a 2.5 L 
fermentor in either the semi-synthetic Frantz medium (FM) containing yeast extract 
and casamino acids (Fredriksen et al., 1991) or the synthetic modified Catlin 6 
medium (MC.6M) containing ferric citrate prepared as previously described (Frasch et 
al., 2001). The detailed composition of the two media is presented in Table 2.2. Outer 
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membrane vesicles were prepared by extraction with Na-deoxycholate as previously 
described (Fredriksen et al., 1991). Three OMV batches were prepared from bacteria 
grown in each of the culture media. For 2D-PAGE, the 6 samples were concentrated 
using Microcon YM-3 filter (Millipore, Livingston, UK) following centrifugation at 
8,000 x g for 15 min and reconstituted in lysis buffer containing 30 mM Tris, 7 M 
urea, 2 M thiourea and 2% (v/v) Triton X-100 (Sigma-Aldrich), pH 8.5 (Vipond et al., 
2006). The protein concentration of the samples was determined using the Bradford 
assay. 
 
Table 2.2 Composition of media used to grow the Norwegian OMV vaccine 
strain H44/76. 
 
Frantz (FM) Modified Catlin-6 (MC.6M) 
Reagent g/L Reagent g/L 
Na2HPO4 ·2H2O 3.5 NaCl 5.8 
KCl 0.09 K2HPO4 4.0 
MgSO4 ·7H2O 0.6 K2SO4 1.0 
Glucose 10.0 NH4Cl 1.0 
Casamino acids 30.0 CaCl2 ·2H2O 0.03 
D-cysteine 
hydrochloride 
0.02 MgCl2 ·6H2O 0.4 
Yeast Extract 1.0 L-Glutamic Acid 3.9 
  L-Cysteine ·HCl 0.1 
  L-Arginine ·HCl 0.15 
  L-Serine 0.5 
  Glycine 0.25 
  Glucose 10.0 
  Fe(III) Citrate 0.04 
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2.5 Fluorescent labelling 
Fluorescent labelling of protein samples was carried out using fluorescent 
cyanine dyes. Two sets of cyanine dyes were used. CyDyeTMDIGE fluor propyl-Cy3 
and methyl-Cy5 (NHS) ester dyes (referred to as Cy3 and Cy5) containing 5 nmol per 
tube were freshly reconstituted in anhydrous dimethylformamide at 100 pmol/µL. IC-
OSu ethyl-Cy3 and ethyl-Cy5 NHS ester cyanine dyes (referred to as IC3 and IC5) 
(NBS Biologicals Ltd, Huntington, UK) were dissolved in 100% methanol and 
individual aliquots of 5 nmol dispensed into clear 1.5 mL tubes. The dyes were 
immediately dried by vacuum centrifugation. The closed tubes were stored at -20oC, 
protected from the light. The 5 nmol IC dyes were used and prepared prior to labelling 
as described for CyDyeTMDIGE dyes. As part of their evaluation prior to use in 
subsequent studies, IC dyes were tested and found comparable to CyDyeTMDIGE dyes 
for labelling of protein samples. Results from this analysis were published (Tsolakos 
et al., 2009) and are available in the electronic copy of this thesis. 
A minimal labelling approach was used where 50 µg of protein extract was 
mixed with 400 pmol of cyanine dye and left on ice for 30 min in the dark. The 
reaction was stopped with the addition of 1 µL of 10 mM L-lysine and incubation on 
ice for an extra 10 min. For DIGE analysis, a two-colour experimental design was 
used where individual samples were labelled with IC5 or Cy5 and internal standards 
were made of equal quantities of all individual samples included in each experiment 
with IC3 or Cy3, respectively (Yan et al., 2002). 50 µg of sample and internal 
standard were mixed and subjected to IEF (described in section 2.6.2).  
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2.6 Protein separation 
2.6.1 SDS-PAGE 
Protein samples (25 µg) were boiled for 5 min in Laemmli sample buffer (Bio-
Rad) (Laemmli, 1970) containing 62.5 mM Tris-hydrochloride, pH 6.8, 25% (v/v) 
glycerol, 2% (w/v) SDS and 0.01% bromophenol blue. They were then loaded on 
Tris-glycine-SDS polyacrylamide gels (16 x 14 x 0.15 cm) comprising a 5% stacking 
and a 12% resolving part. The gels were placed in a SE-600 gel tank apparatus filled 
with SDS running buffer made up of 25 mM Tris base, 192 mM glycine and 0.1% 
(w/v) SDS. Proteins were separated by the application of a constant current of 40 mA 
for 5 hr until the dye front migrated off the bottom of the gel. 
 
2.6.2 Two-dimensional PAGE  
Protein samples were mixed with rehydration buffer made up of 2 M thiourea, 
7 M urea, 2% (v/v) Triton X-100, 1% (v/v) pharmalytes pH 3-10 and 2 mg/mL DTT 
and applied onto 24 cm, non-linear, immobilised pH gradient (IPG) Immobiline 
DryStrips, pH 3-11. Rehydration of the strips was carried out overnight at ambient 
temperature. The strips were then placed on an IPGphor II for IEF using six phases of 
stepped and gradient voltages. The first two phases were identical for all samples and 
included the application of 300 V for 3 hr followed by a gradient of 300-1000 V for 9 
hr. The remaining phases depended on the total focusing time and maximal voltage 
chosen. A maximal voltage of 10,000 V for a total focusing time of 100 KVhr was 
used for whole-cell lysates. For OMV samples, maximal voltages of 3,500, 5,500, 
8,000 and 10,000 V for a total focusing time of 45 KVhr were tested. Following IEF, 
the strips were either used immediately or stored at -20oC. 
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Prior to second dimension SDS-PAGE, each strip was equilibrated by 
incubation for 15 min in 5 mL of equilibration buffer containing 50 mM Tris-
hydrochloride pH 8.8, 2 M thiourea, 7 M urea, 30% (v/v) glycerol, 2% (w/v) SDS and 
20 mg/mL DTT. The equilibration step was repeated by replacing DTT with 
iodoacetamide (IAA) (48 mg/mL) in the equilibration buffer. Dithiothreitol was used 
to aid solubilisation of proteins separated on the strips by disrupting disulfide bonds 
formed by thiol groups of cysteine residues. Iodoacetamide alkylates thiol groups and 
prevents re-formation of disulfide bonds, thus maintaining proteins in a soluble state. 
In this way, transition of proteins from the strips onto the acrylamide gels is enhanced. 
The strips were then placed on 12% Tris-glycine-SDS polyacrylamide gels (26 x 20 x 
0.1 cm) prepared in-house using an automatic gel casting system (NextGen Sciences, 
Huntington, UK). Proteins were separated by the application of 8 mA/1W/gel for 2 hr 
followed by 18 mA/1W/gel until the dye front migrated off the bottom of the gel. 
 
2.7 Protein staining 
  For protein samples requiring staining for visualisation following 
electrophoresis, Coomassie R-350 or Sypro Ruby was used. Gels were stained 
overnight in a 0.1% Coomassie R 350 stain solution made by dissolving a PhastGel 
Blue R tablet in a 40% (v/v) methanol/10% (v/v) acetic acid solution and destained in 
a 40% (v/v) methanol/10% (v/v) acetic acid solution. For Sypro Ruby staining, 
proteins were first fixed in 50% (v/v) methanol/10% (v/v) acetic acid for 30 min, 
incubated in Sypro Ruby gel stain overnight and washed in 10% (v/v) methanol/7% 
(v/v) acetic acid for a final 30 min.  
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2.8 Gel Scanning 
 Gels containing proteins labeled with fluorescent cyanine dyes or Sypro Ruby 
were scanned using the Typhoon 9410 Imager (GE Healthcare). Cy3, IC3 and Sypro 
Ruby were excited by a green laser at a wavelength of 532 nm whilst Cy5 and IC5 by 
a red laser at 633 nm. Emitted light was captured by bandpass filters at 580 nm for 
Cy3 and IC3, 610 nm for Sypro Ruby and 670 for Cy5 and IC5. Scanning resolution 
was set to 100 bpi and photomultiplier tube voltages were adjusted for fluorescence 
intensity readings to fall within the linear dynamic range of the scanner. Images of 
scanned gels were visualized using the ImageQuant tools software v. 3.0.  
 Scanning of the gels stained with Coomassie R-350 was carried out with Bio-
Rad Scanner GS-710 Imaging Densitometer (Hercules, CA, USA) using default 
parameters. 
 
2.9 DIGE quantitative analysis 
Images of proteins subjected to DIGE were imported into DeCyder 2-D 
differential analysis software v. 6.5 for spot detection and quantitative differential 
analysis. Pairs of Cy5/Cy3 or IC5/IC3 images corresponding to sample/internal 
standard pairs run on the same gel were imported simultaneously and assigned to 
individual samples. Co-detection of spots in the sample and internal standard images 
acquired from each gel was performed by the Differential In-gel Analysis (DIA) 
module using an estimated number of 2,500 spots. DIA also calculated and 
normalised fluorescence intensities (abundance) of each spot to the internal standard. 
In particular, normalised abundance was expressed as the ratio of abundance of the 
spot in the sample image against the internal standard image. Normalisation of 
quantitative data to compensate for variability in sample amount, total fluorescence 
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and laser intensity was also applied and was based on the assumption that the modal 
peak of spot ratios is zero (no change in protein expression between samples run in 
the same gel should occur) (Yan et al., 2002). Images from DIA analysis were then 
imported to the Biological Variation Analysis module (BVA) for spot matching and 
comparative analysis. In BVA, samples were first grouped based on the nature of 
treatment. Biological replicates (i.e. samples subjected to the same type of treatment) 
were placed within the same group. With the assistance of Cy3/IC3 internal standard 
images and landmark spots, same protein spots were matched across all samples. 
Normalised abundance of same spots was compared across groups and differences 
were detected. Differences were expressed as the ratio of mean normalised abundance 
between two groups which was termed average ratio. The significance of differences 
observed was determined by application of Student’s t-test and analysis of variance 
(ANOVA). Differences exhibiting a P-value of less than 0.05 were considered 
significant. 
 
2.10 Protein electro-transfer and immunoblotting 
Proteins from gels were transferred to low-fluorescent HyBond-LFP 
polyvinylidine fluoride (PVDF) membranes using a TE70 semi-dry blotter. Gels were 
placed in ice-cold Towbin buffer made up of 25 mM Tris, 192 mM glycine, 0.1% 
(w/v) SDS, 20% (v/v) methanol, pH 8.3, for 15 min while PVDF membranes were 
equilibrated in ice-cold methanol for 5 min followed by 10 min in Towbin buffer. 
Gels and membranes were then assembled into a stack of up to 3 sandwiches 
consisting of 3 sheets of blotting paper, membrane, gel and 3 sheets of blotting paper 
with cellulose sheet in-between sandwiches. Proteins were then transferred onto the 
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membrane by the application of 8 mA/cm2 (180 mA and 437 mA for 1- and 2-D gels, 
respectively) for 3 hr. 
Blotting with antibodies was performed in a Roller-Blot HB-3D Hybridiser 
(Techne, Minneapolis, MN) at ambient temperature using the ECL Plex western 
blotting system for single protein detection. PBS pH 7.4 containing 0.1% (v/v) 
Tween-20 was used for antibody dilutions and membrane rinse steps. Membranes 
were blocked with 5% ECL Advance blocking agent for 1 hr and incubated for 3 hr 
with monoclonal or murine polyclonal antibodies in 1:200 and 1:4,000 dilutions, 
respectively, for 3 hrs. Antibody binding was detected by incubation with 1:2,000 
dilution of a Cy5-conjugated, ECL Plex goat anti-mouse IgG (Sigma-Aldrich) for 1 hr 
and scanning for Cy5 fluorescence using the Typhoon 9410 imager as described in 
section 2.8. 
 
2.11 Spot picking from 2-D preparative gels 
Protein spots were picked from 2-D gels (termed preparative) for MS analysis 
and protein identification. Two-dimensional PAGE of protein samples to be used for 
spot picking was carried out as described in section 2.6.2 with the following 
modifications. A total of 200 µg of protein sample was loaded onto IPG strips 
including 50 µg labelled with IC5 cyanine dye. Prior to gel plate assembly for in-
house gel casting, the sides of low-fluorescent gel plates in direct contact with the gel 
were treated with bind and repel silane, respectively. Final bind silane solution 
contained 18 mL water, 80 mL ethanol, 2 mL acetic acid and 100 µL bind silane. 
When polymerised, polyacrylamide gels were mounted on the plate treated with bind 
silane whilst the plate containing repel silane could be removed to allow for spot 
picking. Following 2D-PAGE, proteins on gels were stained with Sypro Ruby as 
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described in section 2.7. Two images of total protein were acquired, one of Sypro 
Ruby and one of IC3-labelled proteins. Images were imported into the DeCyder 2-D 
differential analysis software v. 6.5 and the DIA module was used for spot detection 
and matching between Sypro Ruby and IC3 images. Proteins were subsequently 
matched to their correlates in analytical gels containing information from DIGE 
analysis or immunoblots. Protein spots aimed for MS analysis were annotated on the 
Sypro Ruby image and x, y coordinates of their position in relation to reference 
markers placed on the gel plates were imported into the Ettan Spot Picker for 
automated spot picking. Gels were placed inside the picker chamber fully submerged 
in water. The position of the picking needle was adjusted based on the same reference 
markers used for annotation of spot position on the gel. The picking needle was 
washed twice with 200 µL of distilled water in between applications on the gel. Gel 
plugs were placed into 96-well plates until further use. 
  
2.12 In-gel protein digestion and peptide extraction  
Protein spots from 2-D gels were transferred to protein LoBind tubes 
(Eppendorf UK Ltd, Cambridge, UK), and destained with 50 mM ammonium 
bicarbonate (VWR International Ltd, Lutterworth, UK), pH 8.5 in 50% (v/v) 
acetonitrile for 1 hr. Spots were alternatively washed with 50 mM ammonium 
bicarbonate, 50 mM ammonium bicarbonate in 50% (v/v) acetonitrile and 100% (v/v) 
acetonitrile by incubation for 20 min at ambient temperature. In-gel digestion was 
carried out overnight at ambient temperature using 0.1 µg of trypsin (Promega, 
Southampton, UK) per spot in 50 mM ammonium bicarbonate. 
Peptides were extracted sequentially by water bath sonication for 4 min, using 
1% (v/v) trifluoroacetic acid (TFA) (VWR Internationalal Ltd), 50% (v/v) 
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acetonitrile/0.2% (v/v) TFA (twice) and 100% (v/v) acetonitrile. The pooled 
extraction solution was dried in the Savant SPD2010 SpeedVac concentrator (Thermo 
Scientific, Basingstoke, UK) and reconstituted in 0.1% (v/v) TFA. 
 
2.13 Mass spectrometric analysis and database searching for protein 
identification 
2.13.1 MALDI-TOF MS and LIFT-TOF MS/MS 
 Digests were desalted and concentrated using a ZipTip C18 (Millipore, 
Watford, UK) according to the manufacturer’s instructions. Briefly, each tip was 
wetted with 3 rounds of 10 µL of 100% (v/v) acetonitrile and equilibrated with 3 
rounds of 10 µL of 0.1% (v/v) TFA. The sample was aspirated and dispensed through 
the tip several times for peptide binding followed by washing with 3 rounds of 10 µL 
of 0.1% (v/v) TFA. Peptides were eluted in 5 µL of 60% (v/v) acetonitrile/0.1% (v/v) 
TFA. As matrix for ionisation α-cyano-hydroxicinnamic acid was prepared at a 
concentration of 10 mg/mL in 50% (v/v) acetonitrile/0.1% (v/v) TFA by vortexing 
and centrifugation for 1 min. One µL of matrix was mixed with 1 µL of sample and 
spotted onto a MALDI target. 
An Autoflex II MALDI LIFT TOF with FlexControl and FlexAnalysis 
software was used for acquisition, calibration and display of spectra (Bruker 
Daltonics, Coventry, UK). A total of 700 laser shots per sample was acquired by 
summing sets of 50 laser shots. MS/MS spectra were acquired by application of LIFT-
TOF on the most intense parent ions. A mixture of 7 reference peptides was used for 
external calibration of spectra. A list of peptide masses from MS and masses of 
fragment ions from MS/MS spectra were produced in FlexAnalysis and imported 
using BioTools v.2.0 (Bruker Daltonics) to a web-based Mascot search engine (Matrix 
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Science, Boston, MA, USA) for database searching and protein identification by PMF 
and MS/MS ion searching, respectively. Search parameters included the protein 
entries of Swiss-Prot and NCBInr for N. meningitidis as the protein databases used for 
searching, trypsin as the enzyme used for digestion allowing one missed cleavage, 
cysteine carbamidomethylation and methionine oxidation as fixed and variable 
modification, respectively, precursor and fragment mass tolerance of 100 ppm, and 
peptide charge of +1. Proteins with a significant (P-value < 0.05) score according to 
Mascot were reported.  
 
2.13.2 Liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
Protein digests were analysed by nano-scale capillary LC-MS/MS using a 
Dionex U3000 HPLC system operated at flow rates of 500 nL/min. Peptides were 
trapped on a Acclaim PepMap100 C18, 5 µm, 300 µm x 5 mm µ-Precolumn for 1 
min, separated on a PepMap100 C18, 3 µm, 75 µm x 5 cm analytical column and 
eluted with a 10 min 2-step gradient of 10-20% (0-6 min) and 20-55% (6-10 min) of 
90% (v/v) acetonitrile in 0.05% (v/v) formic acid. A nano-spray source was interfaced 
to the analytical column to direct peptides into a LTQ Orbitrap Discovery (Thermo 
Scientific, Hemel Hempstead, UK) using a 10 µm coated SilicaTip emitter (New 
Objective, Woburn, MA). MS spectra were acquired in the Orbitrap operated on 
positive mode at a resolution of 30,000. The 5 most intense multiply-charged 
precursor ions in the m/z range of 400-2000 were selected for CID and fragment ions 
were analysed in data-dependent scans using the linear ion trap. The mass 
spectrometer was routinely tuned by direct infusion of 100 fmol of [Glu]-
fibrinopeptide at a flow rate of 500 nL/min. The performance of the LC-MS/MS 
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method was further monitored by MS and MS/MS analysis of bovine serum albumin 
digests (Michrom Bioresources, Auburn, California, USA) at fmol levels. 
Proteome Discoverer v.1.0 (Thermo Scientific) was used for downstream data 
processing and database searching using the Sequest engine and the N. meningitidis 
MC58 sequence entries (UniProtKB/SwissProt release 56.4). Search parameters 
included trypsin as the enzyme used for digestion with one missed cleavage allowed, 
methionine oxidation as a variable modification, a precursor mass tolerance of 10 ppm 
and fragment mass tolerance of 0.5 Da. Only proteins identified by at least three 
peptides of high confidence passing the single threshold filter of Xcorr (1.5, 2.0, 2.5) 
versus charge state (+ 1, 2, 3), respectively, were reported. 
 
2.14 Cloning of vaccine candidate genes 
2.14.1 Small scale DNA extraction and isolation 
Genomic DNA was extracted from N. meningitidis MC58 strain using the 
Wizard Genomic DNA Purification kit (Promega UK). Cells from blood agar plates 
were resuspended in 600 µL of nuclei lysis solution and incubated for 5 min at 80oC. 
The suspension was cooled to room temperature and 3 µL of 4 mg/mL RNase were 
added followed by incubation at 37oC for 30 min. Proteins were precipitated by 
addition of 200 µL of protein precipitation solution and incubation on ice for 5 min. 
The cell-free supernatant containing genomic DNA was recovered by centrifugation 
at 13,000 x g for 3 min and mixed with 600 µL of isopropanol by gentle inversion 
until strings of DNA were visible. DNA was pelleted by centrifugation at 13,000 x g 
for 2 min and the isopropanol was removed carefully. The DNA pellet was washed 
with 600 µL of 70% (v/v) ethanol, air-dried, resuspended in sterile distilled water and 
stored at -20oC.  
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2.14.2 Primer design 
Primer pairs were designed for each gene using the nucleotide sequences from 
the annotated genome of MC58 strain. Potential primer sequences were assessed for 
melting temperature and G/C content using the OligoCalc tool from Northwestern 
University Medical School (www.basic.northwestern.edu/biotools/oligocalc). Primer 
pairs are presented in Table 2.3. The annealing position of the primer pairs in the 
nucleotide sequences of the corresponding genes are shown in Figure A1 (Appendix). 
Primer sequences were designed as close to the cleavage site of the signal 
peptide at the 5’ end and translation termination codon at the 3’ end as possible. 
Primer pairs were required to exhibit melting temperatures no greater than 65oC and 
no more than 5oC difference. A G/C content of 40-60% was also preferred where 
possible. Sequences were also required to terminate with a G or C whilst avoiding 
runs of three or more G/C at the 3’end. Sequence pairs following these properties 
were further assessed for complementarity and hairpin loop formation using 
OligoCalc tool and PrimerSelect from Lasergene software v.8 (DNASTAR, Madison, 
USA) and those exhibiting the lowest number of base pair matches were selected. In 
the case of NmMIP, the anti-sense primer included part of the gene downstream of 
NmMIP to achieve optimal annealing properties. 
As highlighted in Table 2.3, extension sequences for ligation independent 
cloning were also introduced at the 5’ end of each primer. Extension sequences were 
designed which were complementary to the overhangs present in the pET Ek/LIC 
plasmid vector to allow for subsequent gene insertion to the vector downstream of a 
six-His sequence. Anti-sense primers also included a stop codon at the 5’ end after the 
overhang extension sequences. 
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2.14.3 PCR amplification of vaccine candidate genes 
PCR amplification reactions were prepared by mixing 160 µΜ of each dNTP, 
1 µΜ of each primer (Invitrogen, Paisley, UK), 1 U of AmpliTaq DNA polymerase 
(Invitrogen), 10x GeneAmp PCR buffer, 1 mM MgCl2 and 100 ng of genomic DNA 
to a final volume of 10 µL. Reactions were carried out in a Veriti 96 well thermal 
cycler (Applied Biosystems, Warrington, UK) by the application of a primary 
denaturation step at 94oC for 2 min, 30 cycles of 60 sec denaturation, annealing and 
extension steps at 94oC, 63oC and 72oC, respectively, and a final extension step at 
72oC for 5 min. 
 
2.14.4 Purification of PCR products 
PCR products were purified using Polyethylene Glycol 8000 (PEG8000) 
precipitation. 60 µL of PEG8000 in 2.5 M NaCl were mixed with 95 µL of PCR 
product and incubated at 37oC for 10 min. The mixture was centrifuged at 13,000 x g 
for 10 min and the supernatant discarded. The DNA pellet was washed with 500 µL 
80% ethanol, air-dried and resuspended in 25 µL TlowE (10 mM Tris-HCl, 0.1 mM 
EDTA pH 8.0). DNA concentration of purified products was measured using a 
Nanodrop 2000 (Fisher Scientific UK Ltd, Loughborough, UK). 
 
2.14.5 Agarose gel electrophoresis 
PCR amplification products were analysed by agarose gel electrophoresis. 
Gels were made to 0.8% (w/v) in 1x TAE buffer (40 mM Tris-acetate, 1 mM EDTA) 
and 5 µL of SafeView nucleic acid stain (NBS Biologicals Ltd) were added to the 
solution. The solution was poured into 40 mm gel trays and left to polymerise at room 
temperature. PCR products were mixed with 6x loading buffer (15% (v/v) ficoll, 15% 
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(v/v) glycerol, 0.1 M Tris, pH 8.0 and 0.5% bromophenol blue) and loaded into the 
individual wells of the gel. DNA ladders of 1,000 bp and 100 bp (New England 
Biolabs, Ipswich, MA, USA) were run in parallel to allow for DNA fragment size 
determination. Electrophoresis was carried out in 1x TAE buffer by application of 100 
V for 1 hr and DNA bands were visualized using an ultraviolet transilluminator. 
Images of gels were photographed by the GelLogic 1500 Imaging System and 
analysed using Molecular Imaging software (Kodak Ltd, Hemel Hempstead, UK). 
 
2.14.6 T4 DNA polymerase treatment and annealing of vector and PCR products 
PCR products from gene amplification and pET-30 Ek/LIC plasmid vector 
were treated with T4 DNA polymerase for generation of compatible overhang 
sequences. Reactions were prepared to a final volume of 20 µL and included 1 U of 
T4 DNA polymerase, 25 mM dATP, 100 mM DTT, 2 µL of 10x reaction buffer and 
0.4 pmol purified PCR product. Reactions were carried out at 22oC for 30 min and 
stopped by incubation at 75oC for an extra 20 min. T4 DNA polymerase treated vector 
and PCR products were mixed at a 1:2 ratio and annealed by incubation at 22oC for 5 
min followed by addition of 1 µL ethylenediaminetetracetic acid (EDTA) (Sigma-
Aldrich) and an extra 5 min incubation step at 22oC. 
 
2.14.7 Transformation 
The construct prepared from annealing vector and PCR product was used to 
transform NovaBlue GigaSingles E. coli competent cells. 1 µL of the annealing 
reaction was added to a tube containing 20 µL of freshly thawed NovaBlue cells and 
incubated on ice for 5 min. The tube was then placed on a 42oC water bath for exactly 
30 sec and transferred back on ice for 2 min. Cells in each tube were mixed with 250 
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µL of room temperature SOC medium and incubated at 37oC with shaking at 250 rpm 
for 60 min. Transformants were selected by plating 100 µL of the cell suspension on 
Luria-Bertani (LB) agar plates supplemented with 30 µg/mL kanamycin and 
overnight incubation at 37oC. 
 
2.14.8 Colony-PCR 
Screening for colonies carrying the vector construct was carried out by colony-
PCR. The reaction mix contained 10 mM of T7 promoter and terminator primers, 10 
mM dNTPs, 2.5 U AmpliTaq (Applied Biosystems), 10x GeneAmp buffer to a final 
volume of 50 µL. Single colonies were picked from agar plates using a sterile tip and 
mixed with the reaction mix. The same tips were also used to inoculate fresh LB agar 
plates and broths containing kanamycin for overnight growth of clones at 37oC. 
Thermal Cycler conditions included an initial denaturation step at 95oC for 5 min, 30 
cycles of denaturation at 94oC for 1 min, annealing at 43oC for 1 min and extension at 
72oC for 2 min followed by a final extension step at 72oC for 5 min. PCR products 
were loaded onto 0.8% (w/v) agarose gels and the presence of a band at the size of the 
insert indicated a positive clone. 
 
2.14.9 Sequencing 
In-frame insertion of the cloned gene to the Ek/LIC vector was assessed by 
sequencing the part of the vector containing the site of insertion and the inserted gene. 
As a first step, the plasmid vector was purified from Novablue transformed cells using 
the QIAprep Spin MiniPrep kit (QIAGEN Ltd, Crawley, UK) following the 
manufacturer’s instructions. Dye terminator sequencing was carried out using the 
BigDye® terminator v. 3.1 cycling kit (Applied Biosystems) and T7 promoter and 
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terminator primers. 10 µL reactions included 0.5x concentrated BigDye® Ready 
Reaction Premix, 0.5x concentrated BigDye® Sequencing buffer, 0.5 µM of one of 
T7 primers and 10-40 µg plasmid DNA. Sequencing reactions were placed in the 
Veriti 96-well thermal cycler and the thermal profile conditions consisted of 25 cycles 
of 96oC for 30 sec, 50oC for 15 sec and 60oC for 4 min. 
Sequencing reactions were purified by ethanol precipitation. 10 µL of water, 5 
µL of 125 mM EDTA and 80 µL of 100% (v/v) ethanol were added sequentially to 
each reaction and the solution was mixed by vortexing and incubated for 1 hr at room 
temperature. Precipitated DNA was recovered by centrifugation at 3,000 x g for 30 
min and incubated with 200 µL of 70% (v/v) ethanol for 5 min at room temperature. 
Following centrifugation at 1,800 x g for 15 min, the ethanol was discarded and DNA 
pellets were dried by centrifugation of the tubes inverted on blotting paper at 900 x g 
for 2 min. Samples were then resuspended in Hi-DiTM formamide buffer (Applied 
Biosystems) and sequencing products were detected using the ABI PRISM® 3130 
Genetic Analyser (Applied Biosystems) following manufacturer’s instructions. 
 
2.15 Expression and purification of recombinant proteins 
Purified plasmid vectors containing the insert of interest were used to 
transform the E coli BL21 (DE3) pLysS expression strain. Transformation, selection 
of positive clones and confirmation of in-frame insertion were again performed as 
described for Novablue cells (sections 2.14.7-9). Large-scale growth of expression 
cells was carried out by inoculation of 100 mL LB broth cultures containing 30 
µg/mL kanamycin and 1% (w/v) glucose and incubation at 37oC. When an O.D. of 0.6 
was reached, expression cell cultures were supplemented with isopropyl β-D-1-
thiogalactopyranoside (IPTG) to a final concentration of 1 mM for induction of 
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protein expression. Cells were left to grow for an additional 2-5 hr and harvested by 
centrifugation at 5,500 x g for 20 min. Pellets were weighed and stored at -70oC until 
further use.  
Proteins were extracted from cells using the BugBuster Protein Extraction 
Reagent following the manufacturer’s instructions. Briefly, cell pellets were 
resuspended at room temperature by gentle vortexing with 1x concentrated BugBuster 
Reagent added at a ratio of 5 mL per gram of wet cell paste. To assist cell lysis, 10 µL 
of Lysonase Bioprocessing Reagent was added per gram of wet cell paste. Following 
addition of protease inhibitors at 1:100 dilution, the suspension was incubated for 20 
min at room temperature with gentle shaking. Soluble proteins were recovered in the 
supernatant following centrifugation at 12,500 x g for 20 min at 4oC and stored at -
20oC prior to purification. 
Recombinant proteins were purified by metal affinity chromatography in 
gravity flow columns using the His-Bind Resin and His-Bind Buffer kit. Appropriate 
volumes of 1x concentrated buffers were prepared according to the manufacturer’s 
instructions. Binding buffer from His-Bind Buffer kit was supplemented with 0.05% 
(w/v) Z3-14 and Wash and Elution Buffers with 0.2% (v/v) Triton X-100 to enhance 
solubility of the proteins in the respective steps. Approximately 6 mL of His-Bind 
Resin corresponding to 3 mL of bed volume were applied to Novagen 
Chromatography Columns, washed with 3 volumes of sterile deionised water, charged 
with 5 volumes of Charge Buffer (50 mM NiSO4) and equilibrated with 3 volumes of 
Binding Buffer (0.5 M NaCl, 5 mM imidazole, 0.05% (w/v) Z3-14, 20 mM Tris-
hydrochloride, pH 7.9). The protein extract was loaded on the column, mixed with 
resin and left for 20 min for affinity binding to occur. Unbound material was washed 
away by the application of 10 volumes of Binding Buffer followed by 6 volumes of 
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Wash Buffer (0.5 M NaCl, 60 mM imidazole, 0.2% (v/v) Triton X-100, 20 mM Tris-
hydrochloride, pH 7.9). His-tag recombinant proteins were eluted with 6 volumes of 
Elution Buffer (0.5 M NaCl, 1 M imidazole, 0.2% (v/v) Triton X-100, 20 mM Tris-
hydrochloride, pH 7.9). Eluted proteins were dialysed against a buffer containing 10 
mM Tris, pH 7.9, 150 mM NaCl and 0.05% (v/v) Triton X-100 to remove imidazole 
using 10 kDa MW cutoff Slide-A-Lyser Dialysis cassettes (Thermo Scientific). 
Dialysed solutions were concentrated by application to Amicon Ultra-15 Centrifugal 
Filter units (Millipore Ltd, Watford, UK) and centrifugation at 4,000 x g for 20 min at 
room temperature. Protein concentrations were calculated using the BCA assay 
(Thermo Scientific). 
 
2.16 Immunisations and immune sera 
Immunisations with the recombinant meningococcal proteins were carried out 
by the Biological Services Department at NIBSC. Groups of 10 female BALB/c mice, 
6-7 weeks old, were immunized on days 1, 21 and 28 by subcutaneous injection of 10 
µg purified protein mixed with the Sigma Adjuvant system (monophosphoryl lipid A, 
MPL) (Sigma-Aldrich). Control mice received MPL in physiological saline. Blood 
was collected on day 35. Animal work was carried out under license by the Home 
Office, United Kingdom. 
Immune sera from OMV vaccines were a gift from Dr E. Wedege following 
immunisations carried out as described (Tsolakos et al., 2010). Briefly, one OMV 
preparation from each growth medium (FM or MC.6M), made by pooling similar 
amounts of protein from each of the 3 batches, was adsorbed to aluminium hydroxide 
adjuvant (Alhydrogel, Superfos Biosector, Copenhagen, Denmark). Groups of 12 
female NMRI mice received 2 doses subcutaneously of 0.5 or 2.0 µg protein of each 
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OMV vaccine 3 weeks apart. Control mice in groups of 6 received physiological 
saline. Blood samples were collected from the mice 2 weeks after the second dose. 
Immune sera from live N. meningitidis were a gift from Dr Y. Li following 
immunisations carried out as previously described (Li et al., 2006). Briefly, groups of 
10 to 15 6-week old female BALB/c mice were immunised on days 1, 21 and 28 by 
intraperitoneal injection of 1 x 106 colony forming units of N. meningitidis MC58 
grown in BHI medium containing 0.5% (v/v) iron dextran (Sigma-Aldrich). Control 
mice were given BHI medium with iron dextran alone. Blood was collected on day 
35. 
 
2.17 Whole-cell ELISA 
Whole-cell enzyme-linked immunosorbent assays (ELISA) were carried out 
using bacteria from MC58 wild-type and ∆-siaD strains. Bacteria from liquid cultures 
were resuspended in PBS containing 0.05% (v/v) Tween-20 and then heat-inactivated 
at 56oC for 30 min. 96-well microtitre plates were coated with approximately 1.5 x 
107 bacteria/well by overnight incubation at 37oC. Serial dilutions of control or 
immune sera in PBS containing 0.5% (w/v) BSA and 0.01% (v/v) Tween-20 were 
added to the wells and incubated at 37oC for 1 hr. Plates were washed with 0.025% 
(v/v) Tween-20 before and after the addition of sera. Binding of antibodies to the 
surface of bacteria was detected with a horseradish peroxidase goat anti-mouse IgG 
diluted 1:2,000. Following a final wash, 3,3’,5,5’ tetramethylbenzidine (Leinco 
Technologies, St Louis, Missouri)  was added for color development and the reaction 
was stopped with the addition of 1 M sulphuric acid. Optical density readings were 
taken at 450 nm. The assay was repeated 3 times and the mean of the reciprocal of the 
Chapter 2 Materials and Methods 
 82
dilution of serum that gave readings 3 times higher than that of negative control sera 
was reported (Li et al., 2006). 
 
2.18 ELISA 
Antibody levels in murine immune sera against OMV vaccine were measured 
as U/mL in microtiter plates. Wells were coated with 100 µL per well of a reference 
44/76 OMV preparation from a FM cultivation in a 50  L fermentor (5 µg protein/mL) 
and developed with alkaline phosphatase anti-mouse IgG conjugate (Sigma-Aldrich) 
(Rosenqvist et al., 1991).  
 
2.19 Complement deposition assay (CDA) 
Complement deposition assays were performed at the Centre for Emergency 
Preparedness and Response, Health Protection Agency, under supervision of Dr S. 
Taylor as described by Pajon et al. (Pajon et al., 2009). Deposition of complement 
factors C3c and C5b-9 on the surface of meningococcal strains was assessed by flow 
cytometry analysis performed in U-bottom 96-well microtitre plates against strains 
shown in Table 2.1. IgG-depleted human plasma was used as complement source. 
Target bacteria grown on brain heart infusion agar plates were inactivated in 0.2% 
(w/v) sodium azide/PMSF and made into suspension with blocking buffer (1% (w/v) 
BSA in PBS) to an O.D. of 0.1 (600 nm). The cell suspension (90 µL) was mixed with 
5 µL of test serum and 5 µL of IgG-depleted human plasma followed by incubation 
for 30 min with shaking at room temperature. Cells were recovered from suspension 
by centrifugation at 3,000 x g for 5 min, washed twice with 200 µL of blocking buffer 
and incubated for 20 min at 4oC with fluorescein isothiocyanate (FITC) labeled sheep 
anti-human C3c and C5b-9 antibodies diluted 1:500 in blocking buffer. Following 
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washing with blocking buffer, cells were analysed in a Beckman Coulter FC500 flow 
cytometer (Beckman Coulter Ltd, High Wycombe, UK). Horizontal gates in the FITC 
channel were set against a no-antibody control to include approximately 10% of the 
population. A total of 7,500 cells were measured for each sample. A fluorescence 
index (FI) was calculated by multiplying the percentage of cells showing FITC 
fluorescence in the appropriate gate (% gated) with the mean fluorescence of the gated 
population. The final FI-C reported values were calculated by subtracting FI of the 
FITC conjugate only control from the FI of each test serum sample. The assay was 
performed in triplicates for each test serum and control samples. 
 
2.20 Opsonophagocytosis assay (OPA) 
Opsonophagocytosis assays were performed at the Centre for Emergency 
Preparedness and Response, Health Protection Agency, under supervision of Dr 
Steven Taylor as described by Findlow et al. (Findlow et al., 2006). 
Opsonophagocytic activity of test sera was assessed by flow cytometry performed in 
U-bottomed 96-well microtitre plates against strains shown in Table 2.1. Bacteria 
from target strains were prestained internally with 10 µg of 2’, 7’-bis-(2-
carboxyethyl)-5-(and -6)-carboxyfluorescein (BCECF) per mL, acetoxymethyl ester 
(Merck Chemicals Ltd, Nottingham, UK) and fixed with 0.2% (w/v) sodium azide for 
48 hrs. Bacteria were then reconstituted in OP buffer made of Hanks balanced salts 
solution containing 2% Marvel skimmed milk powder (Premier International Foods, 
UK), 1.2 mM CaCl2 and 1 mM MgSO4. 10 µL of 6.25 x 10
8 cells per mL were mixed 
with 20 µL of test sera diluted 1:10 in OP buffer and 10 µL of IgG-depleted human 
complement followed by incubation for 7.5 min at 37oC with shaking. 50 µL of HL60 
phagocytic cells at 7.5 x 107 cells per mL in OP buffer, differentiated with 0.8% (v/v) 
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DMF for 5 days prior to use, were added to the mixture followed by incubation for 7.5 
min at 37oC. Flow cytometry analysis was carried out as described for complement 
deposition assay (section 2.19) measuring 7,500 HL60 cells. 
 
2.21 Complement-mediated serum bactericidal assay (SBA) 
The serum bactericidal assay was performed in 96-well microtitre plates 
against serogroup B meningococcal strains H44/76 and MC58 using baby rabbit 
complement. Test sera were diluted to 1:4 in bactericidal buffer made by dissolving 
0.5 g BSA in Geys balanced salt solution and 20 µL were heat-inactivated at 56oC for 
30 min and placed in wells. Freshly grown bacteria from blood agar plates were 
reconstituted in bactericidal buffer to an O.D. of 0.1 and 10 µL of a 1:2,500 dilution 
were deposited in each well. Following addition of 10 µL of active baby rabbit 
complement, 96-well plates were covered and incubated at 37oC for 1 hr. As a 
complement-independent control, heat-inactivated complement was used in wells 
containing test sera, whilst killing due to complement only was assessed by the 
addition of active complement to wells containing bactericidal buffer in the place of 
test sera. Wells containing heat-inactivated complement and bactericidal buffer were 
also included to assess the number of viable cells irrespective of killing (viable cells 
control). Following incubation, 10 µL from each well were plated out using the tilt 
method. Plates were incubated overnight at 37oC. Colonies were counted the next day 
using the Protocol Colony Counter (Synbiosis, Cambridge, UK). Bactericidal titres 
were expressed as the reciprocal of the final dilution giving ≥ 50% killing compared 
to the viable cells control. The assay was considered successful when the percentage 
of killing measured for the other two controls (killing due to complement or sera) was 
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less than 30. For each sample, the assay was performed in duplicates and results from 
two assays run on different days were included in the calculations.  
 
2.22 Cryo-electron microscopy 
Cryo-electron microscopy was performed by Dr K. McLellan at NIBSC. Gold 
quantifoil grids (Agar Scientific, Stansted, UK) were plasma cleaned for 20 seconds 
in a partially shielded custom grid holder (E.A. Fischione Instruments, Inc., Surrey, 
UK) in a 1020 plasma cleaner (E.A. Fischione). Bacterial suspensions from MC58 ∆-
siaD before and after treatment with proteinase K (20 µg/mL per 109 cells) were 
adsorbed onto the grid for 2 min, by floating the grid onto a 50 µL drop of the 
suspension. The grid was transferred into a Leica EM CPC (Leica, Vienna, Austria) 
plunge freezing device trying to transfer the maximal amount of the sample with the 
grid. The grid was blotted to remove excess liquid and was plunged into liquid ethane 
kept at -154°C. The grid was transferred into a Gatan 924 cryo holder (Gatan, 
Pleasanton, U.S.A) at a temperature below -170°C and was rapidly transferred into a 
pre-cooled JEM 2100 TEM (JEOL, Tokyo, Japan). Images were taken with a Gatan 
4K/4K ultrascan CCD camera (Gatan) at a nominal magnification of 15,000 times. 
 
2.23 Bioinformatic analysis 
2.23.1 Sequence assembly and alignments 
The sequences generated from the sequencing reactions of each of the cloned 
genes were assembled using the SeqMan tool of the LaserGene software v.8 
(DNASTAR) and the consensus sequence inferred. Sequences were assessed for in-
frame insertion of the cloned gene and presence of nucleotide substitutions by 
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comparison to the corresponding nucleotide sequences from the MC58 annotated 
genome. 
Sequence alignments were carried out using the MegAlign tool of DNASTAR 
LaserGene 8 software. Sequences were imported in FASTA format and aligned using 
the ClustalW method. During the report of alignments, residues differing from or 
matching to the consensus were highlighted with colours. Missing residues were 
represented by a hyphen. 
 
2.23.2 Analysis of synonymous and non-synonymous substitutions 
Synonymous and non-synonymous substitutions in NmMIP sequences across 
106 meningococcal isolates (Table A1, Appendix) were detected and their rates 
calculated using the Synonymous Non-synonymous Analysis Program (SNAP) 
available at the URL site 
http://www.hiv.lanl.gov/content/sequence/SNAP/SNAP.html (Korber B, 2000). A 
FASTA file of data from all sequences aligned was imported into SNAP and the 
number of synonymous versus non-synonymous substitutions for all pairwise 
sequence comparisons was calculated based on a method by Nei and Gojobori (Nei 
and Gojobori, 1986). These numbers were subsequently compared to the number of 
potential substitutions to infer the proportion of observed substitutions for each 
pairwise comparison. Following corrections for sites with multiple substitutions, the 
average of synonymous (ds) and non-synonymous (dn) substitutions from all pairwise 
comparisons was calculated. The dn/ds ratio was then used to infer the type of 
immune selection imposed to NmMIP. A dn/ds value of > 1 indicated positive 
selection, a value of 1 no selection and a value of < 1 negative selection pressure. 
Using SNAP the rates of synonymous and non-synonymous substitutions per codon 
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across all sequences aligned were also calculated. Codon-by-codon rates were used to 
assess the nature and distribution of changes in the amino acid sequence of NmMIP. 
 
2.23.3 Phylogenetic analysis 
The clonal structure of the nucleotide sequences from meningococcal isolates 
coding for NmMIP was inferred using ClonalFrame (Didelot and Falush, 2007). 
ClonalFrame is developed to assess clonal relationships between isolates of the same 
species that have been formed from point mutations and recombination events using 
data from single DNA fragments to whole genomes. Version 1.2 of ClonalFrame was 
downloaded from the URL site 
http://www.xavierdidelot.xtreemhost.com/clonalframe. Aligned NmMIP nucleotide 
sequences from MegAlign were transformed into FASTA format and imported into 
ClonalFrame. ClonalFrame calculations were performed using default parameters. 
The output file was imported into the Graphical User Interface module of 
ClonalFrame and converted into a Newick file which was then visualised in the 
Molecular Evolutionary and Genetics Analysis (MEGA) software using the radial tree 
view. Version 5.0 of MEGA was downloaded from the URL site 
http://www.megasoftware.net/ (Tamura et al., 2011).  
 
2.23.4 Topology prediction analysis 
The bioinformatics tools used for in silico prediction of sequence features related 
with protein subcellular location included: PsortB v. 3.0 for prediction of subcellular 
protein location in Gram-negative bacteria (http://www.psort.org/) (Yu et al., 2010), 
LipoP v. 1.0 for prediction of lipoprotein motifs 
(http://www.cbs.dtu.dk/services/LipoP/) (Juncker et al., 2003), SignalP v. 3.0 for 
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prediction of signal peptide sequences (http://www.cbs.dtu.dk/services/SignalP/) 
(Bendtsen et al., 2004) and TOPCONS for prediction of membrane protein topology 
(http://topcons.net/) (Bernsel et al., 2009). The amino acid sequence of each protein to 
be tested was acquired in FASTA format from the Uniprot knowledgebase 
(http://www.uniprot.org/) and imported into the relevant prediction tool. Where 
applicable, the setting for Gram-negative bacteria was selected. In SignaP, both 
analysis methods of Hidden Markov model and Neural Networks were performed.  
 
2.23.5 Construction of 3-D structural model 
The 3-D structural view of NmMIP was constructed using SWISS-MODEL, 
available from URL site http://swissmodel.expasy.org. Structural construction was 
carried out in the automated mode of SWISS-MODEL using the amino acid sequence 
of mature NmMIP from MC58 and LpMIP as template. The pdb file generated was 
visualized in DeepView / Swiss PdbViewer software v. 4.01 (downloaded from 
http://spdbv.vital-it.ch/). 
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3. Characterisation of the surface proteome of the serogroup B N. 
meningitidis MC58 strain 
3.1 Introduction 
Where polysaccharide-based vaccines have been introduced against 
meningococcal strains expressing serogroup A, C W-135 and Y capsular 
polysaccharides, serogroup B isolates remain the predominant cause of bacterial 
meningitis and septicaemia (Tan et al., 2010). The poor immunogenicity of serogroup 
B polysaccharide and the possibility that it is an autoantigen mimicking human glycan 
structures has focused attention on subcapsular proteins as alternative vaccines (Devi 
et al., 1997; Finne et al., 1987).  
As for most bacterial pathogens, the bacterial surface of meningococci 
constitutes the main location of immunogenic proteins. Integral outer membrane 
proteins (OMPs) and lipoproteins can extend beyond the surface of the bacterium. As 
a result of their exposure, surface proteins can be recognised as antigens by the host’s 
immune system triggering an adaptive immune response through the production of 
antibody producing B cells (Rijkers et al., 1998; Vos et al., 2000). This acquired 
immunity is mimicked by vaccines containing surface proteins as their antigenic 
components. Any strategy that can specifically identify the surface proteome would 
greatly contribute towards the discovery of potential vaccine candidates. 
Several proteomic strategies have attracted attention as effective ways for the 
identification of bacterial surface proteins (Cordwell, 2006). The aim of these 
strategies is to specifically isolate those proteins that are part of and/or extend beyond 
the outer membrane and identify them by MS analysis. They can broadly be divided 
into two groups: either those that chemically modify proteins on the surface to 
facilitate their purification from the rest of the proteome, or those that use non-
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modifying reagents to extract surface proteins. Compared to genome-wide analysis 
(Pizza et al., 2000), often described by the term reverse vaccinology, these approaches 
can save considerable experimental time on downstream immunological evaluation 
assays by narrowing down analysis to a subset of proteins with vaccine potential. 
They also make no pre-assumptions as to which proteins might be present on the 
bacterial surface. 
Prior to the current study, proteomics has been used to characterise 
meningococcal OMVs as part of the quality assessment of OMV vaccines (Uli et al., 
2006; Vipond et al., 2006). Outer membrane vesicles are rich in OMPs and have been 
considered as a suitable sample for identification of potential surface protein antigens. 
However, the process employed for extraction of OMVs from whole cells can affect 
OMV protein composition. When extraction involves the use of detergents, cytosolic 
proteins can contaminate the sample. Therefore, the presence of a protein in an OMV 
preparation is no guarantee that it is surface-expressed or immunogenic.  
On the basis that cell surface antigens are accessible to proteases, treatment of 
bacteria with proteases provides a means of analysing the bacterial surface proteome. 
Whole bacteria are incubated with a specific protease (e.g. trypsin) and the peptides 
released from digestion of surface-exposed proteins are recovered in the incubation 
buffer (supernatant) and analysed by MS (Figure 3.1B) (Bledi et al., 2003). This type 
of analysis has been used successfully for the identification of potentially protective 
antigens from streptococci (Doro et al., 2009; Rodriguez-Ortega et al., 2006). 
However, the specificity of the method largely depends on retaining the integrity of 
the cells and the treatment conditions (Dreisbach et al., 2010; Tjalsma et al., 2008). 
Contamination of the supernatant with cytoplasmic components is common, 
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especially in the case of Gram negative bacteria (Doro et al., 2009; Walters and 
Mobley, 2009). 
 
Figure 3.1 Bacterial treatment with proteases: analysis strategies for 
identification of surface proteins. A) Whole-cell protein lysates from bacteria 
incubated with or without proteinase K are collected and subjected to 2D-PAGE. 
Images of 2-D gels are compared to detect gel spots disappearing from treated 
samples as a result of cleavage of surface proteins corresponding to these spots. 
Proteinase K-affected protein spots are then excised from 2-D gels of untreated 
samples, digested with trypsin and identified by LC-MS/MS. B) Bacteria are 
incubated with trypsin and the peptide fragments released from digested surface 
proteins are recovered in the supernatant. Peptide fragments are subjected to an 
additional step of trypsin treatment for completion of digestion and analysed by LC-
MS/MS for identification of the digested proteins. 
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In a different strategy that could potentially overcome contamination issues 
following analysis of supernatants, Sabarth et al. compared the proteomes of whole 
bacteria from Helicobacter pylori treated with a less specific protease, such as 
proteinase K, with untreated bacteria by 2D-PAGE (Figure 3.1A) (Sabarth et al., 
2005). Spots disappearing from 2-D gels as a result of digestion of surface proteins 
were detected and proteins identified by MS. 
This chapter describes the application of protease treatment for the 
identification of proteins on the surface of the serogroup B MC58 meningococcal 
strain. Comparison of whole-cell proteomes by 2D-PAGE was used as the main 
strategy for detection of the digested surface proteins. Various additions to the 
original method are described including the adjustment of proteinase K concentration 
and the use of DIGE to quantify differences in the abundance of protein spots between 
treated and untreated samples on 2-D gels. In addition, the peptides released in the 
incubation buffer upon treatment of MC58 with trypsin were identified by LC-
MS/MS analysis.  
 
3.2 Analysis of the effect of proteinase K treatment on the MC58 proteome 
The main strategy for the identification of proteins on the surface of the 
meningococcus was to treat bacteria with proteinase K and analyse the effect on the 
whole-cell proteome. As a first step, the effect of treatment on the total protein 
content and abundance of specific proteins was assessed by SDS-PAGE and western 
blotting and optimal conditions for specific cleavage of surface proteins were 
established. Subsequent proteomic analysis included: a) quantitative comparison of 
the proteome of treated and untreated meningococci by DIGE for the detection of gel 
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spots with changes in abundance and b) mass spectrometric analysis of the gel spots 
for protein identification. 
  
3.2.1 SDS-PAGE and western blotting 
The capsule-deficient derivative of MC58 was incubated with proteinase K at 
concentrations of 1.25, 2.5, 5, 10, 20, 40 and 80 µg/mL per 109 bacteria as described 
in section 2.3. An untreated control sample from bacteria incubated without addition 
of proteinase K was also prepared. Whole-cell protein extracts were separated on 12% 
acrylamide gels and visualised by fluorescent staining using Sypro Ruby. Similar total 
protein profiles were observed between the untreated sample and those treated with 
concentrations of up to 20 µg/mL. For concentrations of 40 µg/mL or higher, 
extensive loss of proteins of high molecular weight was observed (Figure 3.2).  
The effect of treatment on the abundance of specific proteins was assessed 
following transfer of protein extracts separated by SDS-PAGE to PVDF membranes 
and blotting with appropriate antibodies (Figure 3.3). The outer membrane porin PorA 
was used as marker for surface-exposed proteins. PorB, an outer membrane porin 
which is protease-resistant in live, intact cells (Minetti et al., 1998), and two 
autofluorescent proteins present in blots (one identified as the predicted inner 
membrane-associated protein cytochrome c5, data presented in Table A2, Appendix) 
were used to assess cell integrity. Complete cleavage of PorA was detected following 
incubation at proteinase K concentrations as low as 5 µg/mL. In contrast, PorB and 
the autofluorescent proteins remained unaffected by concentrations of up to 20 
µg/mL. Consistent with results from SDS-PAGE, some cleavage of the PorB and 
autofluorescent proteins was observed at the two highest concentrations tested. When 
lysed meningococci were subjected to proteinase K treatment, the same proteins were 
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Proteinase K concentration  
(µg/mL) per 109 bacteria 
shown to be completely digested indicating they were not resistant to proteolytic 
cleavage under the conditions used (Figure 3.3, right panel). 
 
 
 
Figure 3.2 SDS-PAGE of protein extracts from meningococci treated with 
various concentrations of proteinase K. Protein extracts collected from bacteria 
were incubated with proteinase K at concentrations ranging from 0 to 80 µg/mL (per 
109 bacteria) and separated on a 12% polyacrylamide gel. 25 µg of protein were 
loaded on each lane, separated by electrophoresis for 4 hr and stained with Sypro 
Ruby fluorescent stain. Horizontal numbers correspond to proteinase K 
concentrations. M: Wide-range MW reference protein marker (SigmaMarker™, 
Sigma-Aldrich). The MW (in kDa) of bands of the protein marker is shown on the 
left. 
 
To further assess cell integrity during protease treatment, bacteria treated with 
20 µg/mL of proteinase K were examined by cryo-electron microscopy and images 
were compared to those obtained from untreated bacteria. A representative image of a 
diplococcus before and after treatment is shown in Figure 3.4. There were no 
differences in the morphology and integrity of cells between treated and untreated 
bacteria. From images acquired from both samples, a limited number of dead cells 
116 
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84 
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55 
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36 
29 
24 
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was detected. However, the proportion of dead cells could not be accurately 
calculated and compared between the two samples owing to the tendency of 
meningococci to clump. 
 
 
Figure 3.3 Effect of proteinase K treatment on specific proteins. Protein extracts 
from intact (left) or lysed (right) meningococci treated with various concentrations of 
proteinase K were separated on 12% polyacrylamide gels, transferred to PVDF 
membranes and either scanned directly for detection of autofluorescent proteins AF1 
and AF2 or blotted with anti-PorA or anti-PorB monoclonal antibodies to detect PorA 
and PorB. A Cy5-conjugated goat anti-mouse IgG was used for detection of antibody 
binding. AF2 was identified as cytochrome c5 (Table A2, Appendix). 
 
Figure 3.4 Cryo-electron microscopy of meningococci. Bacteria before (left) and 
after (right) digestion with 20 µg/mL proteinase K. 
 
aPorA 
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proteinase K concentration 
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3.2.2 DIGE 
Although used to assess total protein content from proteinase K-treated 
meningococci, SDS-PAGE lacks the resolving power to separate proteomes enough to 
allow for differences in protein abundance upon treatment to be detected. Two-
dimensional DIGE was instead used which combines high resolution of protein 
separation with fluorescence labelling technology for the quantitative comparison of 
proteomes. In 2-D gels, protein spots representing the intact form of surface proteins 
might be expected to show a decrease in abundance or disappear from gels of treated 
samples. Also, new spots corresponding to protein fragments retained in the cell wall 
upon treatment could potentially be formed and detected by a marked increase in 
abundance. 
Figure 3.5 summarises the DIGE analysis of proteinase K-treated 
meningococci. Aliquots of approximately 12 × 109 bacteria were incubated with 
proteinase K at concentrations ranging from 0 to 20 µg/mL. A total of 3 samples per 
proteinase K concentration were generated from 3 bacterial liquid cultures. Protein 
lysates from whole cells from each sample were labeled with IC5 fluorescent dye, 
mixed with IC3-labeled internal standard and separated on 2-D gels. A total of 18 2-D 
gels were run and generated 18 sample images, each accompanied by an internal 
standard image. Representative images of 2-D separation of meningococcal 
proteomes from treated and untreated bacteria are shown in Figure 3.6. 
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Figure 3.5 DIGE analysis of whole-cell lysates from meningococci treated with 
increasing concentrations of proteinase K. Aliquots from each of three bacterial 
cultures were incubated with proteinase K, each at a different concentration. The 
concentrations used were 1.25, 2.5, 5, 10 and 20 µg/mL per 109 bacteria. Untreated 
samples (0.0) were also prepared from bacterial cultures. A total of three samples per 
concentration were generated. Protein lysates from each sample were collected, 
labelled with IC5 fluorescent dye, mixed with equal amount of an IC3-labelled 
internal standard made up of all samples prepared and subjected to 2D-PAGE. Images 
from treated samples were grouped and compared to the untreated group for 
identification of protein spots with a significant change in abundance across all treated 
groups.  
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Figure 3.6 Representative images of 2D-PAGE of proteins from N. meningitidis 
MC58 ∆-siaD. Proteins from untreated meningococci (A) and meningococci treated 
with proteinase K (B) were separated by pI using IEF of IPG strips, pH 3-11 and 
subsequently by MW in 12% polyacrylamide gels. The spots exhibiting decreased 
abundance as a result of proteinase K treatment of meningococci are highlighted in 
(A) (numbers 1-37). New spots are highlighted in (B) (numbers 38-42). Quantitation 
was carried out using DeCyder differential analysis software and spots with consistent 
difference in abundance between untreated and treated samples are reported (P-value 
< 0.05). 
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Images were imported into DeCyder differential analysis software and 
grouped into 6 groups according to the proteinase K concentrations used during 
treatment. Five hundred and forty one protein spots were matched and their 
fluorescence intensities compared across the different sample groups. The number of 
spots with a significant decrease (P-value < 0.05) in each treated group compared to 
the untreated group are presented in Table 3.1.  
 
Table 3.1 Total number of spots showing changes in abundance upon treatment 
of N. meningitidis ∆-siaD strain with proteinase K. Fluorescence intensities 
measured for each spot in each treated group were compared against those from the 
untreated group. Spots with a significant decrease or increase in abundance (P-value < 
0.05) were chosen for further analysis. 
 
 Proteinase K concentration (µg/mL per 10
9
 bacteria) 
 1.25 2.5 5
 
10 20
 
Decreased 53 56 52 45 55 
Increased 13 12 14 10 8 
 
 
Of the protein spots with an observed decrease in abundance in 1 or more 
treated groups, 37 were consistent across all treated groups, indicating the proteolytic 
cleavage of the corresponding intact proteins. Figure 3.6A indicates the position of 
these spots on the 2-D gel image. Proteinase K-affected protein spots were found in 
both the acidic and basic regions of the gels and varied in MW. The exact values of 
decrease for each protein spot across treated groups are presented in the Appendix 
(Table A3, spots 1-37). Values of decrease were expressed as the average ratio of the 
calculated standardised abundance in each treated group against that from the 
untreated group. Values of decrease in abundance varied from very high (30-fold) to 
very low (1.2-fold or 20%) across protein spots indicating different degrees of 
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cleavage. Spots 1, 2, 3, 5, 6, 7, 8, 9, 14 and 19 exhibited the greatest decrease (> 2.5-
fold). For the rest of the proteinase K-affected spots, the decrease was generally 
between 1.5 and 2-fold. Plots of the standardized abundance against proteinase K 
concentration were generated for each of the 37 spots. These plots are presented 
collectively in the Appendix (Figure A2) and as separate plots in section 3.2.4 in 
relation to the results from protein identification. In general, plots indicated that 
different proteins decreased at different proteinase K concentrations and to a different 
extent. 
Five new spots with consistently increased abundance across treated samples 
were also detected corresponding to fragments of proteins digested by proteinase K. 
Their position on 2-D gels is indicated in Figure 3.6B and exact values of increase 
across sample groups are presented in the Appendix (Table A3, spots 38-42). Spots 39 
and 41 exhibited the highest increase which gradually declined with increasing 
concentrations of proteinase K. In contrast, the increase in abundance of spot 42 
followed the increase in proteinase K concentration. 
 
3.2.3 Identification of proteinase K-affected proteins by LC MS/MS 
Twenty-six of the protein spots with decreased abundance and the 5 new spots 
detected in gels upon proteinase K treatment were analysed by LC-MS/MS. 
Preparative gels from untreated samples were used to pick spots of decreased 
abundance. Conversely, new spots formed were picked from gels of treated samples. 
For each spot, 2 samples from 2 independent gels were prepared and analysed and 
only proteins reproducibly identified in both samples are reported. A total of 24 
proteins were unambiguously identified and are presented in Table 3.2 together with 
information on the spots of origin and MS analysis. 
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Of the identified proteins, PorA, Omp85, pilin PilE, the amino-acid ABC 
transporter NMB1612 and NmMIP were detected in multiple spots of similar MW 
and different pI. A single protein was identified in each of 20 spots. With the 
exception of H.8 and fHbp, the position of these spots on the gel was consistent with 
the predicted pI and MW of the corresponding proteins identified by MS. The H.8 
protein (spot 20) migrated with a higher MW than calculated from its amino acid 
sequence. Conversely, the fHbp (spot 19) migrated with a lower than expected MW.  
Two or more proteins were identified in each of 6 spots. Specifically, spots 7, 
21, 24 and 26 contained 2 and spots 4 and 13, 3 co-migrating proteins. For these 
spots, differences were observed in the number of peptides matched to each protein. 
These differences are likely to be associated with differences in protein abundance on 
the spot. In general, the increased amount of a protein increases the chances of 
identifying more peptides.  PorA, ABC transporters NMB0462 and NMB1612 and 
PilO were identified by the highest number of peptides in spots 7, 4, 13 and 21, 
respectively, and were probably the most abundant proteins in these spots. In contrast, 
proteins H.8 and NMB1468 identified in spot 24 and PilE and 30S ribosomal protein 
S5 identified in spot 26 were represented by similar amounts. 
 
3.2.4 Detailed DIGE results of identified proteins 
As mentioned in section 3.2.2, the decrease in abundance resulting from 
proteinase K treatment varied between proteins. How this related to the extent of 
proteolytic cleavage is presented in Table 3.3, which shows a 3-D view of the trace of 
each affected protein spot before and after treatment, in relation to the calculated fold 
decrease values. Spots exhibiting a decrease in abundance greater than 3.5-fold were 
shown to almost disappear from the gels, an indication of almost complete proteolytic 
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cleavage. In contrast, spots with low decrease values, falling below 2.6-fold, 
corresponded to partially cleaved proteins.  
Proteins that were completely cleaved included PorA (spots 5, 6, 7, 8, and 9), 
OpcA (spot 14) and fHbp (spot 19). Based on the abundance profiles (Figure 3.7), the 
amount of proteinase K needed for the maximum cleavage to be achieved varied and 
could be linked to the expression level of each protein (as inferred by the size of the 
spot as seen in Figure 3.6) Highly abundant PorA and OpcA required proteinase K 
concentrations of at least 5 µg/mL to be completely digested whilst fHbp, which is 
expressed at lower levels was completely digested by 1.25 µg/mL.  
Of the proteins that were only partially cleaved, Omp85 (spots 1 and 2), fadL-
like NMB0088 (spot 3) and OpcA spot 15 decreased the most. Their abundance 
profiles also showed gradual decrease with increasing proteinase K concentration. The 
remainder, including NMB1946, H.8, NmMIP, NMB1468, PilP, PilO, ABC 
transporters NMB0462, NMB1612 and NMB0787 and thiol-disulfide interchange 
protein DsbA2, decreased less and there was no correlation with their relative levels 
of expression. These proteins had similar abundance profiles that did not alter 
significantly upon increase in the concentration of proteinase K (Figure 3.7). 
Total cleavage was observed for all spots identified as PorA but the values of 
decrease in abundance differed. Specifically, PorA spots 8, 9, 7 and 6 exhibited a 
decrease of up to 30.72, 13.72, 12.36 and 3.69-fold, respectively. More marked 
decreases might also be associated with higher expression levels as inferred by spot 
size (Figure 3.6). Similarly, OpcA spots 14 and 15 had markedly different fold 
decrease values (14.37 and 2.37, respectively), which might correspond to different 
degrees of cleavage since the size of the 2 spots was similar. 
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Table 3.3 Extent of proteolytic cleavage of surface proteins. The degree of 
cleavage of the proteinase K-digested surface proteins was assessed by analysis of the 
3-D views of the corresponding gel spots from untreated and treated samples. Three-
dimensional spot views were generated using DeCyder software. The highest fold-
values of decrease measured per spot are also shown. 
 
Protein name 
Spot 
number 
Fold-
decrease 
3-D spot views  
(untreated – treated) 
Completely cleaved proteins 
PorA 
6 3.69 
 
7 12.36 
 
8 30.72 
 
9 13.72 
 
OpcA 14 14.37 
 
fHbp 19 4.02 
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Protein name 
Spot 
number 
Fold-
decrease 
3-D spot views  
(untreated – treated) 
Partially cleaved proteins 
Omp85 
1 2.31 
 
2 2.61 
 
OpcA 15 2.37 
 
fadL-like 
NMB0088 
3 2.3 
 
NmMIP 
11 1.91 
 
10 1.41 
 
NMB1468 26 1.89 
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Protein name 
Spot 
number 
Fold-
decrease 
3-D spot views  
(untreated – treated) 
Partially cleaved proteins 
DsbA2 17 1.95 
 
Lipoprotein 
NMB1946 
12 1.85 
 
NMB1612 
13 1.67 
 
16 2.17 
 
NMB0787 18 1.52 
 
H.8 20 1.59 
 
PilP 22 1.57 
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Protein name 
Spot 
number 
Fold-
decrease 
3-D spot views  
(untreated – treated) 
Partially cleaved proteins 
PilO 21 1.58 
 
Spermidine / 
putrescine ABC 
transporter 
4 1.6 
 
Bacterioferritin 
A 
25 1.74 
 
PilE 
23 1.23 
 
24 1.2 
 
Chapter 3 Characterisation of the surface proteome of the MC58 strain 
 111
  
PorA
0
2
4
6
8
0 1.25 2.5 5 10 20
9
8
7
6
Completely cleaved proteins 
OpcA (14)
0
2
4
6
8
0 1.25 2.5 5 10 20
fHbp
0
1
2
3
4
0 1.25 2.5 5 10 20
Partially cleaved proteins 
Omp85
0
1
2
3
4
0 1.25 2.5 5 10 20
1
2
fadL-like NMB0088
0
1
2
3
4
0 1.25 2.5 5 10 20
OpcA (15)
0
1
2
3
4
0 1.25 2.5 5 10 20
NmMIP
0
1
2
3
4
0 1.25 2.5 5 10 20
10
11
Lipoprotein NMB1946
0
1
2
3
4
0 1.25 2.5 5 10 20
NMB1468
0
1
2
3
4
0 1.25 2.5 5 10 20
Proteinase K concentration (µg/mL) 
S
ta
n
d
a
rd
is
ed
 a
b
u
n
d
a
n
ce
 
Chapter 3 Characterisation of the surface proteome of the MC58 strain 
 112
Figure 3.7 DIGE abundance profiles of identified proteins. Mean abundance 
values calculated for each protein spot using DeCyder software were plotted against 
the concentration of proteinase K used during treatment of bacteria. Error bars show 
the standard deviation of the values calculated from triplicates for each concentration. 
Spot numbers correspond to those in Figure 3.6. 
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3.2.5 Prediction of cellular location of proteins cleaved by proteinase K  
Proteins digested by proteinase K were sorted according to their predicted 
location in the meningococcal cell (Table 3.4). Predictions for proteins of the outer 
and inner membrane, cytoplasm, periplasm and extracellular space (secreted) were 
based on PsortB algorithm (Yu et al., 2010). LipoP, which is not part of PsortB 
analysis, was used to detect proteins with a lipoprotein motif recognized by signal 
peptidase II (grouped as lipoproteins in Table 3.4) (Juncker et al., 2003).  
Four outer membrane and 9 lipoprotein-predicted proteins were identified in a 
total of 24 proteins. Outer membrane proteins included PorA, OpcA, Omp85 and 
FadL-like protein NMB0088. Among predicted lipoproteins were factor H-binding 
protein, NmMIP, amino acid-binding ABC transporter proteins encoded by 
NMB0787 and NMB1612, H.8, PilP, thiol-disulfide interchange protein DsbA2, and 
proteins encoded by NMB1946 and NMB1468. PilE was predicted to be secreted into 
the extracellular space, PilO to be part of the inner membrane and the 
spermidine/putrescine ABC transporter protein encoded by NMB0462 to reside in the 
periplasmic space. Proteins RecA, bacterioferritin A, succinyl-CoA ligase [ADP-
forming] subunit beta, thiazole synthase, 30S ribosomal protein S5 and arginine 
biosynthesis bifunctional protein ArgJ were predicted to function in the cytoplasm. 
Finally, no conclusion could be made for the cellular location of 2 proteins, namely 
UbiH family protein and the protein encoded by NMB0478. UbiH was found to 
contain a signal peptide sequence suggesting it is not retained in the cytoplasm. No 
particular features regarding the subcellular location of protein NMB0478 were 
predicted. 
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Table 3.4 Prediction of cellular location of proteins cleaved by proteinase K. 
Proteins were classified into outer membrane, extracellular, inner membrane, 
periplasmic and cytoplasmic based on PsortB algorithm. Lipoproteins were predicted 
using LipoP algorithm. The location of proteins for which no conclusive prediction 
could be made was assigned as unknown. 
 
Cellular location
 
Protein name 
Outer membrane PorA 
 OpcA 
 Omp85 
 FadL-like protein NMB0088 
  
Extracellular PilE 
  
Lipoproteins Outer membrane lipoprotein NMB1946 
 Factor H binding protein 
 
Probable FKBP-type peptidyl-prolyl cis-trans isomerase 
(macrophage infectivity potentiator) 
 Thiol-disulfide interchange protein DsbA2 
 
Amino acid ABC transporter, periplasmic  amino-acid binding 
protein NMB0787 
 Putative uncharacterized protein NMB1468 
 PilP 
 
Amino acid ABC transporter, periplasmic  amino-acid binding 
protein NMB1612 
 Outer membrane protein H.8 
  
Inner membrane PilO 
  
Periplasmic Spermidine/putrescine ABC transporter NMB0462 
  
Unknown Putative uncharacterized protein NMB0478 
 UbiH family protein 
  
Cytoplasmic Succinyl-CoA ligase [ADP-forming] subunit beta 
 Protein recA 
 Bacterioferritin A 
 30S ribosomal protein S5 
 Arginine biosynthesis bifunctional protein ArgJ 
 Thiazole synthase 
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3.3 Comparison of the expression levels of proteins digested by proteinase K 
between wild-type and ∆-siaD MC58 strains. 
Protein expression levels can be critical for binding of antibodies on the 
bacterial surface and hence for the protective effect and vaccine potential of an 
antigen. Here, the proteins of the capsule-deficient ∆-siaD MC58 digested by 
proteinase K were investigated for their presence and relative expression levels in the 
wild type homologous strain. The whole-cell proteomes of ∆-siaD and wild type 
MC58 were compared by DIGE using the experimental design presented in Table 3.5. 
Triplicates of whole-cell lysates from the different strains were prepared and labelled 
with Cy5. An internal standard made up of the samples to be analysed was labelled 
with Cy3 and mixed with each of the Cy5-labelled samples prior to 2D-PAGE. A total 
of 6 2-D gels were prepared and the images imported in DeCyder for spot matching 
and relative quantitation. The exact position of protein spots digested by proteinase K 
in images from this DIGE experiment was confirmed by matching to the master image 
from the DIGE analysis of surface proteome (shown in Figure 3.6). 
 
Table 3.5 Experimental design of DIGE comparison of proteomes from wild type 
and ∆-siaD MC58. Different batches were prepared from independent cell cultures of 
the corresponding strain. The internal standard was made from pooling equal amounts 
of each of the 6 samples compared. 
 
Gel No Cy3 label (50 µg) Cy5 label (50 µg) 
1 Pooled internal standard wild type batch 1 
2 Pooled internal standard wild type batch 2 
3 Pooled internal standard wild type batch 3 
4 Pooled internal standard ∆-siaD batch 1 
5 Pooled internal standard ∆-siaD batch 2 
6 Pooled internal standard ∆-siaD batch 3 
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Table 3.6 lists the proteins digested by proteinase K exhibiting a significant 
difference in expression levels between ∆-siaD and wild-type MC58 strains (P-value 
< 0.05). Factor H-binding protein and a spot corresponding to Omp85 showed 
decreased expression in ∆-siaD MC58. In contrast, amino acid binding protein 
NMB0787, OpcA, one PorA and one Omp85 spot exhibited decreased expression in 
wild-type MC58. The remaining proteins digested by proteinase K were expressed at 
similar levels in the two strains. 
 
Table 3.6 Proteins digested by proteinase K with significantly altered expression 
in ∆-siaD compared to wild-type MC58 (P-value < 0.05, n=3). 
 
Protein name
 
Spot No.
a
 
Fold 
difference 
P-value 
Decreased expression in ∆-siaD 
Omp85 1 -1.68 0.0018 
Factor H-binding protein 19 -1.75 0.0017 
    
Increased expression in ∆-siaD 
Omp85 2 4.34 2.6e-04 
PorA 9 6.85 2.3e-04 
OpcA 14 1.55 0.037 
OpcA 15 1.5 0.044 
Amino acid binding 
protein NMB0787 
18 2.5 0.0019 
a As in Figure 3.6. 
3.4 Analysis of peptides recovered in the supernatant following treatment of 
meningococci with trypsin 
As a complementary strategy to identify the proteins digested upon treatment 
of whole meningococci with proteases, the peptides recovered in the incubation buffer 
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(cell-free supernatant) were directly analysed by LC MS/MS. Trypsin was used in 
place of proteinase K to facilitate generation of peptides that favour identification by 
MS. Same treatment conditions to those of proteinase K treatment were used and 
trypsin concentrations ranged from 1.25 to 20 µg/mL. Triplicate samples from 3 
independent bacterial cultures were generated for each trypsin concentration used. 
Upon collection, supernatants were subjected to a second round of overnight trypsin 
digestion to ensure complete digestion of large peptide fragments. Supernatants 
collected before and after incubation of cells for 45 min with no protease added were 
used as controls (termed pre- and post-incubation control, respectively). The proteins 
identified in each sample by two or more peptides meeting the MS searching criteria 
(see Methods section 2.13.2) are shown in the Appendix (Table A4).  
A total of 118 proteins were identified. The number of proteins identified per 
sample varied as did the number of peptides detected for each protein across different 
samples. Thirty-four proteins were unique to samples treated with trypsin and were 
termed protease-specific. For most protease-specific proteins, identification was not 
consistent across samples treated with different concentrations of trypsin. The 
remaining 84 proteins included proteins identified in both controls and treated 
samples and were termed non protease-specific. 
Predictions on the subcellular location of the proteins identified were 
performed using PsortB and LipoP algorithms and results are presented in the 
Appendix (Table A4). The predicted cellular distribution of proteins from each 
category is shown in Table 3.7. The majority of both non specific and specific 
proteins were predicted to function in the cytoplasm. 
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Table 3.7 Subcellular distribution of proteins identified in the incubation buffer 
of trypsin-treated meningococci 
 
Subcellular location Non-protease specific Protease specific 
Cytoplasm 67 26 
Inner membrane 3 1 
Periplasm 1 - 
Outer membrane 1 3 
Lipoproteins 1 3 
Extracellular 1 1 
Unknown 10 0 
Total 84 34 
 
3.5 Discussion 
This chapter presented analyses of the meningococcal proteome for 
identification of potentially surface-exposed proteins that hold promise as vaccine 
candidates. Although a considerable number of surface protein antigens have been 
identified based on in silico analysis of the meningococcal proteome (Pajon et al., 
2009; Pizza et al., 2000), no proteomic studies specifically investigating the 
meningococcal surface subproteome have been reported. The method used in this 
study included the digestion of proteins in situ in whole bacteria by proteolytic 
enzymes followed by proteomic analysis of the resulting cell extracts and cell-free 
supernatants. Protease treatment provides a physical way to analyse the proteins that 
are exposed on the cell surface. Its specificity is mainly dependent upon the nature of 
the protein itself, in this case the exposure of protease cleavage sites on the bacterial 
surface. 
Previous reports of protease treatment of bacterial proteins have highlighted 
the need for careful choice of treatment conditions to maximise cleavage of surface 
proteins without compromising cell integrity (Dreisbach et al., 2010; Tjalsma et al., 
2008). For encapsulated bacteria like the meningococcus, the thickness of the capsular 
Chapter 3 Characterisation of the surface proteome of the MC58 strain 
 119
polysaccharide on the cell surface may affect the accessibility of antigenic proteins to 
other proteins such as proteases and antibodies. It may, for example, explain apparent 
differences in the exposure of neisserial surface protein A (NspA) (Moe et al., 1999a). 
Non-encapsulated strains offer a way of circumventing this problem and have been 
used in studies with streptococci (Rodriguez-Ortega et al., 2006). The current study 
used a siaD, capsule-deficient, derivative of the serogroup B meningococcal strain 
MC58. 
From analysis of total protein content and abundance of specific proteins with 
SDS-PAGE and western blotting, it was demonstrated that treatment can be specific 
to surface proteins when proteinase K is used at concentrations of up to 20 µg/mL per 
109 bacteria. Under these conditions, bacteria remained intact and any changes in 
protein abundance could be attributed to the effect of proteinase K. Limited cell lysis 
was also observed based on microscopic analysis of meningococci but was 
independent of proteinase K treatment. A limited number of dead or dying cells would 
be expected within a bacterial population harvested at the late exponential phase. The 
time lapsed between cell harvest and analysis on the microscope might have also 
contributed to this. 
The results from DIGE suggest that combining proteinase K treatment of 
whole cells with comparison of proteomes between treated and untreated cells is an 
effective way of distinguishing potential surface antigens within the meningococcal 
proteome. Twenty-three of the 26 spots that were analysed (88.5%) contained proteins 
that could be potentially found on the meningococcal surface based on their predicted 
cellular location. These included 4 outer membrane proteins, 9 lipoproteins and 1 
secreted protein. Experimental evidence exists for the surface exposure and 
antigenicity of the majority of these proteins including OMPs PorA, OpcA, Omp85 
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and FadL-like NMB0088, lipoproteins fHbp, NMB1946, H.8, thiol-disulfide 
interchange protein DsbA2, amino acid ABC transporter NMB0787 and 
uncharacterized protein NMB1468 and the extracellular protein PilE (summarized in 
Table 3.8).  
The meningococcal porin PorA and the adhesin OpcA are 2 highly expressed 
outer membrane proteins with multiple extensive loops exposed on the bacterial 
surface (Tsai et al., 1981). PorA and OpcA are the dominant antigens in OMV 
vaccines and the main targets of human immune responses as suggested by analysis of 
sera from human vaccinees (Wedege et al., 2007). Omp85 is another outer membrane-
embedded protein forming a beta barrel-like channel for lipid transport and 
contributing to the assembly of other beta barrel OMPs in the meningococcus 
(Voulhoux et al., 2003). Its susceptibility to proteolytic cleavage has been previously 
reported following treatment of cell envelopes with trypsin (Robert et al., 2006). 
Omp85-specific antibodies have been identified in sera from humans vaccinated with 
OMVs suggesting Omp85 contributes to immune responses (Wedege et al., 2007). Its 
essential role in bacterial survival also suggests that Omp85 must be a conserved 
antigen across the meningococcal population. NMB0088 is an OMP sharing 
homology with FadL proteins involved in transport of hydrophobic molecules. 
NMB0088 has been suggested to contain 3 variable regions located in extracellular 
domains (Yero et al., 2010). NMB0088 was able to induce bactericidal antibodies in 
mice (Sardinas et al., 2009). PilE is the major pilin of tfp which extends beyond the 
meningococcal outer membrane facilitating adhesion to human epithelial cells 
(Pelicic, 2008). Anti-PilE antibodies have been found in acute and convalescent sera 
from patients (Poolman et al., 1983).  
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Table 3.8 Known surface-exposed proteins identified folowing proteinase K 
treatment of meningococci. Information on the antigenic properties of the proteins is 
presented. 
 
Protein name 
Determination of surface 
exposure 
Antigenic properties 
PorA 
Analysis of variable, exposed 
loops 
Flow cytometry 
Induces bactericidal 
antibodies in mice and 
humans 
OpcA Structural analysis 
Induces bactericidal 
antibodies in mice and 
humans 
Omp85 Structural analysis 
Induces bactericidal 
antibodies in mice and 
humans 
fadL-like NMB0088 Flow cytometry 
Induces bactericidal 
antibodies in mice 
PilE Functional analysis, microscopy 
Induces immune response 
in humans 
Factor H binding 
protein 
Sructural analysis, flow 
cytometry 
Induces bactericidal 
antibodies in mice and 
humans 
NMB1946 Flow cytometry 
Induces bactericidal 
antibodies in mice 
Thiol disulphide 
interchange proteins 
DsbA2 
Flow cytometry Not determined 
NMB1468 Flow cytometry 
Protects mice from lethal 
challenge with live 
meningococci 
ABC transporter 
NMB0787 
Flow cytometry 
Does not induce 
bactericidal antibodies in 
mice 
H.8 Immunogold labelling 
Does not induce 
bactericidal antibodies in 
mice. Blocks bactericidal 
acitivity of antibodies 
against other antigens 
 
Factor H-binding protein is a fully exposed lipoprotein found on the surface of 
the majority of invasive serogroup B meningococcal strains. Antibodies against fHbp 
are bactericidal in mice and humans and are also present in healthy carriers and 
convalescing patients (Litt et al., 2004; Masignani et al., 2003). Factor H-binding 
protein is a promising vaccine candidate currently undergoing clinical evaluation 
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alone or as part of a multi-protein vaccine preparation (Giuliani et al., 2006). Using 
flow cytometry to assess binding of protein specific antibodies on the surface of live 
meningococci, exposure of predicted lipoproteins NMB1946, thiol-disulfide 
interchange protein DsbA2, amino acid ABC transporter NMB0787 and NMB1468 
has been demonstrated (Ferrari et al., 2006; Grifantini et al., 2002b; Hsu et al., 2008; 
Pizza et al., 2000). NMB1946 and NMB1468 have also been shown to protect against 
meningococcal disease in mice (Hsu et al., 2008; Pizza et al., 2000). In contrast, 
amino acid ABC transporter NMB0787 reportedly failed to elicit bactericidal 
antibodies in mice (Grifantini et al., 2002b). Finally, H.8 is another example of a 
meningococcal lipoprotein. The surface exposure of the gonococcal H.8 homologue 
has been studied using anti-H.8 sera in immunogold labelling experiments (Hitchcock 
et al., 1985). Antibodies directed against H.8 were not bactericidal in mice and were 
recently shown to block bactericidal activity of human sera or antibodies against other 
meningococcal antigens (Bhattacharjee et al., 1990; Ray et al., 2011). 
Little information exists on the cellular location and immunogenicity of the 
remaining proteins identified by DIGE analysis. Among proteins that warrant further 
investigation, the macrophage infectivity potentiator NmMIP, PilP, amino acid 
binding protein NMB1612 and PilO are of particular interest as judged by their 
predicted cellular location and function. NmMIP is a predicted lipoprotein bearing a 
palmitate group and belongs to the family of peptidyl-prolyl cis-trans isomerases that 
contribute to protein folding. Members of this family constitute virulence factors in 
other bacteria by initiating infection of macrophages (Cianciotto and Fields, 1992; 
Fischer et al., 1992). The gonococcal homologue NgMIP is surface-exposed and 
promotes gonococcal survival in macrophages (Leuzzi et al., 2005). The amino acid 
binding protein NMB1612 is also a predicted lipoprotein and a member of the family 
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of ABC transporters with a putative role in the transport of amino acids across the 
bacterial cell wall. NMB1612 was recently identified as a target of the human immune 
system as inferred by analysis of sera from colonised subjects (Williams et al., 2009). 
PilP is a lipoprotein involved in biogenesis of type IV pili, the structures that facilitate 
meningococcal adherence to human epithelial cells (Drake and Koomey, 1995). PilP 
was also suggested to mediate processes of pilus motility through its interaction with 
the secretin PilQ (Balasingham et al., 2007). PilO, predicted to reside in the inner 
membrane, is also required for tfp expression (Drake et al., 1997). The gene encoding 
PilO was upregulated during interaction of MC58 ∆-siaD meningococci with 
epithelial HEp-2 cells (Dietrich et al., 2003) suggesting a putative role in adhesion 
and colonisation processes. 
Among the proteins identified by MS analysis were 6 proteins predicted to 
function in the cytoplasm. With the exception of bacterioferritin A, these proteins 
were found in spots containing other non-cytoplasmic proteins which were more 
likely targets of proteinase K. Therefore, it is suggested that the identification of these 
cytoplasmic proteins is more a result of their co-migration in the same spot with 
proteins sharing the same pI and MW and not their exposure on the surface.  
As well as identifying surface proteins affected by proteinase K treatment on 
the meningococcal surface, results from DIGE analysis of cell extracts provided 
evidence for the extent of this effect on each protein. The presence of groups of 
completely and partially digested proteins could be inferred by the traces of proteins 
on 2-D gels and the values of decrease in abundance. Complete digestion of PorA, 
OpcA and fHbp confirmed their extensive exposure on the meningococcal surface 
which is also responsible for their immunodominance (Mascioni et al., 2008; Prince et 
al., 2002; van der Ley et al., 1991). What caused the partial digestion of the rest of 
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identified proteins could be a result of partial surface exposure or weak accessibility 
to proteases or a combination of both. Accessibility of proteases to some surface 
proteins can indeed be hindered by factors including other surface structures of 
topological relationship (Bunikis and Barbour, 1999; Waldemarsson et al., 2006). As 
an example, in the outer membrane of Borrelia burgdorferi protein P66 was masked 
by members of the Osp lipoproteins and could not be accessed by trypsin (Bunikis et 
al., 1999). Uneven distribution of these structures on the bacterial surface could be 
accused for the non-uniform cleavage of meningococcal proteins observed. Partial 
exposure can be expected when proteins function in multiple locations on the cell. In 
this case, only part of their population would be exposed on the surface at any given 
point. Collectively, this information suggests a possible association between surface 
accessibility of proteins and their extent of cleavage by proteases. More studies on the 
surface exposed regions of partially digested proteins will allow for more certain 
conclusions to be made.  
From analysis of the 2-D gel spots, the formation of spot trails of same protein 
origin was also demonstrated. Proteins identified in multiple spots included OMPs 
PorA and Omp85, pilin PilE, the amino-acid ABC transporter NMB1612 and 
NmMIP. Spot trails is a common phenomenon in 2-D gels and is usually attributed to 
post-translational modifications, most likely phosphorylation, which results in a shift 
in the protein’s pI (Schaefer et al., 2006). From the proteins identified in multiple 
spots in this study, PilE has been previously shown to undergo glycosylation (Power 
et al., 2000). NmMIP and NMB1612 are also predicted lipoproteins with NmMIP 
predicted to undergo palmitoylation. For NmMIP, which has a potential peptidyl-
prolyl cis-trans isomerase activity, multiple spots could also represent different 
enzymatic isoforms (isozymes). For PorA and Omp85, similar spot trails have been 
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previously reported following 2D-PAGE of meningococcal OMVs (Vipond et al., 
2006). Although their post-translational modification cannot be excluded, it has been 
suggested that PorA and Omp85 multiple spots are more likely the result of different 
conformational equilibria formed during protein denaturation under the conditions 
used for 2-D PAGE. In 2-D gels of Porphyromonas gingivalis and Methylococcus 
capsulatans, a single spot from a 2-D separated spot trail could give rise to the same 
spot trail when re-subjected to 2-D analysis highlighting a conformational response of 
the protein to the experimental conditions (Berven et al., 2003; Veith et al., 2001). 
The presence of multiple transmembrane domains in PorA and Omp85 sequence 
which form highly hydrophobic beta barrels in the outer membrane could explain the 
model of multiple conformational isoforms. 
Mass spectrometric analysis of the peptides recovered in the incubation buffer 
following treatment of meningococci with trypsin was alternatively used for 
identification of surface-exposed proteins. This type of analysis suffered from under-
representation of proteins known or predicted to reside on the meningococcal surface 
and over-representation of cytoplasmic predicted proteins. Of the 34 proteins 
identified in the incubation buffer of trypsin-treated samples only 6 were predicted 
lipoproteins or OMPs. These included proteins NMB1468, PilE, NmMIP and amino 
acid-binding protein NMB0787 previously identified by DIGE to be digested by 
proteinase K, PilQ, an OMP involved in tfp biogenesis and TspA, a predicted OMP 
involved in cell wall degradation. None of PorA, OpcA or fHbp that were 
demonstrated to be completely cleaved by proteinase K were among the proteins 
identified in the incubation buffer of trypsin-treated meningococci. This is rather 
surprising considering these proteins are extensively exposed on the meningococcal 
surface and therefore expected to release multiple peptides in the incubation buffer 
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upon trypsin treatment. It is possible that the size of the exposed peptides released 
from these proteins might have not been ideal for MS analysis. Other proteins, shown 
to be partially cleaved by proteinase K in DIGE, also failed to be identified by 
analysis of the incubation buffer. The absence of enough accessible trypsin cleavage 
sites in these proteins might have possibly hindered the release in the incubation 
buffer of enough peptides to allow their identification. 
The high proportion of cytoplasmic predicted proteins identified in the trypsin-
treated samples is in agreement with studies from other bacteria (Doro et al., 2009; 
Dreisbach et al., 2010; Tjalsma et al., 2008; Walters et al., 2009). Contamination with 
cytoplasmic components was observed in Gram-positive bacteria such as Bacillus 
subtilis and Staphylococcus aureus which persisted even after extensive optimisation 
of treatment conditions (Dreisbach et al., 2010; Tjalsma et al., 2008). The leakage of 
proteins from the cytoplasm could be the result of a possible destabilisation of the 
bacterial cell wall upon proteolytic cleavage of surface structures, which would 
otherwise provide mechanical support to the cell. In Gram-negative bacteria, this 
leakage could be further enhanced by the presence of large porin complexes 
transversing the outer membrane which pose as potential escape sites for proteins 
through passive diffusion (Tan et al., 2008). This explains higher levels of 
contamination observed in this study and in a study of protease treatment of E. coli 
(Walters et al., 2009). 
Extensive representation of cytoplasmic proteins was also observed in control 
samples. The most likely explanation for this observation is the lysis of cells as a 
result of osmotic stress during incubation in the buffer selected. Cell lysis was found 
to be limited in cell images from cryo-TEM. Although not enough to alter total 
protein abundance levels, few dead cells can seemingly provide the incubation buffer 
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with proteins from various cell compartments and at sufficient concentrations to be 
detected by a highly sensitive mass spectrometer. Some of the proteins identified 
could also represent proteins loosely attached to the meningococcal surface which 
were physically detached upon resuspension in the buffer (Tjalsma et al., 2008). Of 
the proteins identified in controls, elongation factor Tu, chaperone DnaK, enolase, 
peroxiredoxin 2 family protein and macrophage infectivity potentiator-related protein 
have been previously detected on the surface of meningococci by flow cytometry 
(Ferrari et al., 2006; Grifantini et al., 2002b; Knaust et al., 2007). Similarly, 
elongation factors Ts and G and the 30S ribosomal protein S1 have been found on the 
surface of other bacteria (Lei et al., 2000; Sanchez-Campillo et al., 1999). It is 
possible that the attachment of these proteins on the bacterial surface occurred 
following their release from dead cells during cell culture (Tjalsma et al., 2008). Upon 
release, these proteins could have been attracted to the surface of live bacteria through 
affinity to cell wall structures.  
 
3.6 Concluding remarks 
In this part of the study, treatment of meningococci with proteases coupled 
with proteomic analysis was used for the identification of the meningococcal surface 
proteome. The success of this strategy was dependent upon the cell fraction analysed 
following protease treatment. The analysis of whole-cell proteomes provided more 
specific and conclusive results compared with the analysis of the peptides released in 
the incubation buffer. The surface proteome consisted of known antigens as well as 
other potentially surface-exposed proteins that warrant further investigation as 
possible vaccine candidates. 
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4. Characterization of meningococcal serogroup B OMV vaccines 
from strain H44/76 after growth in rich and minimal media 
4.1 Introduction 
The meningococcus is highly adaptive to changes in its environment and has 
evolved mechanisms for survival under the conditions posed by its host. One strategy 
involves regulation of its gene expression for selective production of proteins 
involved in acquisition of nutrients essential for its growth during colonisation and 
infection. Such proteins are normally located on the bacterial surface to facilitate 
direct interaction with nutrient sources. The significance of these proteins in 
meningococcal survival and infection can also render them key targets of the immune 
system of the host. Typical examples include OMPs involved in iron acquisition under 
iron-limiting conditions such as proteins involved in binding of lactoferrin and 
transferrin (Lbps and Tbps) (Legrain et al., 1993; Pettersson et al., 1993; Pettersson et 
al., 1998). Expression of Lbps and Tbps is regulated by the ferric uptake regulatory 
protein (Fur) which, in the presence of iron, binds to a consensus sequence next to the 
promoter region of the iron-regulated gene and blocks transcription by RNA 
polymerase (Escolar et al., 1999). The ability of Lbp and Tbp to protect against 
meningococcal disease has also been confirmed in experimental animal models 
(Ala'Aldeen et al., 1996; Pettersson et al., 2006). 
In this chapter, the effect of growth medium on the expression of 
meningococcal proteins was investigated. Frantz medium (FM) containing yeast 
extract and casamino acids was chosen as a rich medium for bacterial growth whilst 
the synthetic modified Catlin-6 medium (MC.6M) was used for growth under minimal 
nutrient supply. Growth conditions under these media have been previously 
established during production of OMV vaccines against outbreak strains CU385, 
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H44/76 and NZ98/254 used in protection trials in Cuba, Norway and New Zealand, 
respectively (Fredriksen et al., 1991; Oster et al., 2005).  
Meningococci from H44/76, a strain of similar genetic background to MC58, 
were grown in each of the 2 media and OMV preparations were assessed for changes 
in expression levels of proteins present in the outer membrane. Analysis was carried 
out using both traditional SDS-PAGE and DIGE. SDS-PAGE has been used for 
analysis of the presence and abundance of major antigens as part of the evaluation of 
OMV vaccines (Frasch et al., 2001; Fredriksen et al., 1991; Vipond et al., 2005). 
DIGE has also been used to investigate the consistency in the manufacturing of OMV 
vaccines by comparing expression levels of both key and minor antigens across 
different OMV batches (Vipond et al., 2006). In general, 2D-PAGE coupled to mass 
spectrometry has facilitated characterisation of the OMV proteome of the strains 
responsible for outbreaks of serogroup B disease in Cuba and New Zealand (Uli et al., 
2006; Vipond et al., 2006). Together with DIGE comparative analysis, similar 
characterisation of the protein content of OMVs from H44/76 strain was attempted 
and is presented in this chapter. 
In addition, in collaboration with the Norwegian Centre of Public Health, 
OMV vaccine formulations from meningococci grown in the different media were 
prepared and their efficacy compared in ELISA and serum bactericidal assays (SBA). 
In this way, possible relationships between the detected changes in protein levels and 
vaccine-induced immune responses could be investigated and novel protein targets for 
vaccine development suggested. Collectively, results from analysis of both antigen 
composition and immunogenicity would offer additional insights to such an important 
variable as the growth medium during OMV vaccine manufacturing and its effect on 
protein-based vaccines quality and efficacy. 
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NspA 
4.2 SDS-PAGE  
Batches of OMVs, produced from meningococci grown in FM or MC.6M 
were first compared by SDS-PAGE (Figure 4.1). Relative expression levels for the 
most abundant proteins present on the gels were measured by scanning densitometry 
of the corresponding protein bands. The identity of protein bands was confirmed by 
immunoblotting using protein-specific antibodies.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 SDS-PAGE of three batches of OMVs from meningococcal strain 
44/76 grown in either FM or MC.6M. Two µg of OMV protein was applied in each 
lane. The MW reference is shown to the left, and the main outer membrane protein 
bands are identified to the right. The gel was stained with Coomassie R-350 and 
photographed with Bio-Rad Scanner GS-710 Imaging Densitometer. 
 
No significant differences in the expression levels of the major OMPs PorA 
(P1.7,16), PorB3 (serotype 15) and RmpM were detected. The ranges of the staining 
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intensities of these protein bands in percentage of total band intensity were 18-24%, 
25-33% and 15-20%, respectively. The level of Omp85 (range 4-6%) was also similar 
among the different preparations. Two high MW proteins, a 100 kDa species 
identified as TonB-dependent receptor TdfH and a 80 kDa species just below Omp85 
were more abundant in MC.6M OMVs (band intensity levels not determined), as was 
OpcA with an intensity range of 21-25% compared with 16-19% in FM OMVs (P-
value = 0.008). Relative to the intensity of the PorA band, there was 1.6-fold more 
OpcA in the MC.6M OMVs than in those from FM (P-value = 0.021). NspA also 
exhibited somewhat higher levels in OMVs produced in MC.6M (band intensity 
levels not determined). Batch-to-batch variations in both media were observed with 
respect to the level of expression of the iron-regulated protein FetA (range 1-8%). 
Scanning of the L3 and L8 LPS bands in silver-stained gels after loading 
equivalent amounts of OMV protein from the 6 batches showed higher levels of both 
bands in MC.6M OMVs (P-value < 0.005) compared with the FM OMVs. From the 
sum of L3 and L8 bands in reference LPS samples, applied in the same gel, the 
MC.6M OMVs contained 0.13 µg LPS/µg protein (range 0.12-0.16 µg LPS/µg 
protein) and the FM OMVs 0.09 µg LPS/µg protein (range 0.08-0.10 µg LPS/µg 
protein). 
  
4.3 2D-PAGE 
SDS-PAGE has relatively low resolution efficiency during protein separation 
meaning protein bands do not necessarily represent single protein species. This, in 
turn, prevents its use as a fully quantitative method since differences in expression 
levels cannot be directly linked to a single protein. The superior separation 
performance of 2D-PAGE over traditional SDS-PAGE was therefore utilised in this 
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study and coupled to DIGE technology for comparative analysis of OMVs from 
meningococci grown in the different media. Prior to DIGE, tests on 2D-PAGE 
conditions were carried out to ensure optimal quality of separation of proteins present 
in OMVs. 
 
4.3.1 Establishing optimal 2D-PAGE conditions for separation of H44/76 OMVs 
Outer membrane vesicles, rich in highly hydrophobic OMPs, are difficult to 
solubilise in the buffers used during IEF, the first dimension of 2D-PAGE. 
Additionally, meningococcal proteins are dominated by major OMPs like PorA and 
PorB whose efficient separation in 2-D gels can be challenging. A previous study on 
meningococcal OMVs reported the use of the surfactant Triton X-100 in the 
solubilisation buffer for effective protein solubility and a total focusing time of 45 
kVh (Vipond et al., 2006). Both conditions were incorporated in the protocol used for 
the 2D-PAGE analysis presented in this chapter. Optimisation of additional 
parameters that can impact on protein solubilisation and separation during IEF were 
attempted and presented here. 
As a first step, two surfactants, Triton X-100 and CHAPS, were tested for their 
effect on protein solubilisation when added in the buffer used to rehydrate the IPG 
strips prior to IEF. Two-dimensional gels were produced from H44/76 OMV samples 
applied to IPG strips and rehydrated overnight with the different buffers. All other 
parameters were kept identical throughout 2D-PAGE. The results are presented in 
Figure 4.2. Considerable under-representation of proteins on the gel from the sample 
rehydrated with CHAPS was observed judging by the number and pattern of 2-D 
spots compared to that rehydrated with Triton X-100. Many spots present on the gel 
from the Triton X-100 sample were missing on that from CHAPS sample, especially 
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in the low MW region (indicated by arrows in Figure 4.2). Therefore, a rehydration 
buffer containing Triton X-100 was chosen for all subsequent optimisation and 
investigative work. 
 
 
 
 
 
 
 
 
 
Figure 4.2 Effect of IPG strip rehydration buffer on 2D-PAGE of H44/76 OMVs. 
Outer membrane vesicles (100 µg) from meningococci grown in FM were labeled 
with Cy5 dye and applied to IPG strips (3-11, non-linear). IPG strips were rehydrated 
overnight with buffers containing either Triton X-100 or CHAPS and subjected to 
isoelectric focusing for 45 KVhr using a maximal voltage of 3,500 V. Second-
dimension SDS-PAGE was carried out in 12% polyacrylamide gels. Gel images were 
acquired by fluorescence scanning at the Cy5 channel. Arrows in the ‘Triton X-100’ 
image highlight protein spots missing in the ‘CHAPS’ image. 
 
Two more parameters of the 2D-PAGE protocol were assessed, the maximal 
voltage used for IEF and the duration of strip equilibration prior to second dimension 
SDS-PAGE. Maximal voltages tested were 3,500, 5,500, 8,000 and 10,000 V. Strips 
focused under these voltages were then incubated sequentially with DTT- and 
iodoacetamide-containing equilibration buffer at durations of 10 and 5 min, 
respectively, or 15 min for both incubations. Images of the gels produced from each 
combination of conditions tested are presented in Figure 4.3. No major differences in 
protein separation and representation were observed across images. Spot patterns were 
reproducible regardless of IEF voltage or equilibration time. 
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The highest voltage (10,000 V) was chosen for subsequent analysis to reduce IEF 
experimental times. Fifteen-minute equilibration steps were also chosen for consistent 
and easy to handle experimental times. 
 
4.3.2 DIGE 
DIGE was used to compare protein expression levels between the two OMV 
preparations made from H44/76 meningococci grown in FM or MC.6M media. Three 
individual OMV batches were prepared for each growth medium. A 2-colour DIGE 
experimental design was used where individual batches were labeled with Cy5 dye 
and an internal standard sample generated from pooling all individual batches was 
labeled with Cy3 dye (Table 4.1A). Each batch was run on a single gel together with 
the internal standard resulting in a total of 6 gels. Images acquired from fluorescence 
scanning of gels are presented in Figure 4.4. Acquired gel images were imported on 
DeCyder software v.6.5 and grouped on the basis of culture medium (3 gels per 
group) for subsequent statistical analysis. Fluorescence intensities were calculated for 
each protein spot across all images and compared between the 2 groups. 
Results from quantitative analysis are summarised in Table 4.1B. A total of 
2,005 spots were matched across the 6 gel images. The level of expression of 1941 
spots (97%) was less than 10% different between the two OMV preparations (Table 
4.1B, fold change < 1.1). Sixty four spots exhibited a greater than 10% difference in 
the amount of protein (P-value = 0.00023 – 0.049).  
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Table 4.1 DIGE analysis of OMVs from meningococcal strain H44/76 grown in 
FM or MC.6M. A). Detailed two-colour DIGE experimental design; B). Summary of 
quantitative data analysis. 
A). 
Gel No Cy3 label (50 µg) Cy5 label (50 µg) 
1 Pooled internal standarda FM batch 1 
2 Pooled internal standard FM batch 2 
3 Pooled internal standard FM batch 3 
4 Pooled internal standard MC.6M batch 1 
5 Pooled internal standard MC.6M batch 2 
6 Pooled internal standard MC.6M batch 3 
a made from equal quantity of all batches 
 
B). 
Fold change 
Total no. of spots 
showing 
differential 
expressionb 
Protein expression in MC.6M compared 
to FM (no. of spots)b 
Increased Decreased 
≥ 2 41 24 17 
< 2 and ≥ 1.1 23 17 6 
< 1.1 1941 - - 
Total 2005 41 23 
b results in number of spots from the application of a P-value < 0.05 are displayed (n=3). 
 
The majority of these spots exhibited greater than 2-fold change (41 out of 64, 
64%). Forty-one proteins were more abundant in OMVs produced in MC.6M, 
whereas 23 were more abundant in OMVs produced in FM. The position of spots with 
differential expression between the two OMV preparations is highlighted in Figure 
4.5. Most spots were found in the basic region and included a range of molecular 
masses. High abundance spots, identified as the major OMPs, i.e. PorA, PorB and 
OpcA, were excluded from accurate quantitative comparison due to their saturation in 
fluorescence intensity which exceeded the linear range of scanning conditions. Details 
about the extent of change in expression levels are provided in Table 4.2 for those 
protein spots for which MS identification was carried out.  
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Figure 4.5 Position on 2-D gel of proteins with differential expression in OMVs 
from meningococci grown in FM and MC.6M. A) Complete gel image from 2D-
PAGE of H44/76 OMVs. B) – E). Enlarged sections of A) highlighting the protein 
spots with increased (circles) and decreased (squares) expression in MC.6M OMVs 
(fold change > 1.1, P-value = 0.00023 – 0.049). Arrows indicate the spots identified 
by MS (shown in Table 4.2). 
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4.4 MS identification of proteins expressed at different levels in FM and MC.6M 
OMVs 
Spots showing different expression levels between OMVs prepared in FM and 
MC.6M were picked from a set of preparative gels. Following in-gel digestion of 
spots by trypsin, proteins were identified using MALDI PMF as the main mass 
spectrometric method. MALDI measures the masses of peptides present in the sample 
which are then correlated to theoretically predicted masses from proteins present in 
the database used during searching. Combined with the resolving power of 2D-PAGE, 
MALDI PMF can accurately identify proteins from 2-D spots. For some of the spots, 
additional peptide fragmentation (MS/MS) was performed to increase confidence of 
identification through correlation to peptides sequences. 
Seven proteins were identified from MS analysis of 10 spots and are presented 
in Table 4.2. TonB-dependent receptor TdfH, OpcA and protein encoded by 
NMB2134 were each identified in 2 spots whilst FadL-like NMB0088, adhesin MafA, 
lipoprotein NMB1126/1164 and NspA were each identified in a single spot. Proteins 
identified belonged to spots with increased levels in OMVs from MC.6M medium 
(Table 4.2). Two-fold or greater increase was observed for all identified proteins. 
TdfH exhibited the highest increase in expression in MC.6M OMVs among the 
identified proteins. Differences were observed in the fold-increase values calculated 
for the same protein appearing in different spots, i.e. TdfH (spots 1 and 5), OpcA 
(spots 4 and 8) and NMB2134 (spots 2 and 3) and can be mostly attributed to 
differences in the amount of protein present in each spot. 
Taking together the results from SDS-PAGE and DIGE-MS, TdfH, OpcA and 
NspA were confirmed by both methods to be produced at higher levels in MC.6M 
OMVs. Additionally, FadL-like NMB0088, MafA, NMB2134 and NMB1126 were 
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identified by DIGE MS to also be part of the proteins over-expressed in MC.6M 
OMVs. The 80 kDa protein below Omp85 that was shown by SDS-PAGE to be more 
abundant in MC.6M OMVs was not identified by DIGE-MS. Spots of higher 
expression in MC.6M OMVs were detected in the area of Omp85 migration on 2-D 
gels (Figure 4.5) which might belong to the 80 kDa protein of interest. However, the 
high abundance of Omp85 and low spot resolution in the area prevented confident 
detection of the differentially expressed protein. 
 
Table 4.2 Summary of DIGE and MS results from comparison of FM and 
MC.6M OMVs. Quantitative comparison between OMVs grown in either FM or 
MC.6M was carried out using DeCyder 2-D differential analysis software v. 6.5. 
Differentially-expressed proteins were subjected to MALDI PMF and/or MS/MS for 
identification. Spot numbers correspond to the numbers in Figure 4.5. 
 
Protein name 
Spot 
No.
 
Fold 
increase 
in 
MC.6M 
OMVs
 
P value
 
MS method 
Protein 
coverage / 
No. of unique 
peptides 
sequenced or 
matched 
TdfH (TonB-
dependent receptor 
NMB1497) 
1 8.27 0.000023 MALDI PMF 26% / 19 
5 6.72 0.0013 MALDI PMF 32% / 26 
Hypothetical protein 
NMB2134  
2 2.90 0.023 MALDI PMF 13% / 7 
3 3.22 0.038 MALDI PMF 25% / 13 
Class 5 OMP OpcA 
4 3.14 0.026 LC MS/MS 28% / 5 
8 1.75 0.037 MALDI PMF 45% / 9 
OMP NMB0088 6 2.36 0.034 
MALDI PMF  39% / 14 
MALDI 
MS/MS 
7% / 2 
Adhesin MafA 7 5.46 0.011 MALDI PMF 55% / 14 
Lipoprotein 
NMB1126/NMB1164 
9 4.0 0.016 MALDI PMF 45% / 7 
NspA 10 2.29 0.033 
MALDI PMF 30% / 6 
MALDI 
MS/MS 
10% / 1 
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4.5 Antibody levels in immunised mice 
OMVs from meningococci grown in either FM or MC.6M were adsorbed to 
aluminium hydroxide and used to immunise groups of mice. Doses of 2.0 µg for both 
OMV vaccine formulations were given. A lower 0.5 µg dose of MC.6M OMV was 
also administered in one group. Antibodies present in the generated immune sera were 
first tested for total levels in ELISA. Mice immunised with 2.0 µg of MC.6M OMVs 
had significantly higher serum IgG levels (P-value = 0.0002) than those receiving the 
0.5 µg dose (Figure 4.6A). There was no significant difference between the IgG levels 
induced by the 2.0 µg dose of the MC.6M and FM OMV vaccines. No antibodies 
were detected in the negative control sera from mice immunised with physiological 
saline. 
Serum bactericidal activity induced by OMV vaccines has been shown to 
correlate with protection against meningococcal disease in humans (Holst et al., 
2003). Here, murine immune sera from the different OMV vaccine preparations were 
tested and compared for bactericidal activity against the H44/76-SL strain in the 
presence of human complement source (hSBA). hSBA titers of ≥ 8 (3 when expressed 
in log2 scale) were measured and results are presented in Figure 4.6B. The titers 
obtained with the 2.0 µg dose of both vaccines were significantly higher (P-value < 
0.001) than those of the saline control group, whereas no significant differences were 
observed between the saline control and 0.5 µg of the MC.6M OMV vaccine. 
However, the 2.0 µg dose of MC.6M OMV vaccine induced significantly higher titers 
(P-value = 0.032) than the same dose of the FM OMV vaccine. MC.6M OMV vaccine 
also elicited a significant dose response in bactericidal titers (P-value < 0.0003), as 
observed by comparing results from the two MC.6M OMV doses used. 
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Figure 4.6 Antibody levels in mice immunised with FM or MC.6M OMV 
vaccines. Groups I and II received 0.5 µg and 2.0 µg of the MC.6M OMV vaccine, 
respectively; group III 2.0 µg of the FM OMV vaccine and group IV physiological 
saline. A). IgG antibody levels (U/mL) measured in ELISA. B). Bactericidal 
antibodies measured in SBA. The titres are given as log2 of the highest reciprocal 
serum dilution showing > 50% killing of the 44/76-SL target strain. The starting 
dilution was 1:8 (3 in log2 scale) and lower titres were assigned a value of 1. The SBA 
was performed blinded with respect to the groups of mice. 
 
B. SBA 
A. ELISA 
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Specific antibody levels in immunized mice to the major OMPs were 
measured on immunoblots using the MC.6M OMV as antigen. The 2.0 µg dose of 
both vaccines induced similar Ig levels to Omp85, PorA, PorB, RmpM, OpcA, and 
OpaJ129 which were the main immunogenic bands on the blots. Significantly lower 
levels (P-value = 0.001 – 0.046) to these antigens were induced by 0.5 µg of the 
MC.6M vaccine. Antibodies to PorA contributed markedly to the bactericidal activity 
of the murine sera as there was a significant correlation between the Ig binding 
intensity to PorA on the blots and the bactericidal titres with both doses of each OMV 
vaccine (range of Pearson product moment correlation or Spearman rank order 
correlation coefficients 0.580–0.856; P-value = 0.0004–0.048). 
 
4.6 Characterisation of the protein content of H44/76 OMVs 
Further to OMV proteins with altered expression levels due to bacterial growth 
conditions, other proteins present in H44/76 OMVs were identified by analysis of 
additional 2-D spots picked from preparative gels. In total, 94 spots picked from gels 
of OMVs prepared in both media were assigned a protein identity following LC-
MS/MS. For 26 spots MALDI analysis (PMF and/or MS/MS) was carried out in 
parallel. A list of the identified proteins is presented in Table 4.3. In total, 74 proteins 
were identified as part of H44/76 OMVs. 
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Table 4.3 Characterisation of the protein composition of OMVs from the 
Norwegian meningococcal vaccine strain 44/76. Three OMV batches were made 
from meningococci grown in FM or MC.6M. One mg of pooled OMV protein lysate 
from all batches was separated on 2D-PAGE and the gel was post-stained with 
Coomassie R-250. Spots with high intensity were manually excised and proteins 
digested and analysed by nano-scale capillary LC-MS/MS as described in section 
2.13.2 with the following modifications. Liquid chromatography was carried out in a 
nanoAcquity UPLC (Waters, Elstree, UK) delivering a flow of approximately 300 
nL/min. A C18 Symmetry 5 µm, 180 µm x 20 mm µ-Precolumn (Waters, Elstree, 
UK), trapped the peptides prior to separation on a C18 BEH130 1.7 µm, 75 µm x 100 
mm analytical UPLC column (Waters). Tandem mass spectra were searched against 
Uniprot KB13.6 entries using MASCOT. Scaffold (version 2.1.03, Proteome Software 
Inc., Portland, OR) was used to validate MS/MS based protein identifications. Protein 
identifications were accepted when probability was greater than 95% and at least 2 
peptides were identified. 
Gene 
locus
a Protein name
a 
Protein 
coverage / No. 
of unique 
peptides
b 
Subcellular 
location
c
 
NMB2134 Putative uncharacterised protein 21% / 13 Outer membrane 
NMB2130 Putative uncharacterised protein 38% / 2 Unknown 
NMB2101 30S ribosomal protein S2 24% / 4 Unknown 
NMB2095 Putative adhesion complex protein 25% / 5 Outer membrane 
NMB2039 Major outer membrane protein PorB 53% / 10 Outer membrane 
NMB1998 Serine-type peptidase 1.7% / 2 Outer membrane 
NMB1988 Iron-regulated outer membrane 
protein FrpB (FetA) 
53% / 32 Outer membrane 
NMB1985 Adhesion and penetration protein 
App 
4.4% / 5 Outer membrane 
NMB1972 
60kDa chaperonin 57% / 27 
Cytoplasm (surface-
exposed) (Ferrari et 
al., 2006) 
NMB1969 Putative serotype-1-specific antigen 6.7% / 6 Outer membrane 
NMB1934 ATP synthase subunit beta 11% / 3 Inner membrane 
NMB1829 TonB-dependent receptor 7.5% / 3 Outer membrane 
NMB1812 Type IV pilus biogenesis and 
competence protein PilQ 
50% / 27 Outer membrane 
NMB1762 Putative hemolysin activation 
protein HecB 
5.9% / 3 Outer membrane 
NMB1737 Putative secretion protein 16% / 6 Outer membrane 
NMB1714 Multidrug efflux pump channel 
protein 
14% / 4 Outer membrane 
NMB1710 
Glutamate dehydrogenase, NADP-
specific 
7.2% / 2 
Cytoplasm (surface-
exposed) (Gharbia 
and Shah, 1995) 
NMB1668 Hemoglobin receptor 14% / 8 Outer membrane 
NMB1623 Copper-containing nitrite reductase 6.2% / 2 Outer membrane 
NMB1580 Putative uncharacterised protein 22% / 5 Cytoplasm 
NMB1567 Macrophage infectivity potentiator 
(NmMIP) 
25% / 6 Outer membrane 
NMB1559 Glutathione synthetase 19% / 5 Cytoplasm 
NMB1540 Lactoferrin-binding protein A 25% / 17 Outer membrane 
NMB1498 Aspartokinase 11% / 3 Cytoplasm 
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Gene 
locus
a Protein name
a 
Protein 
coverage / No. 
of unique 
peptides
b 
Subcellular 
location
c
 
NMB1497 Probable TonB-dependent receptor 30% / 21 Outer membrane 
NMB1483 Putative lipoprotein NlpD 6.7% / 2 Non-cytoplasmic 
NMB1429 Major outer membrane protein PorA 42% / 12 Outer membrane 
NMB1313 
Trigger factor 11% / 3 
Cytoplasm (surface-
exposed) (Ferrari et 
al., 2006) 
NMB1190 Sulfite reductase [NADPH] 
flavoprotein alpha-component 
16% / 5 Unknown 
NMB1053 Class 5 outer membrane protein 
OpcA 
59%/ 14 Outer membrane 
NMB0964 Probable TonB-dependent receptor 30% / 16 Outer membrane 
NMB0956 2-oxoglutarate dehydrogenase, E2 
component, dihydrolipoamide 
succinyltransferase 
16% / 3 
Cytoplasm / Inner 
membrane 
NMB0928 Uncharacterised protein NMB0928 
(NlpB) 
13% / 3 Periplasm 
NMB0758 Polyribonucleotide 
nucleotidyltransferase 
25% / 13 Cytoplasm 
NMB0707 Putative rare lipoprotein B 42% / 6 Unknown 
NMB0703 Competence lipoprotein ComL 41% / 9 Non-cytoplasmic 
NMB0700 IgA-specific serine endopeptidase 11% / 15 Outer membrane 
NMB0663 Outer membrane protein NspA 20% / 2 Outer membrane 
NMB0634 Major ferric iron-binding protein 15% / 4 Periplasm 
NMB0631 Putative phosphate acetyltransferase 
Pta 
30% / 10 Non-cytoplasmic 
NMB0589 50S ribosomal protein L19 17% / 2 Cytoplasm 
NMB0554 
Chaperone protein DnaK 45% / 20 
Cytoplasm (surface-
exposed) 
(Montigiani et al., 
2002) 
NMB0496 Hemolysin activator-related protein 6.4% / 3 Outer membrane 
NMB0462 Spermidine/putrescine ABC 
transporter, periplasmic 
spermidine/putrescine-binding 
protein 
10% / 3 Periplasm 
NMB0461 Transferrin-binding protein 1 21% / 15 Outer membrane 
NMB0426 Cell division protein FtsA 23% / 7 Cytoplasm 
NMB0387 ABC transporter, ATP-binding 
protein 
19% / 7 Inner membrane 
NMB0382 Outer membrane protein class 4 
RmpM 
38% / 7 Outer membrane 
NMB0375/ 
NMB0652 
Adhesin MafA 54% / 12 Outer membrane 
NMB0359 Glutamine synthetase 5.5% / 2 Cytoplasm 
NMB0325 50S ribosomal protein L21 19% / 2 Unknown 
NMB0313 TPR repeat-containing protein 
NMB0313 
31% / 12 Non-cytoplasmic 
NMB0281 Peptidyl-prolyl cis-trans isomerase 18% / 5 Periplasm 
NMB0280 LPS-assembly protein 24% / 13 Outer membrane 
NMB0219 3-oxoacyl-(Acyl-carrier-protein) 23% / 5 Inner membrane 
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Gene 
locus
a Protein name
a 
Protein 
coverage / No. 
of unique 
peptides
b 
Subcellular 
location
c
 
synthase II 
NMB0182 Outer membrane protein Omp85 67% / 40 Outer membrane 
NMB0167 30S ribosomal protein S4 21% / 3 Cytoplasm 
NMB0166 30S ribosomal protein S11 18% / 3 Unknown 
NMB0161 50S ribosomal protein L15 14% / 2 Unknown 
NMB0158 50S ribosomal protein L18 22% / 2 Cytoplasm 
NMB0157 50S ribosomal protein L6 28% / 5 Unknown 
NMB0154 50S ribosomal protein L5 21% / 3 Cytoplasm 
NMB0144 50S ribosomal protein L23 35% / 2 Unknown 
NMB0143 50S ribosomal protein L4 41% / 6 Unknown 
NMB0142 50S ribosomal protein L3 14% / 2 Cytoplasm 
NMB0140 30S ribosomal protein S10 30% / 5 Cytoplasm 
NMB0138 
Elongation factor G 20% / 10 
Cytoplasm (surface-
exposed) (Ferrari et 
al., 2006) 
NMB0128 50S ribosomal protein L1 62% / 12 Unknown 
NMB0124/ 
NMB0139 Elongation factor Tu 40% / 12 
Cytoplasm (surface-
exposed) (Ferrari et 
al., 2006) 
NMB0109 
Putative uncharacterised protein 6.2% / 2 
Outer membrane / 
non-cytoplasmic 
NMB0088 Outer membrane protein NMB0088 32% / 10 Outer membrane 
NMB0010 Phosphoglycerate kinase 12% / 4 Cytoplasm 
Not 
available 
Opacity protein OpaB128 40% / 10 Outer membrane 
Not 
available 
Opacity protein OpaJ129 6.8% / 3 Outer membrane 
a The name and corresponding gene locus of the identified proteins were derived from the annotated 
MC58 genome (http://www.tigr.org). 
b For proteins identified to be present in more than one spot the highest protein coverage detected is 
reported. 
c Prediction of protein localisation was carried out using the PSORTb v.3.0 subcellular localisation 
prediction tool. 
 
 
Based on the protein localisation prediction algorithm PsortB v. 3.0 (Yu et al., 
2010), 32 out of the 74 identified proteins (43%) were predicted OMPs (Table 4.3). 
Four proteins were predicted to be located in the inner membrane and four in the 
periplasm. For proteins NMB0313, NMB1126/NMB1164, putative lipoprotein NlpD, 
putative phosphate acetyltransferase Pta and competence lipoprotein ComL, a signal 
peptide sequence was detected, but no further prediction as to their exact position on 
the cell could be deduced. Of the remaining proteins, 19 were predicted cytoplasmic 
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proteins 6 of which have also been detected on the meningococcal surface (Ferrari et 
al., 2006; Gharbia et al., 1995; Montigiani et al., 2002). There were also examples of 
proteins bearing no sequence features to be associated with a specific cell 
compartment (labeled “unknown” in Table 4.3).  
PsortB-predicted distribution in the bacterial cell of identified proteins from 
H44/76 OMVs was compared to that from previously published OMV protein datasets 
(Table 4.4). Specifically, results from proteomic studies on detergent-extracted OMVs 
from the New Zealand outbreak strain NZ98/254 (Ferrari et al., 2006; Vipond et al., 
2005; Vipond et al., 2006), the Cuban outbreak strain CU385 (Gil et al., 2009; Ramos 
et al., 2008; Uli et al., 2006), and MC58 (Williams et al., 2007) were used for 
comparison. Presence of each of the PsortB-predicted outer membrane and 
membrane-associated periplasmic proteins from H44/76 OMVs in OMVs derived 
from the above mentioned meningococcal strains was also assessed (Table 4.5). 
Similar numbers of OMPs were present in all detergent-extracted OMVs whilst the 
number of proteins of the cytoplasm and other cell compartments varied, as did the 
total number of identified proteins in each study. Of the 35 outer membrane and 
membrane-associated proteins found in H44/76 OMVs, 13 were also present in 
OMVs from all other strains compared and 32 were present in OMVs from at least 
one of the strains compared. Putative lipoprotein NlpD, hemolysin activator-related 
protein and copper-containing nitrite reductase AniA were identified in H44/76 
OMVs alone. Additionally, 21 of the 35 OMPs from H44/76 OMVs were also found 
in naturally-released OMVs from gna33 mutant strain (Table 4.5) (Ferrari et al., 
2006). 
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Table 4.4 Number and distribution on the bacterial cell of proteins identified in 
detergent-extracted OMVs. Results from this study on H44/76 OMVs were 
compared to datasets from proteomic studies on OMVs derived from other 
meningococcal strains. The strains compared and corresponding studies are 
highlighted in the top row.  
 
Cellular 
location 
H44/76 
(this 
study) 
NZ98/254 
(Ferrari et 
al., 2006) 
NZ98/254 
(Vipond et 
al., 2005; 
Vipond et 
al., 2006) 
CU385 
(Gil et 
al., 
2009) 
CU385 
(Ramos 
et al., 
2008) 
MC58 
(Williams 
et al., 
2007) 
outer 
membrane 
32 34 29 31 28 23 
cytoplasm 19 75 25 23 37 45 
other
a
 23 39 9 52 32 43 
total 74 148 63 106 97 111 
a Includes proteins located in the periplasm, inner membrane and proteins with unknown or multiple 
locations in the bacterial cell. 
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4.7 Discussion 
As part of its adaptation to the environments it encounters during survival and 
infection of the human host, the meningococcus has established ways to differentiate 
its protein repertoire. Being the result of phase-variable genes, sequence substitutions 
or regulation of gene expression, the protein content of the organism can vary 
substantially under different conditions posed by the host. In this chapter, the 
differences in antigen composition and immunogenicity of OMV vaccines in response 
to meningococcal growth in media of different nutrient composition were assessed. 
Growth media were selected on the grounds of their previous use in OMV vaccine 
preparations and included the rich complex FM and the synthetic minimal MC.6M 
medium. 
Overall, the results showed that the OMVs produced using the two culture 
media had a similar protein composition. The major porins, PorA and PorB, were 
expressed at similar levels, as were Omp85 and RmpM, which are involved in outer 
membrane synthesis and stability, respectively (Jansen et al., 2000; Voulhoux et al., 
2003). About 3% (64/2,005) of the proteins were differentially expressed. The 
majority (41/64, 64%) of the differentially expressed proteins were present in higher 
amounts in OMVs produced in MC.6M. They included the proteins OpcA, MafA, 
NspA, TdfH, OMP NMB0088, lipoprotein NMB1126/1164 and the uncharacterized 
OMP NMB2134, which constitute confirmed or predicted proteins of the cell surface. 
As MC.6M is less complex than FM, it was not surprising to find that in adapting to 
the synthetic medium the meningococcus increased the expression of specific cell 
surface proteins. 
Expression of the FetA protein, which belongs to the family of TonB-
dependent receptors, is normally repressed in iron-rich media (Carson et al., 1999). Its 
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inconsistent expression in both FM and MC.6M suggested that batches of both media 
varied in the amount of readily available iron for meningococcal growth. However, 
variations in iron availability alone were unlikely to account for all observed changes. 
There was no evidence of increased expression of other iron-repressed surface 
proteins, such as transferrin-binding protein or haem receptors, in the OMV 
preparations from bacteria grown in MC.6M. Like iron-regulated proteins, TdfH also 
belongs to the family of TonB-dependent receptors. It shares homology with haem 
receptors but does not appear to be involved in iron uptake (Turner et al., 2001). 
Unlike FetA, it was found to be expressed consistently and at increased levels by 
different batches of meningococci grown in MC.6M, suggesting that the induction of 
TdfH was not dependent upon fluctuations in iron levels. Other metal ions present 
solely or in higher amounts in MC.6.M might be responsible for the observed 
regulation of the gene coding for TdfH. Zinc was recently suggested to regulate 
expression of another member of the TonB-dependent receptor family encoded by the 
NMB0964 gene locus (Stork et al., 2008). Similarly to TdfH, NspA, a surface antigen 
encoded by an iron-activated gene had consistently elevated levels in MC.6M (Shaik 
et al., 2007). Increased production of NspA in MC.6M suggests that the expression of 
the respective nspA gene is affected by additional factors that have yet to be 
identified. 
Consistent with the similar expression levels observed for major antigens 
PorA, PorB, RmpM and Opc85, the two OMV vaccines induced the same levels of 
specific antibodies to these proteins in mice. A high correlation between the titres in 
SBA of the mice sera and the levels of PorA-specific antibodies was observed in 
support of previous findings that PorA is the primary target for bactericidal antibodies 
in mice (Saukkonen et al., 1989; Weynants et al., 2007). However, mice vaccinated 
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with 2.0 µg of the MC.6M OMV vaccine elicited significantly higher bactericidal 
titres than those vaccinated with the same dose of the FM OMV vaccine. The SBA 
result was probably attributable to the increased expression of the small number of 
surface proteins, LPS or a combination of the two. Of the surface proteins with 
increased expression in MC.6M, OpcA, MafA, NspA and NMB0088 have all 
previously been shown to induce bactericidal antibodies in humans or mice (Grifantini 
et al., 2002b; Poolman et al., 1983; Sardinas et al., 2009). Proteins encoded by 
NMB1126 and NMB2134 have been included in a study for discovery of novel 
vaccine candidates with no reports for their vaccine potential (Pajon et al., 2009) 
whilst TdfH remains to be tested. LPS also induces bacterial antibodies in mice 
(Saukkonen et al., 1989) but can also act as an adjuvant through the induction of a 
TLR4-dependent response (Zughaier et al., 2004). The expression of meningococcal 
LPS has previously been shown to be affected by growth conditions (Zhu et al., 
2001). The relative contribution of antibodies to OpcA may have been underestimated 
in this study, as the target strain used in the SBA only expressed low levels of the 
protein (Jolley et al., 2001; Rosenqvist et al., 1995; Rosenqvist et al., 1993). In 
addition, combination of antibodies to less abundant upregulated OMPs may also 
have contributed synergistically to increase the bactericidal titres obtained with the 
vaccine prepared from cells grown in MC.6M (Weynants et al., 2007).  
In contrast to SBA results, total IgG levels were similar between the 2 OMV 
vaccines. This finding may be explained by the use of a reference FM OMV as the 
common antigen in ELISA; however, it is more likely that the relatively few antigens 
with increased expression in MC.6M OMVs contributed only marginally to the total 
antibody levels. 
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The protein composition of OMVs extracted from H44/76 strain by 
deoxycholate treatment was similar to that reported for OMVs from outbreak strains 
CU385 and NZ98/254 and laboratory strain MC58 prepared in the same way (Ferrari 
et al., 2006; Gil et al., 2009; Ramos et al., 2008; Uli et al., 2006; Vipond et al., 2005; 
Vipond et al., 2006; Williams et al., 2007). Varying numbers of cytoplasmic proteins 
were found in all OMV preparations as a result of the detergent extraction process. 
Since the studies differed in the method and conditions used during protein separation 
and MS analysis, some differences in the number and identity of identified proteins 
were expected. Inter-strain variations in the expression of specific proteins on the 
meningococcal outer membrane are also possible. The majority of identified OM 
proteins are involved in transport systems, adhesion to host cells, cell wall biogenesis 
and post-translation protein modification and folding. Whilst including many 
characterised potential vaccine candidates, the list of identified proteins contained 
additional interesting members of the bacterial cell surface not previously evaluated 
for their vaccine potential. Examples included the macrophage infectivity potentiator 
NmMIP, putative adhesin complex protein (NMB2095), putative secretion protein 
(NMB1737) and proteins potentially involved in hemolysin activation (NMB1762, 
NMB0496).  
 
4.8 Concluding remarks 
This study demonstrated that changes in the composition of the growth 
medium used for the production of OMV vaccines affected the expression of both 
protein and LPS antigens. Differences in antigen expression levels were associated 
with the ability of the vaccines to elicit a functional antibody response. Known 
protective protein antigens were identified which could have contributed to the 
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observed increase in vaccine-induced SBA in the minimal MC.6M medium. 
Antibodies against other differentially expressed proteins or OM proteins present in 
H44/76 OMVs with a yet unknown protective character might also have had a 
synergistic effect on results. Evaluation of such proteins in immunological assays 
would indicate their potential as new vaccine candidates. 
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5. Immunoproteomics of serogroup B N. meningitidis  
5.1 Introduction 
The proteomic approaches presented in Chapters 3 and 4 helped to identify 
proteins on the surface of the meningococcus. The next step was to address which of 
these proteins can elicit an immune response and thus constitute potential antigens. 
Western blots using immune sera from various sources have often been used to assess 
response against meningococcal OMPs. Conventional 1-D gel blots allow quick 
detection of immunoreactive proteins but often fail to pinpoint the identities of these 
proteins as a result of protein co-migration onto the same band (Utt et al., 2002). With 
the development of 2D-PAGE these limitations could be minimised and the workflow 
of immunoproteomics followed. In immunoproteomics, proteins are separated on 2-D 
gels and transferred to membranes which are then blotted with immune sera for 
detection of those proteins eliciting an IgG response (Kornilovs'ka et al., 2002; Utt et 
al., 2002). Immunoreactive proteins can be subsequently identified by MS analysis of 
the respective gel plugs. 
Two-dimensional immunoproteomics has been used for analysis of 
immunogenic proteins from a range of bacterial pathogens including different species 
of Helicobacter (Kornilovs'ka et al., 2002; Utt et al., 2002) and Streptococcus (Lei et 
al., 2000; Ling et al., 2004), Staphylococcus epidermidis (Sellman et al., 2005) 
Clostridium difficile (Wright et al., 2008) and Haemophilus parasuis (Zhou et al., 
2009). Two reports on the meningococcal immunoproteome have also been recently 
published (Mendum et al., 2009; Williams et al., 2009). Using sera from colonised or 
infected individuals, both studies aimed at identifying protein targets of natural cross-
protective immunity. In the study by Mendum et al. (Mendum et al., 2009), pairs of 
acute and convalescent sera from patients with mild or severe septicaemia were 
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assessed on immunoblots whilst Williams et al. (Williams et al., 2009) used sera from 
humans collected before and after their colonisation by serogroup B meningococcal 
strains. A varying set of immunoreactive proteins depending on the sera tested was 
identified by these studies some of which might be involved in protection against 
meningococcal disease. 
In this chapter, the meningococcal proteins with ability to evoke an immune 
response in mice were identified by immunoproteomics. Although not a natural host 
for meningococci, mice are widely used for generation of immune sera to assess 
vaccine-induced responses during evaluation of vaccine preparations. Immune sera 
were raised against live meningococci and OMVs from MC58 and H44/76 strains, 
respectively, both formulated with aluminium hydroxide for administration in mice. 
Protein lysates from MC58 whole cells and H44/76 OMVs separated by 2D-PAGE 
were used as antigens in immunoblots. Immunoreactive protein spots detected in 2-D 
gels were subsequently identified by MS and also by matching to the information on 
protein identity of these samples presented in Chapters 3 and 4. 
 
5.2 Immunoproteome of MC58 whole cells 
5.2.1 Protein separation and immunoblotting 
Total protein extracts from the N. meningitidis MC58 ∆-siaD strain were 
separated on 2-D gels using the same experimental conditions as those employed 
during analysis of the surface proteome (Chapter 3). A small amount of the protein 
sample labelled with the IC3 fluorescent dye was used as ‘spike’ to generate an image 
of total protein profile. This allowed the tracking of the efficiency of 2-D 
electrophoresis and transfer and facilitated subsequent matching of immunoblots to 
the surface proteome map generated in Chapter 3. Total protein profiles on-gel and 
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on-membrane following 2D-PAGE and electro-transfer are shown in Figure 5.1A and 
B, respectively. Comparing gel and membrane images, an almost identical spot 
pattern was revealed indicating the uniform and efficient transfer of proteins from gels 
to membranes. Membranes were incubated with serum from mice immunised with 
live N meningitidis MC58 in the presence of iron dextran. The immunoreactive 
proteins detected are presented in Figure 5.2A (shown in pseudo-red) superimposed 
on the total protein content (shown in pseudo-green). As negative control, serum from 
mice given medium with iron dextran alone was used (Figure 5.2B). Immunoblots 
revealed a number of immunoreactive proteins the position of which matched to 
proteins present on the total-protein image. Most fluorescence signals of bound 
antibody were detected in the region of medium to low MW with varying intensities. 
Low fluorescence signals were detected on negative control blots which did not match 
to any of the proteins reacting to immune sera. These are the autofluorescent proteins 
also observed in SDS-PAGE gels at similar molecular masses (Table A2, Appendix). 
 
5.2.2 Identification of immunoreactive proteins from MC58 whole cells 
Immunoreactive proteins were identified by comparison with the surface 
proteome from which protein identities were available (Chapter 3). Spot matching 
between immuno- and surface 2-D proteomes was carried out using the IC3 images. 
In this way, proteins sharing both characteristics of immunoreactivity and surface 
exposure were detected. Results from immuno- and surface proteome comparison are 
presented in Figure 5.3, together with information on protein identity. In total, 18 out 
of the 26 spots of the surface proteome identified by MS also evoked an immune 
response in mice.  
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Figure 5.1 Electrotransfer of proteins from N. meningitidis MC58 ∆-siaD. 
Proteins labeled with IC3 dye (green) were separated on 2-D gels (pI 3-11, 12% 
polyacrylamide gels) (A). Proteins were subsequently transferred to PVDF 
membranes by application of a 437 mA current for 3.5 hr on a semi-dry device (B). 
Images of gels post-transfer were also acquired to check efficiency of transfer (C). 
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Immunoreactive spots belonged to 12 distinct proteins including PorA, OpcA, 
fHbp, lipoproteins NMB1946 and H.8, uncharacterized protein NMB1468, NmMIP, 
PilE, PilP, amino acid ABC transporters NMB1612 and NMB0787 and thiol-disulfide 
interchange protein DsbA2. The presence of different protein isoforms identified in 
previous analysis of 2-D gels was also observed in immunoblots. Trains of spots from 
antibodies binding to isoforms of PorA, NmMIP and PilE were detected. Also, 
lipoprotein NMB1946 and DsbA2 possibly generated spot trails although MS analysis 
for all isoform spots was not carried out. Antibody spot trails suggest different 
isoforms of the same protein could bind to specific antibodies present in immune 
serum. Smears on the trains also indicate their higher immunoreactivities compared to 
the other antigens. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 Identity of proteins reacting to sera from mice immunised with live 
bacteria from N. meningitidis MC58 strain. Images from 2-D immunoblots were 
matched to those from DIGE analysis of proteins from proteinase K-treated 
meningococci. Immunoreactive spots were matched to protein spots affected by 
proteinase K (highlighted by blue areas) and identities assigned based on MS results 
presented in Table 3.2. Matched spots are numbered according to Figure 3.6. 
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5.2.3 Comparison of immunoblots using MC58 wild-type and ∆-siaD proteins as 
antigens 
Immunoblots were also prepared using the protein extract from wild-type 
MC58 strain as antigen. In this way, differences in the presence of immunogenic 
proteins between wild-type and ∆-siaD strains could be investigated and correlated 
with differences in protein expression levels observed by DIGE (Chapter 3, section 
3.3). Immunoreactive proteins from wild type MC58 is shown in Figure 5.4, in 
comparison to those from ∆-siaD. 
Differences in the antibody binding profiles between blots from the two strains 
were observed. Differences were mainly associated with immunoreactive spots being 
present solely or exhibiting more intense fluorescent signals of bound antibody in one 
of the blots. Antibody binding against the amino acid ABC transporter NMB0787, 
PilP and a third protein of an approximate molecular weight of 45 kDa was detected 
in the ∆-siaD blot only. Likewise, proteins forming a train of spots at about 70 kDa 
reacted with sera only in wild-type blots. The intensity in the fluorescence signal was 
somewhat higher for thiol-disulfide interchange protein DsbA2 in ∆-siaD blots whilst 
the trains of spots formed by DsbA2 and lipoprotein NMB1946 in ∆-siaD were not 
obvious in wild-type blots. Also in blots from wild-type MC58, an increase in signal 
and number of spots binding to antibody was observed for proteins forming a train of 
spots at an approximate molecular weight of 80 kDa. Although fluorescence signals of 
bound antibodies against other proteins could also be regarded as differing 
considerably, the significance of these variations in relative levels of protein-specific 
antibody binding was not assessed. 
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5.3 Immunoproteome of H44/76 OMVs 
5.3.1 Protein separation and immunoblotting 
Images of gels and PVDF membranes following 2D-PAGE and electro-
transfer of OMV proteins from H44/76 strain, respectively, are shown in Figure 5.5. 
Similar protein patterns were detected from gels and membranes indicating efficient 
protein transfer. Membranes were blotted with serum from mice immunised with 
MC.6M OMV vaccine. Immunoreactive proteins in pseudo-red are shown in Figure 
5.6A superimposed onto the total OMV protein (shown in pseudo-green). Response 
was mainly directed against the major OMPs as judged by the overlaid image. A 
fluorescence signal of similar magnitude to major OMPs was also detected against a 
minor protein of acidic pI and an approximate molecular mass of 30 kDa. Detectable 
fluorescence signals of antibodies binding to other minor proteins were also observed 
in gel areas around major OMPs. Vertical streaking caused by major OMPs during 
second dimension SDS-PAGE was apparent in images from both gels and blotted 
membranes. 
 
5.3.2 Identification of immunoreactive proteins from H44/76 OMVs 
Identification of OMV proteins reacting to immune sera was carried out by 
MS analysis of gel plugs from preparative 2-D gels. Preparative gels of OMVs were 
made under identical 2D-PAGE conditions used for immunoblots. Following 
matching of protein patterns from gels and blots, those protein spots from gels 
corresponding to the immunoreactive spots on blots were excised and subjected to 
trypsin digestion. Protein digests were subsequently analysed by LC MS/MS for 
identification of immunoreactive proteins.  
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Figure 5.5 Electrotransfer of OMV proteins from N. meningitidis H44/76 strain. 
Proteins labeled with IC3 dye (green) were separated on 2-D gels (pI 3-11, 12% 
polyacrylamide gels) (A). Proteins were subsequently transferred to PVDF 
membranes by application of a 437 mA current for 3.5 hr on a semi-dry device (B). 
Images of gels post-transfer were also acquired to check efficiency of transfer (C).
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In total, 24 protein spots were analysed and 8 distinct proteins identified. The 
position and name of identified immunoreactive OMV proteins is shown in Figure 
5.7. Additional information on identified proteins and MS analysis is presented in 
Table 5.1. Among the proteins with strong reaction to sera were major OMPs PorA, 
PorB, Omp85 and OpcA. The 30 kDa minor protein of acidic pI reacting with sera at 
levels similar to the major OMPs was identified as the NmMIP. Other proteins 
binding to antibodies present in OMV sera were major OMP RmpM, a component of 
a multidrug efflux pump channel (MtrE) and FadL-like protein encoded by 
NMB0088. 
Figure 5.7 Identity of proteins reacting to sera from mice immunised with 
H44/76 OMV vaccine. Two-dimensional immunoblots were matched to images from 
preparative gels of OMV proteins using DeCyder software v.6.5. Protein spots from 
preparative gels matching to immunoreactive proteins on blots were excised and 
subjected to digestion with trypsin followed by LC-MS/MS analysis. Immunoreactive 
spots identified by LC-MS/MS are highlighted and numbered. Information on MS 
analysis is presented in Table 5.1. 
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Table 5.1 Mass spectrometric identification of proteins reacting to sera from 
mice immunised with H44/76 OMV vaccine. Gel plugs corresponding to the 
position on 2-D gels of proteins binding to antibodies present in sera were excised and 
digested by trypsin. Digests were analysed by LC-MS/MS on an Orbitrap Discovery. 
Proteins identified by three or more unique peptides passing the Xcorr vs charge state 
threshold of Sequest search engine are reported. 
 
Gel spot 
number
a Protein name
 Accession 
No
b NMB
c
 
pI / 
MW 
(kDa) 
No of 
peptides 
sequenced 
1 PorA Q51240 1429 
8.73 / 
40.1 
5 
2 Omp85 Q9K1H0 0182 
8.37 / 
86.3 
34 
3 Omp85 Q9K1H0 0182 
8.37 / 
86.3 
32 
4 Omp85 Q9K1H0 0182 
8.37 / 
86.3 
28 
5 Omp85 Q9K1H0 0182 
8.37 / 
86.3 
10 
6 FadL-like protein NMB0088 Q9K1M2 0088 
9.28 / 
48.1 
16 
5 PorA Q51240 1429 
8.73 / 
40.1 
4 
6 PorA Q51240 1429 
8.73 / 
40.1 
9 
7 
Multidrug efflux pump 
channel protein (MtrE) 
Q9JY68 1714 
8.34 / 
50.5 
17 
8 PorA Q51240 1429 
8.73 / 
40.1 
6 
9 PorA Q51240 1429 
8.73 / 
40.1 
6 
10 PorA Q51240 1429 
8.73 / 
40.1 
11 
11 PorA Q51240 1429 
8.73 / 
40.1 
15 
12 PorA Q51240 1429 
8.73 / 
40.1 
21 
13 PorA Q51240 1429 
8.73 / 
40.1 
20 
14 PorA Q51240 1429 
8.73 / 
40.1 
23 
15 PorA Q51240 1429 
8.73 / 
40.1 
18 
16 PorB P30690 2039 
6.54 / 
33.8 
29 
17 PorB P30690 2039 
6.54 / 
33.8 
23 
18 PorB P30690 2039 
6.54 / 
33.8 
22 
19 PorB P30690 2039 
6.54 / 
33.8 
17 
20 
RmpM P0A0V3 0382 
6.26 / 
24.0 
6 
PorB P30690 2039 
6.54 / 
33.8 
3 
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Gel spot 
number
a Protein name
 Accession 
No
b NMB
c
 
pI / 
MW 
(kDa) 
No of 
peptides 
sequenced 
21 
RmpM P0A0V3 0382 
6.26 / 
24.0 
5 
PorB P30690 2039 
6.54 / 
33.8 
5 
22 
Macrophage infectivity 
potentiator (NmMIP) 
Q9JYI8 1567 
5.5 / 
26.9 
12 
23 
Macrophage infectivity 
potentiator (NmMIP) 
Q9JYI8 1567 
5.5 / 
26.9 
9 
24 OpcA Q7DDI3 1053 
9.68 / 
28.1 
19 
a Spot numbers as they appear in Figure 5.7. 
b Accession numbers were derived from UniProtKB/Swiss-Prot database. 
c Gene locus numbers (NMB) are based on the annotated MC58 genome sequence. 
 
5.4 Discussion 
The use of immunoproteomics in combination with fluorescence technology 
offered an accurate tool for detection of immunoreactive meningococcal proteins. 
Overlaid images of gels and blots from both whole-cell and OMV protein 
preparations helped matching individual immunoreactive proteins to their position on 
2-D gels. Correct assignment of the position of proteins on gel, in turn, allowed 
identification of proteins by correlation to previously existing protein identities or MS 
analysis of the corresponding gel plugs from preparative gels. 
Among the identified immunoreactive proteins were major OMPs and known 
immunogens PorA, OpcA, PorB, RmpM and Omp85. Response against these proteins 
has been reported in studies assessing immunity induced by OMV vaccines as well as 
analysis of sera from naturally infected humans (Delvig et al., 1996; Litt et al., 2004; 
Mandrell et al., 1989; Wedege et al., 2007; Wedege et al., 1998). Antibodies to major 
OMPs PorB, RmpM and Omp85 were detected in 2-D immunoblots using sera from 
mice immunised with OMV vaccines but not the whole organism. A different 
topology leading to weaker exposure of these proteins to immune system mechanisms 
on the surface of live meningococci as opposed to OMVs could explain this 
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observation. Weak binding of PorB antibodies on the surface of live meningococci 
has been previously documented in flow cytometry experiments (Michaelsen et al., 
2001). 
Twelve minor proteins were shown to react to murine sera raised against 
whole meningococci or OMV vaccine. Of these, 9 (fHbp, PilE, H.8, NMB1946, 
NMB1612, NMB1468, DsbA2, NMB0787 and PilP) were recognized by sera against 
whole meningococci and 2 (MtrE and FadL-like NMB0088) by sera against OMV 
vaccine. NmMIP was the only minor protein that reacted to both sera tested. The 9 
proteins that were not recognised by OMV sera had not been identified during 
characterisation of H44/76 OMVs (section 4.6) and might indeed not be present in 
OMV preparations. These proteins could either be located away from the outer 
membrane or be stripped off the membrane upon detergent extraction of OMVs. On 
the other hand, absence of MtrE and FadL-like specific antibodies in sera from whole 
meningococci might reflect weak exposure of these proteins on the surface of live 
bacteria. The possible enrichment of these proteins in OMV preparations as opposed 
to whole bacteria might have also contributed to their ability to evoke an immune 
response in mice immunized with OMV vaccine formulations.  
Minor immunoreactive proteins included previously reported immunogens 
fHbp, pilin PilE, lipoproteins H.8 and NMB1946, the amino acid ABC transporter 
encoded by NMB1612, FadL-like protein and protein encoded by NMB1468. 
Antibodies against fHbp and H.8 have previously been detected in human sera from 
convalescing patients (Black et al., 1985; Litt et al., 2004). Pilin PilE and amino acid 
ABC transporter NMB1612 have also exhibited reactivity to sera from humans 
colonised by serogroup B meningococcal strains (Williams et al., 2009) whilst 
antibodies specific for NMB1468 have been detected in sera from mice immunised 
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with a menB strain different to the one used in this study (Hsu et al., 2008). The 
presence of antibodies against lipoprotein NMB1946 or FadL-like protein in murine 
sera generated against whole meningococci has not been reported elsewhere, 
however, specific antibodies generated against these proteins in mice have been 
assessed in SBA and confirmed to be bactericidal (Pizza et al., 2000; Sardinas et al., 
2009). 
For minor proteins NmMIP, PilP, DsbA2 and amino acid ABC transporter 
encoded by NMB0787 this study was the first to report their immunogenic properties. 
NMB0787 has been previously assessed for its potential as vaccine candidate but 
failed to produce bactericidal antibodies in a study by Grifantini et al. (Grifantini et 
al., 2002b), the rest remain to be tested. Low expression of NMB0787 was detected in 
wild-type MC58 by DIGE (section 3.3) which was also confirmed by immunoblots 
from this strain where no antibody binding to NMB0787 was observed. Low 
expression levels could explain failure of NMB0787 specific antibodies to kill 
meningococci in SBA. Conversely, the decreased antibody binding to DsbA2 
observed in blots from wild-type MC58 compared to ∆-siaD was not the result of 
lower expression levels of DsbA2 in the wild-type strain. Similarly, antibody binding 
to PilP was absent from immunoblots against wild-type MC58 which could not be 
explained by differences in relative expression levels between the two strains. On the 
contrary, a strong response against NmMIP was detected regardless of sera or 
meningococcal strain type used in blots suggesting NmMIP could be a promising 
candidate to be prioritised in immunological assays. 
The immunoproteomes presented in this study bear little similarity to the two 
published immunoproteomes assessing reactivity to human sera from colonised 
individuals and convalescing patients (Mendum et al., 2009; Williams et al., 2009). 
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PorA was the only protein present on immunoblots from all studies whilst H.8, PilE 
and amino acid ABC transporter NMB1612 were recognised by both post-
colonisation sera and murine sera against whole meningococci. The remaining 
proteins reacting to murine sera were not recognised by human sera in the published 
immunoproteomes. On the other hand, there were proteins recognised by human sera, 
which were absent in blots with murine sera presented in this study. These results 
highlight a highly variable response depending on the source of sera which can be 
explained when considering human is the only host for meningococci as opposed to 
mice which do not contract meningitis. Part of the discrepancies in the results 
presented here and in published studies could also be attributed to technical variation 
during 2-D immunoblotting. Such variations can be caused during the choice of 
meningococcal strain, protein sample used as antigen and 2D-PAGE conditions. In 
fact, this and published immunoproteomic studies varied in all these parameters. This 
could also explain why OpcA and fHbp with known ability to elicit an immune 
response in humans were identified in this study but not in the published 
immunoproteomes. Another explanation to the absence of known immunogenic 
proteins from blots might be the fact that electrophoretic protein separation is carried 
out under denaturing conditions. In this way, proteins recognised by antibodies 
through conformational epitopes would be missed. 
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6. Evaluation of meningococcal surface proteins as potential vaccine 
candidates 
6.1 Introduction 
 Surface exposure is not the only prerequisite for a protein to be considered as a 
vaccine candidate. The protein’s ability to elicit an immune response, i.e. functional 
antibodies that offer the potential of protecting against meningococcal infection 
should be demonstrated. Factors that can influence this ability include the sequence 
diversity and abundance of the protein on the bacterial surface. High protein 
expression levels can result in high antibody density on the surface of meningococci 
facilitating recruitment of complement and initiation of bacterial killing. Sequence 
variability as a result of positive immune selection is also considered an indication of 
a strong immunogen. Addressing these qualities is therefore an important element of 
the evaluation of a protein’s vaccine potential.  
This chapter presents information towards the evaluation of the vaccine 
candidacy of 4 meningococcal proteins, namely NmMIP, PilP, PilO and the putative 
adhesion complex protein NMB2095. These proteins were identified through 
proteomic analyses described in chapters 3, 4 and 5 as potentially surface-exposed, 
and in some cases, immunoreactive. During the design and performance of this study, 
no report existed regarding the characterisation of any of these proteins as protein 
vaccine candidates. 
 Macrophage infectivity potentiator, NmMIP, is a predicted lipoprotein and a 
member of the family of FKBP-type peptidyl-prolyl cis-trans isomerases involved in 
protein folding. Macrophage infectivity potentiators are virulence factors in 
intracellular bacterial pathogens contributing to persistence or survival in 
macrophages (Cianciotto et al., 1992). In the current study, NmMIP was found to be 
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part of both the surface and OMV proteomes. NmMIP peptides were also detected in 
the supernatants of trypsin-treated meningococci. A strong reaction of NmMIP to 
antibodies present in sera from mice immunised with live N. meningitidis or 
meningococcal OMV preparations was also observed in 2-D immunoblots. 
 PilP and PilO are 2 of the proteins required for tfp expression (Drake et al., 
1997). Lipoprotein PilP is also involved in tfp assembly through interactions with the 
secretin PilQ (Balasingham et al., 2007). Both PilP and PilO were identified in the 
study of the surface proteome where they were partially cleaved by proteinase K. PilP 
was additionally shown to react with sera from mice immunised with live bacteria 
from N. meningitidis MC58 strain. In a previous study, the gene encoding PilO was 
upregulated during interaction of meningococci with human epithelial cells (Dietrich 
et al., 2003). 
The putative adhesin complex protein NMB2095 shares homology with 
adhesion components from other neisserial and bacterial species and bears a signal 
peptide sequence. Based on its detection in supernatants prior to incubation of 
meningococci with proteases, this protein was suggested to be loosely attached to the 
surface of meningococci. NMB2095 was also found to be part of the OMV 
preparations analysed in this and other studies (Ferrari et al., 2006; Williams et al., 
2007). 
As part of their evaluation, the genes corresponding to these proteins were 
cloned in plasmid expression vectors and expressed in E. coli. The resulting 
recombinant proteins were extracted, purified and used to immunise groups of mice 
for production of protein-specific polyclonal antibodies. Immune sera were 
subsequently used in protease-treatment assays and whole-cell ELISA for assessing 
the surface exposure of proteins. Immune sera were also evaluated in immunological 
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assays for detection of antibody-dependent complement deposition, 
opsonophagocytosis and complement-mediated killing of meningococci. 
NmMIP was further assessed for sequence variation using sequence data from 
a panel of 106 meningococcal strains encompassing isolates from various serogroups 
and clonal complexes. Sequence data were also used to detect regions of selective 
pressure and draw phylogenetic relationships between sequence variations and 
genotypic background of strains. Information on a possible topological and structural 
model of NmMIP is also presented. 
 
6.2 Bioinformatic analysis of potential vaccine candidates 
 To facilitate subsequent primer design and cloning into plasmid vectors, the 
potential candidates were assessed for their prevalence and sequence conservation 
across the annotated N. meningitidis genomes as well as for presence of predicted 
signal peptide sequences. 
 
6.2.1 Sequence characteristics and alignments 
At the time of analysis of sequence data, the annotated genome sequences of 
10 N. meningitidis strains were freely available from Genbank 
(www.ncbi.nlm.nih.gov/genbank). These included invasive strains MC58 (ST-32, 
serogroup B), Z2491 (ST-4, serogroup A), FAM18 (ST-11, serogroup C), 8013 (ST-
18, serogroup C), 053442 (ST-4821, serogroup C), WUE2594 (ST-5, serogroup A) 
and carriage strains alpha14 (ST-53, unencapsulated), alpha153 (ST-60, serogroup 
29E), alpha275 (ST-22, serogroup W-135) and alpha710 (ST41/44, serogroup B). The 
presence of ORFs encoding NmMIP, PilP, PilO and adhesin complex protein in these 
genomes is presented in Table 6.1. Open reading frames corresponding to NmMIP 
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and adhesin complex protein were detected in all annotated genomes. In contrast, PilP 
and PilO were detected in some strains and their presence was irrespective of 
serogroup or sequence type. No homologues of PilP were present in carrier strains. 
However, these results are only based on the 10 publically available annotated 
genomes and this limited dataset may not be representative of the entire 
meningococcal population. 
 
Table 6.1 Presence of potential vaccine candidates in the annotated N. 
meningitidis genomes. Genome sequences for the strains presented are available from 
Genbank. The + / - symbols correspond to presence / absence of a homologous gene 
sequence in the genome of strains following BLAST with the corresponding 
nucleotide sequence of each candidate from MC58 genome. 
 
N. meningitidis 
strain 
Protein name 
 NmMIP PilP PilO 
Putative 
adhesin 
complex 
protein 
MC58 + + + + 
Z2491 + + - + 
FAM18 + + + + 
8013 + - - + 
053442 + + + + 
WUE2594 + - + + 
alpha14 + - - + 
alpha153 + - - + 
alpha275 + - + + 
alpha710 + - - + 
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The amino acid sequences deduced for each potential candidate were aligned 
using the MegAlign tool from DNASTAR Lasergene software v.8. Alignments are 
presented in Appendix (Figure A3). For NmMIP sequences, a 30-amino acid amino-
terminal (N-terminal) extension was observed in some strains while missing from 
others. A 4-amino acid deletion was also present in some strains. The remaining 
sequence was 96.5% identical across all ten strains. PilP and PilO sequences exhibited 
99.5% and 99% identity, respectively. Finally, adhesion complex protein appeared to 
have a 62-amino acid-extended N-terminal domain in 4 out of 10 strains. From the 
124 amino acid sequence that was common across all strains, 123 amino acids were 
identical (99.2%). 
 
6.2.2 Signal peptide sequences 
 Signal peptides are cleavable sequences at the N-terminal of the protein which 
are responsible for activating the translocation machinery for protein secretion across 
the cytoplasmic inner membrane and into the periplasm. Here, the chosen proteins 
were examined for the presence and exact cleavage site of signal peptides to 
determine the sequence of the mature protein. The nucleotide sequence corresponding 
to the mature protein sequence subsequently formed the template for primer design 
and cloning into plasmid vectors. 
 The presence and location of signal peptide cleavage sites in the amino acid 
sequences from the annotated MC58 genome was investigated using SignalP 3.0 
(Bendtsen et al., 2004). SignalP predicts signal peptidase I cleavage sites based on a 
combination of neural network (NN) and hidden Markov model (HMM) algorithms. 
The HMM calculates the probability of the presence of a signal peptide to 
differentiate between secreted and non-secreted proteins whilst the NN detects the site 
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of cleavage by assigning different scores to amino acids indicating if they are part of 
the signal sequence and if they are next to a cleavage site. 
The amino acid sequence corresponding to NmMIP was shown to contain 
multiple possible cleavage sites with similar scores based on the NN algorithm. Two 
positions between amino acids 31-32 and 22-23 were suggested as the most likely 
cleavage sites. However, a low S-score was calculated for the sequence between 
amino acids 23 and 31 suggesting that this region has a low probability to form part of 
the signal peptide. Further confirmation that cleavage would more likely occur 
between amino acids 22 and 23 was provided by the HMM algorithm, which 
calculated a high cleavage probability for this site. 
PilP amino acid sequence also exhibited multiple cleavage sites based on 
results from NN with the position between amino acids 23-24 being the most probable 
cleavage site and position 19-20 exhibiting the second best score. The HMM 
algorithm suggested position 19-20 as the most probable cleavage site with high 
probability score. According to von Heijne (Von Heijne, 1983), the most common 
amino acids expected at position -1 of the cleavage site are alanine, glycine, serine, 
cysteine, glutamine and threonine whilst the least expected amino acids at position -3 
are lysine, arginine, asparagine, glutamine, tyrosine, aspartic acid, glutamic acid, 
tryptophan, phenylalanine and histidine. Taking this into account, the site between 
amino acids 19-20 which has glycine and serine at positions -1 and -3, respectively, 
was the most likely cleavage site as opposed to the site between amino acids 23-24 
with leucine and glutamic acid at positions -1 and -3, respectively.  
The amino acid sequence of PilO contained a possible cleavage site between 
amino acids 32 and 33 according to the NN algorithm. Although the HMM also 
detected a cleavage site at the same position, it calculated a higher score for the 
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position between amino acids 40 and 41. However, the HMM is mainly designed to 
predict the presence of the signal sequence and is not as accurate in predicting the 
cleavage site as the NN algorithm. Additionally, the average length of signal peptides 
from Gram-negative bacteria is expected to lie within 20 to 30 amino acids (Bendtsen 
et al., 2004); therefore, cleavage after the 40th amino acid for PilO would be highly 
unlikely. 
Finally, for the putative adhesin complex protein, both the NN and HMM were 
in agreement suggesting that signal peptide cleavage site was between amino acids 21 
and 22. 
 
6.3 PCR amplification 
Conditions for PCR amplification were optimised using the primer pair 
designed for NmMIP. Parameters assessed included the annealing temperature, the 
starting amount of genomic DNA and concentration of MgCl2. Annealing 
temperatures were tested in the range of 54oC to 69oC and MgCl2 at concentrations 
between 0 and 2 mM. Figure 6.1 shows the PCR products yielded for each 
combination of conditions tested. PCR reactions at 63oC in the presence of 1 mM 
MgCl2 gave the most specific product. The different amounts of genomic DNA tested 
had little effect on results and the lowest amount was chosen for subsequent analysis. 
Under these conditions, PCR products for all 4 genes were obtained (Figure 6.2). 
From agarose gel electrophoresis, the size of PCR fragments was shown to correspond 
to the expected size of each amplified gene. 
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Figure 6.1 Optimisation of PCR amplification conditions for fkpA (NmMIP). 
Reaction mixtures containing 0.5 or 1 µL of genomic DNA extracted from MC58 N 
meningitidis were prepared and supplemented with MgCl2 at concentrations of 1 or 2 
mM. Mixtures with no added MgCl2 were also prepared (0 mM). Aliquots were 
subjected to PCR at different annealing temperatures at a range of 54 to 69 oC. PCR 
products were run on a 0.8% TAE agarose gel at 40 mA for 2 hr. DNA was stained 
with SafeView nucleic acid stain and visualized using the KODAK Gel Logic 1500 
imaging system. DNA ladder sizes are shown in kbp on the left and right edges. L1: 1 
kbp DNA ladder, L2: 100 bp DNA ladder. 
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Figure 6.2 Agarose gel electrophoresis of PCR products. Genes fkpA (NMB1567), 
pilP (NMB1811), pilO (NMB1810) and NMB2095 were amplified from N. 
meningitidis MC58 genomic DNA. Primers were designed to introduce sequences for 
ligation-independent cloning (LIC) of the genes to the pET30 Ek/LIC vector system 
(listed in Table 2.3). The size of bands from the DNA ladder is presented on the left in 
bp. L: 100 bp DNA ladder. 
 
6.4 Production and purification of recombinant meningococcal proteins 
PCR products were cloned into pET Ek/LIC plasmid vectors in frame and 
downstream of a sequence coding for a 6-Histidine tag to facilitate subsequent protein 
purification by affinity chromatography. Plasmids containing the gene of interest were 
then used to transform Novablue E. coli competent cells. Successful in-frame 
insertion of all 4 genes into plasmid vectors was achieved as assessed by a) colony-
PCR of E. coli transformants and b) sequencing of plasmids purified from E. coli 
cultures. No nucleotide substitutions were detected when sequencing data were 
compared to the sequences from the annotated MC58 genome. 
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Escherichia coli BL21 pLysS strain was used for expression of protein 
candidates following transformation with the purified plasmids containing the 
corresponding gene. BL21 pLysS cells express the T7 RNA polymerase required for 
transcription of the gene of interest, which is under the control of T7 promoter in the 
pET plasmid vector. Protein expression is achieved through IPTG induction of the lac 
UV5 promoter of T7 RNA polymerase. Additionally, the T7 lysozyme encoded by the 
pLysS gene ensures low background expression levels of the target protein in the 
absence of IPTG. Protein production for up to 5 hr upon IPTG induction was assessed 
by SDS-PAGE of crude extracts from E. coli cell cultures and presented in Figure 6.3. 
Crude extracts were prepared from resuspension of E. coli cell pellets into Laemmli 
sample buffer and were directly applied onto polyacrylamide gels. SDS-PAGE of 
extracts from non-induced cultures is also shown in comparison. All 4 proteins were 
shown to be produced in relatively high levels in the IPTG-induced samples. The 
amount of NmMIP produced reached a maximum after 3 hours of IPTG induction. 
Similarly, the highest yield for PilP, PilO and adhesin complex protein was achieved 
at 5, 4 and 2 hours following addition of IPTG, respectively. Bands corresponding to 
over-expressed proteins were not present in non-induced samples. Total E. coli 
protein levels were shown to be reduced in IPTG-induced samples probably as a 
compensation for the high rate of protein synthesis required for expression of 
recombinant meningococcal proteins. 
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Figure 6.3 SDS-PAGE of crude extracts from cultures of E. coli cells 
transformed with plasmid expression vectors (continues in the next page). 
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Figure 6.3 SDS-PAGE of crude extracts from cultures of E. coli cells 
transformed with plasmid expression vectors (continues from previous page). 
Equal volumes of samples were collected from cell cultures over a period of 4-5 hr 
following induction with IPTG, reconstituted in Laemmli sample buffer and run on a 
12% polyacrylamide gel. Samples from non-induced cultures were also collected and 
run alongside as a negative control. The MW (in kDa) of bands of the protein marker 
is shown on the left. M: SigmaMarkerTM wide-range MW protein marker.  
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Following the lysis of E. coli cells using the BugBuster extraction reagent, 
both the soluble supernatant and insoluble cell debris fractions were collected and 
assessed for the presence of the recombinant proteins in SDS-PAGE. NmMIP, PilP 
and adhesin complex protein were found in the soluble fraction whilst PilO was in the 
insoluble fraction (Figure 6.4). Proteins in the soluble fractions were directly 
processed for affinity purification. The insoluble cell pellet containing PilO was 
instead processed for purification of inclusion bodies by urea treatment. During this 
process, the majority of PilO was recovered in the soluble fractions prior to urea 
treatment, which were then used for affinity purification (Figure 6.4, PilO lane 3). 
The soluble fractions containing the recombinant proteins were applied to 
nickel-charged resins and retained by affinity binding of their His-tag sequence to 
nickel ions. Selective elution of recombinant proteins was achieved by increasing 
concentrations of imidazole. After E. coli proteins were washed away at low 
imidazole concentrations, His-tagged proteins were released at high imidazole 
concentrations through the competition of imidazole for nickel ions. Elution fractions 
containing the purified recombinant proteins were analysed by SDS-PAGE and are 
presented in Figure 6.5. High purity was achieved for NmMIP, PilO and adhesin 
complex protein. The bands corresponding to these proteins exhibited approximate 
MW of 36, 26 and 18 kDa, respectively. In the PilP fraction, two main bands of 
similar high abundance and MW of 25 and 12 kDa were detected. The higher MW 
band probably corresponded to intact PilP whilst the12 kDa band was more likely a 
truncated version of PilP. Traces of other proteins with potential non-specific affinity 
to nickel ions were also observed in the PilP fraction. The experimental MW of the 
intact form of all 4 proteins was higher by a factor of 6 kDa compared to the 
theoretical values for the mature proteins. This 6 kDa increase corresponds to the 
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plasmid vector sequence upstream of the corresponding cloned gene which contains 
the His-tag sequence. 
 
Figure 6.4 SDS-PAGE of fractions used for affinity purification of recombinant 
proteins. The soluble supernatant fractions following BugBuster protein extraction 
are shown for NmMIP, PilP and NMB2095. For PilO, the crude fraction containing 
soluble and insoluble material (lane 1), the soluble supernatant (lane 2) and the 
soluble fraction with recovered PilO during inclusion body purification (lane 3) are 
shown. 25 µg of each fraction were loaded on a 12% polyacrylamide gel and a 40mA 
current was applied for 4 hr. The position of the expressed recombinant proteins is 
highlighted with arrows. The MW (in kDa) of bands of the protein marker is shown 
on the left. M: SigmaMarkerTM wide-range MW protein marker.  
 
6.5 Production of protein-specific polyclonal antibodies 
Immune sera from mice immunised with purified fractions of each of the 
recombinant proteins were assessed in western blots for generation of protein-specific 
antibodies. Whole-cell extracts from N. meningitidis MC58 strain separated on SDS-
PAGE were used as antigen. Antibody binding was detected in the Cy5 channel by a 
Cy5-conjugated goat anti-mouse IgG. Immune serum against each of the recombinant  
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Figure 6.5 SDS-PAGE of His-tag purified recombinant proteins. Proteins 
NmMIP, PilP, PilO and NMB2095 were produced in E. coli BL21 (DE3) pLysS cells 
and purified by gravity-flow affinity chromatography using a NiSO4-charged resin. 10 
µg of each protein were loaded on a 12% polyacrylamide gel and a 40 mA current 
was applied for 4 hr. The MW (in kDa) of bands of the protein marker is shown on the 
left. M: SigmaMarkerTM wide-range MW protein marker.  
 
proteins reacted strongly with a single band (Figure 6.6, pseudo-red). Reacting bands 
were detected at positions corresponding to the theoretical MW of the mature form of 
the meningococcal proteins. In PilP western blots, weak binding to a high MW protein 
was also observed. The position of the band correlated with a protein, which co-
purified with PilP during affinity purification, and was present in the fraction used to 
immunise mice (shown in Figure 6.5). Other bands were also detected in the green 
channel across all blots (Figure 6.6, pseudo-green) and were attributed to protein 
autofluorescence signals. As shown in Table A2 (Appendix), intrinsic fluorescence of 
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certain meningococcal proteins can be detected during fluorescence scanning. 
Although more prevalent in the green channel, these protein bands were also present 
in the red channel suggesting wide emission spectra, a common property of 
intrinsically fluorescent proteins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6 Western blots of cell extracts from N. meningitidis MC58 strain with 
murine immune sera against NmMIP, PilP, PilO and adhesin complex protein 
NMB2095. Cell extracts were separated on 12% polyacrylamide gels and transferred 
to PVDF membranes. Serum from mice immunised with each protein was used as the 
primary antibody (1:2,000 dilution for NmMIP and 1:1,000 for PilP, PilO and 
NMB2095). Cy5-conjugated goat anti-mouse IgG was used to detect antibody binding 
(red bands). Green bands correspond to autofluorescent proteins. The MW (in kDa) of 
bands of the protein marker is shown on the left. M: Pre-stained wide range MW 
protein marker (GE Healthcare). 
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6.6 Investigation of surface exposure of meningococcal vaccine candidate 
proteins 
The immune serum generated against each of the selected meningococcal 
proteins was used to investigate their potential exposure on the bacterial surface. 
Immune sera were assessed for binding to the surface of meningococci in whole-cell 
ELISA and for susceptibility of proteins to protease cleavage carried out in situ in live 
meningococci. 
 
6.6.1 Whole-cell ELISA 
Wild-type and ∆-siaD MC58 strains were used to assess any differences in 
binding due to the presence of the capsule. Figure 6.7 shows the O.D. measured 
across the series of serum dilutions. Starting dilutions as low as 1:50 were used for 
immune sera against PilP, PilO and adhesin complex protein. Due to signal saturation, 
the starting dilution for NmMIP immune sera and positive controls was 1:1,000. A 
cutoff line corresponding to 3 times the optical density measured from the negative 
control serum was generated to determine antibody binding. Readings falling above 
this line were considered as a result of specific binding of antibodies to the 
meningococcal surface (Li et al., 2006). Table 6.2 presents the antibody binding titers 
expressed as the reciprocal of the lowest dilution at which specific binding was 
observed. NmMIP, PilP and adhesin complex protein specific antibodies were shown 
to bind to the surface of both strains tested. NmMIP sera exhibited the highest titers in 
both strains. Differences in optical density and titers measured between the 2 strains 
were also observed but were not significant for any sera tested. 
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Figure 6.7 Optical density measurements from binding of immune sera on the 
surface of N. meningitidis MC58 wild-type and ∆-siaD meningococci in whole-cell 
ELISA. Immune sera were collected following immunisation of mice with purified 
fractions of NmMIP, PilP, PilO or adhesion complex protein NMB2095 mixed with 
MPL adjuvant. As positive control, binding of the anti-PorA monoclonal antibody 
P1.7 was tested. Cutoff thresholds corresponded to 3 times the optical density 
measured with immune sera collected from mice immunised with adjuvant alone. 
Error bars show the standard deviation of the mean values calculated from 3 readings. 
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Table 6.2 Whole-cell ELISA titers showing binding of protein-specific immune 
sera to the surface of MC58 wild-type and ∆-siaD strains
a
.  
 
Protein Antibody wild-type ∆-siaD
 
P-value
b
 
NmMIP a-NmMIP pooled sera 7,751 12,393 0.054 
PilP a-PilP pooled sera 689 844 0.17 
PilO a-PilO pooled sera - - - 
NMB2095 
a-NMB2095 pooled 
sera 
890 778 0.64 
PorA P1.7 monoclonal 84,045 81,180 0.89 
a Whole-cell ELISA was performed by coating plates with the target strain and probing with pooled 
immune sera from groups of 10 mice immunised with the equivalent protein. Results are given as the 
reciprocal of the dilution of serum that gave positive readings 3 times greater than the negative control 
serum (from mice immunised with adjuvant alone). Mean values from triplicate analysis is reported. 
The hyphen corresponds to negative readings. 
b P-values from one-way ANOVA of titers from wild-type and ∆-siaD strains for each protein are 
given. 
 
6.6.2. Digestion of proteins by proteinase K in whole meningococci 
In Chapter 3, NmMIP and PilP were shown to be partially cleaved upon 
treatment of whole meningococci from MC58 ∆-siaD strain with proteinase K. 
Analysis was based on quantitative comparison of the amount of protein on 2-D gels 
before and after treatment. Here, immune sera were used to assess the effect of 
proteinase K treatment on the amount of each protein on 1-D western blots. Treatment 
of both wild-type and ∆-siaD meningococci was carried out using the same range of 
proteinase K concentrations as described in Chapter 3. The results are shown in 
Figure 6.8. Monoclonal antibodies against PorA, which was identified to be 
completely cleaved by proteinase K on the surface of meningococci, were used as 
positive control. Binding of NmMIP sera was observed in treated and non-treated 
fractions from both strains. A reduction in binding in the treated samples from ∆-siaD 
was observed. No obvious reduction in antibody binding was observed for PilP 
between treated and non-treated samples in both strains. However, bands of lower 
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MW appeared in the treated samples of PilP blots which might correspond to 
proteolytic fragments. PilP fragments were more abundant in ∆-siaD blots but were 
also present in blots from wild-type. Complete cleavage of PorA was confirmed in 
blots from both strains. 
 
Figure 6.8 Western blots of proteins digested with proteinase K in whole 
meningococci. Whole-cell protein extracts from MC58 strains treated with different 
concentrations of proteinase K were separated on 12% polyacrylamide gels and 
transferred to PVDF membranes. Membranes were incubated with immune sera from 
mice immunised against NmMIP or PilP. Monoclonal antibodies against the P1.7 
variable region of PorA were used as positive control. Cy5-conjugated goat anti-
mouse IgG was used for detection of antibody binding. 
 
wild type ∆-siaD 
0 1.25 2.5 5.0 10 20 0 1.25 2.5 5.0 10 20 
proteinase K concentration 
(µg/mL per 109 cells) 
PorA 
NmMIP 
PilP 
Chapter 6 Evaluation of surface proteins as potential vaccine candidates 
 197
6.7 Immunologic evaluation of potential vaccine candidate proteins 
Complement deposition, opsonophagocytosis and complement-mediated 
meningococcal killing were used to assess whether protein-specific antibodies 
generated in mice are functional. 
 
6.7.1 Complement deposition assay (CDA) 
C3c and C5b-9 are two factors formed in the late stages of both classical and 
alternative complement pathways and their binding on the surface of meningococci is 
essential for initiation of cell lysis and bacterial clearance (Densen, 1989). Binding of 
C3c and C5b-9 on the meningococcal surface in the presence of immune sera against 
the chosen vaccine candidate proteins and human complement source was assessed by 
flow cytometry (Figure 6.9). Binding to the surface of serogroup B strains from 
various clonal complexes was tested. Significant increases in the deposition of both 
C3c and C5b-9 were observed with NmMIP sera compared to negative control sera in 
all strains tested except H44/76-SL. Binding of C3c in the presence of PilP, PilO and 
NMB2095 sera increased significantly only on the homologous MC58 strain. No 
significant increase in C5b-9 deposition was observed in the presence of sera against 
these 3 proteins in all strains tested. The highest increase in C3c deposition on the 
MC58 strain was observed with NmMIP sera. 
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Figure 6.9 Deposition of complement factors on the surface of meningococci in 
the presence of protein-specific immune sera (continues in the next page). 
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Figure 6.9 Deposition of complement factors on the surface of meningococci in 
the presence of protein-specific immune sera (continues from previous page). 
Meningococci from each of the tested strains were incubated with IgG-depleted 
human plasma and murine immune sera against NmMIP, PilP, PilO and adhesin 
complex protein (NMB2095). Immune sera from mice immunised against adjuvant 
alone (aluminium hydroxide-AlOH or MPL) or against OMV preparations from each 
of the tested strains were used as negative and positive controls, respectively. Binding 
of C3c and C5b-9 complement factors was detected using FITC-labelled sheep anti-
human C3c and C5b-9 antibodies and analysis of FITC fluorescence on a flow 
cytometer. FI-C’ values correspond to FITC fluorescence measured for each test 
serum corrected for fluorescence from a FITC-labelled conjugate only control. 
Information on the strains used can be found in Table 2.1. Error bars show the 
standard deviation of the mean values calculated from 3 readings. 
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6.7.2 Opsonophagocytic assay (OPA) 
The ability of immune sera to induce phagocytosis of meningococci in the 
presence of HL60 phagocytic cells and human complement source was investigated. 
Internalisation of stained bacteria by HL60 cells was detected by flow cytometry 
(Figure 6.10). Opsonophagocytic (OP) activity was tested against the homologous 
MC58 and other serogroup B strains from various clonal complexes. NmMIP specific 
antibodies demonstrated OP activity against 7 out of the 8 strains tested. The only 
exception was the NZ98/254 strain. Immune sera against PilP, PilO and adhesion 
complex proteins failed to show OP activity against any of the strains tested. 
 
6.7.3 Serum bactericidal assay (SBA) 
The serum bactericidal assay was used to test the potential of protein-specific 
antibodies to kill bacteria in the presence of complement source. Results from SBA of 
human sera correlate with protection against meningococcal disease in the presence of 
human complement source (Borrow et al., 2005). Given the scarcity of human 
complement and the use of sera generated in mice, rabbit complement was used in 
SBAs in this study. Bactericidal titers were expressed as the reciprocal of antibody 
dilution where 50% killing of meningococci is observed. Sera generated against each 
of the chosen candidates were tested at dilutions of 8 or greater. This titer has been 
previously used during preclinical evaluation of murine antibodies against other 
potential protein antigens in SBAs in the presence of rabbit complement. When 
immune sera generated against the chosen candidate proteins were tested in SBAs 
against H44/76 strain, no killing of ≥ 50% of meningococci was observed for 
dilutions ≥ 1:8 (Figure 6.11). In contrast, monoclonal antibodies against the PorA type 
expressed by H44/76 strain exhibited a titer of ≥ 16,000. Immune sera from mice 
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against OMVs derived from H44/76 were also bactericidal against the homologous 
strain at a titre of 4,000. Bactericidal activity of NmMIP serum was also tested against 
MC58 strain and similarly no killing was detected. A bactericidal titer of 500 was 
measured for PorA monoclonal antibodies against MC58 strain. 
Figure 6.10 Opsonophagocytosis of meningococci in the presence of protein-
specific immune sera. BCECF-stained meningococci from each of the tested strains 
were incubated with human complement and immune sera against one of NmMIP, 
PilP, PilO and adhesin complex protein NMB2095 followed by incubation with HL60 
phagocytic cells. Internalisation of stained bacteria by HL60 cells was assessed by 
detection of BCECF fluorescence (fluorescein equivalent) by flow cytometry. Positive 
and negative controls were used and FI-C’ values calculated as described in Figure 
6.9 and section 2.19. Error bars show the standard deviation of the mean values 
calculated from 3 readings. 
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Figure 6.11 Complement-mediated killing of meningococci in the presence of 
protein-specific immune sera. Meningococci were incubated with serial dilutions of 
immune sera against NmMIP, PilP, PilO and adhesin complex protein NMB2095 in 
the presence of rabbit complement source. The percentage of killing was calculated by 
comparison of colony counts between test samples and control samples containing 
heat-inactivated complement. Additional controls testing bacterial killing by active 
complement alone were included. Anti-PorA monoclonal antibodies P1.7 and P1.16 
were used for MC58 and H44/76, respectively, as positive SBA control. Serum 
against MPL adjuvant alone was used as negative SBA control. Error bars show the 
standard deviation of the mean values calculated from 4 readings. 
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6.8 Investigation of the meningococcal macrophage infectivity potentiator 
(NmMIP) 
From immunologic analysis of the 4 potential candidate proteins, NmMIP was 
the only one to provide evidence of potential to protect against meningococci. This 
prompted further investigation into other properties of NmMIP including sequence 
variability and structural predictions inferred from comparison with NmMIP 
orthologues in other bacteria. 
 
6.8.1 Sequence analyses 
6.8.1.1 Sequence characteristics and phylogenetic analysis 
Nucleotide and amino acid sequences from 106 meningococcal isolates 
encoding for NmMIP were extracted from BIGS database (Jolley and Maiden, 2010), 
access to which was kindly provided by Prof  M.  Maiden group, University of 
Oxford. The panel of meningococcal isolates corresponds to the MLST dataset and 
encompasses strains from various hypervirulent serogroup B lineages as well as 
invasive and carrier strains from other serogroups (Table A1, Appendix). Sequences 
were aligned using the MegAlign tool from DNASTAR Lasergene software v.8 and 
alignments are presented in the electronic copy provided. Results on the number of 
substitutions and the sequence types are shown in Table 6.3. Thirty polymorphic 
nucleotide sites and 13 polymorphic amino acid sites were detected resulting in 18 
unique nucleotide sequences (allele types) and 10 unique amino acid sequences 
(sequence types), respectively. The 18 unique allele types are presented aligned in 
Appendix (Figure A4). In total, 777 out of 807 (96.3%) base pairs and 255 out of 268 
(95.2%) amino acids were identical across all aligned nucleotide and protein 
sequences, respectively. An in-frame deletion of 12 bp was also observed in 28 
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isolates. As presented in Table A1, isolates carrying the deletion belonged to the 
lineages ST-5, ST-11 and ST-37. 
 
Table 6.3 Polymorphism and allele statistics for NmMIP based on sequences 
from 106 meningococcal isolates. Allele types and amino acid sequence types 
correspond to unique nucleotide and amino acid sequences. The panel of isolates used 
in analysis is presented in Table A1 (Appendix). 
 
Alignment (bp) 819 
Number of allele types 18 
Number of polymorphic nucleotide sites 30 
Number of amino acid sequence types 10 
Number of polymorphic amino acid sites 13 
 
To assess a possible connection between clonal complexes and MIP allele type 
phylogenetic trees were constructed by ClonalFrame using the aligned nucleotide 
sequences from the 106 isolates. ClonalFrame assesses the clonal relationships of 
isolates by accounting for both point mutations and homologous recombination. 
Results from ClonalFrame were visualized using MEGA software v.5 and presented 
as radial trees (Figure 6.12). In these phylogenetic views, each leaf represents a 
meningococcal isolate and each internal node corresponds to the most recent common 
ancestor of the descendant isolates. Based on NmMIP sequences, isolates were 
divided into 2 groups / clades linked to a single common ancestor. One group 
contained the isolates carrying the 12 bp deletion. The only exceptions were isolates 
numbered 657 and 658 which do not carry the deletion and formed a distinct clade 
within this group. Isolates of the same clonal complex, namely ST-5, ST-11 and ST-
37 were shown to cluster together. The other group contained all remaining isolates 
which further clustered by clonal complex into four subclades. ST-4, ST-8 and ST-32 
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formed distinct subclades whilst ST-1, ST-18 and ST41/44 grouped together in the 
same subclade. Notably, 2 isolates from ST-5 lacking the deletion (numbered 239 and 
299) clustered together with ST-4 isolates. Overall, there was an evident relationship 
between clonal complex and changes in the NmMIP gene and a low rate of sequence 
reassortment between isolates of different lineages. 
ClonalFrame was also used to calculate the ratio of changes resulting from 
recombination to those occurring through point mutations (r/m). Recombination 
versus mutation values less than 1 indicate low, 1-2 intermediate, 2-10 high and 
greater than 10 very high recombination rates. The r/m value calculated for NmMIP 
gene was 1.54 suggesting intermediate levels of recombination between 
meningococcal isolates affecting NmMIP gene. 
6.8.1.2 Synonymous and non-synonymous substitutions 
Base substitutions are the most common form of mutation which can either 
alter (non-synonymous) or have no effect (synonymous) on the amino acid sequence 
due to redundancy of the genetic code. The ratio of non-synonymous (dn) against 
synonymous (ds) substitutions is used as an indicator of whether or not sequences are 
under selective pressure. Positive selective pressure works towards sequence 
variability and favours non-synonymous substitutions. A protein under positive 
selective pressure would therefore be expected to exhibit a dn/ds ratio ≥ 1 (Nei and 
Kumar, 2000). This is a common observation for immunogenic proteins where 
alterations occur in the epitopic regions and help meningococci to evade host 
immunity (Derrick et al., 1999). To assess possible selective pressures imposed to 
NmMIP by the immune system, the dn/ds ratio was calculated using SNAP 
programme which is based on a method developed by Nei and Gojobori (Nei and 
Gojobori, 1986).  
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Figure 6.12 Clonal relationships of meningococcal isolates based on NmMIP 
nucleotide sequence. Aligned NmMIP sequences from 106 meningococcal isolates 
were analysed by ClonalFrame and results visualised using MEGA v.5. Evolutionary 
distance is presented using the radial tree view. Isolates are numbered according to 
Table A1 (Appendix) and color-coded by sequence type (ST). 
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The average dn and ds numbers calculated from all pairwise sequence 
comparisons were 0.0037 and 0.0241, respectively, resulting in a dn/ds value of 0.15, 
indicative of negative selective pressure favoring sequence conservation. SNAP was 
also used to calculate the rate of synonymous and non-synonymous substitutions for 
every single codon. Figure 6.13 shows the rate, type and distribution of substitutions 
across the amino acid sequence. No region of high variability was identified. Instead, 
the few substitutions were shown to be evenly distributed along the amino acid 
sequence. 
 
Figure 6.13 Distribution of synonymous and non-synonymous substitutions in the 
NmMIP amino acid sequence. Rates of substitutions were calculated using the 
SNAP algorithm (http://www.hiv.lanl.gov) following alignment of NmMIP amino 
acid sequences from 106 strains (Table A1, Appendix). 
 
6.8.2 Topological and structural characteristics of NmMIP protein 
6.8.2.1 Topology predictions 
Based on PsortB and LipoP analysis described in Chapter 3, NmMIP is a 
predicted lipoprotein associated with the outer membrane via a palmitoyl group. In 
Gram-negative bacteria like N meningitidis, lipoproteins possess a signal peptide 
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sequence which targets them to the inner (cytoplasmic) membrane and a lipobox 
sequence, usually L-(S/A)-(G/A)-C. In NmMIP, the first 22 amino acids serve as the 
signal peptide sequence (see section 6.2.2) and amino acids 18-21, a sequence of L-S-
A-C, constitute the lipobox. Following cleavage of the signal peptide by peptidases 
and lipid modification of the cysteine residue of the lipobox, the protein can be either 
retained on the inner membrane or released for association to the outer membrane 
(Tokuda and Matsuyama, 2004). This is determined by sequence signals recognised 
by the Lol system, a group of inner membrane, periplasmic and outer membrane 
proteins found in E. coli and other Gram-negative bacteria. Homologues of the Lol 
system in MC58 were identified through BLAST searches with E. coli amino acid 
sequences for proteins LolA-E. Open reading frames coding for Lol proteins in MC58 
included NMB0622 (LolA), NMB0873 (LolB), NMB1235 (LolC/E) and NMB1234 
(LolD). A known lipoprotein-sorting signal recognized by Lol proteins is the first 
residue carboxy-terminal to the modified cysteine (position 2). Any amino acid other 
than aspartic acid in this position allows for the release of the protein from the inner 
membrane and its recognition by proteins LolA and LolB for subsequent attachment 
to the outer membrane. In NmMIP, a glycine residue is found in position 2 suggesting 
NmMIP is associated to the outer membrane. What determines the orientation of an 
outer membrane-attached lipoprotein is still poorly understood and no general 
sequence patterns have been proposed so far. 
The membrane topology prediction server TOPCONS was used to identify 
other potential sequence features of NmMIP in an attempt to conclude to a more 
accurate model of NmMIP topology on the cell envelope. TOPCONS brings together 
different methods for prediction of transmembrane domains based on both sequence 
statistics (PRO-TMHMM, PRODIV-TMHMM) and physicochemical principles 
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(SCAMPI) (Bernsel et al., 2009). One transmembrane domain was identified in the 
region between amino acids 3 and 22 which exhibited the lowest ∆G value (Figure 
6.14). This is the region corresponding to the signal peptide sequence which is 
cleaved upon targeting of the lipoprotein to the inner membrane and does not form 
part of the mature protein. No additional transmembrane helices were identified. 
 
Figure 6.14 TOPCONS membrane topology prediction for NmMIP protein. The 
proposed topological model from the individual methods is presented (top). Graphs 
indicate predicted Z-coordinates and free energy (∆G) values across the sequence. 
 
6.8.2.2 Structural model 
NmMIP belongs to a group of proteins predominantly present in intracellular 
bacterial pathogens which assist to the survival and multiplication of the pathogen 
within macrophages (Cianciotto et al., 1992). Bacterial MIPs also belong to the wider 
family of FK506-binding proteins (FKBP) whose functional role is the catalysis of the 
amino acid sequence 
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cis-trans isomerisation of peptidyl-prolyl bonds during protein folding (Galat and 
Metcalfe, 1995). FKBP-type proteins are also found in humans. Legionella 
pneumophila MIP (LpMIP) is the most studied bacterial MIP and its structure has 
been resolved (Riboldi-Tunnicliffe et al., 2001). LpMIP consists of two distinct 
domains. The N-terminal domain is composed of alpha helices, which are involved in 
protein dimerisation and exhibit high sequence diversity across different species. The 
C-terminal domain forms 6 beta-strands with a fold typical of FKBP-type proteins. 
The C-terminal domain exhibits isomerase activity and is well conserved across 
FKBPs. LpMIP has been confirmed to reside on the cell surface of L. pneumophila 
(Helbig et al., 2001). 
The structural characteristics of NmMIP were investigated by a) alignment of 
NmMIP amino acid sequence from MC58 with MIP orthologues from other bacteria 
and a member of the FKBP family from human (Figure 6.15) and b) reconstruction of 
a 3-D model based on LpMIP published structure (Figure 6.16). Sequence sites 
involved in dimerisation and interactions with FK506 were inferred from LpMIP 
structural elucidation and are marked in the alignment. A good degree of homology 
was observed across bacterial MIP sequences where approximately 40% of amino 
acid residues were identical. The human FKBP2 sequence included in the alignment 
exhibited similarity with the C-terminus of bacterial MIPs. Most identical residues 
across all aligned sequences were found in the C-terminal domain which carries the 
enzymatic centre of FKBPs and is therefore expected to be more conserved. Two 
methionines in helix α2 of LpMIP are thought to be involved in interactions between 
the monomers for formation of the dimeric structure. One of these methionines is also 
present in NmMIP (position 85) with the other residue being a phenylalanine (position 
81). Residues involved in interaction with FK506 have also been identified in LpMIP. 
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FK506 is an immunosuppressant macrolide antibiotic which inhibits the 
prolylisomerase activity of FKBPs. All residues are found in the C-terminal domain 
and were conserved across bacterial MIPs and the human FKBP2 sequence. This 
provides further evidence for the conserved character of the enzymatic centre of 
FKBPs. 
The predicted structure of NmMIP protein is presented as a 3-D model in 
Figure 6.16. The generated structure belongs to the region between amino acids 49 
and 255 of the 272 amino acid-long NmMIP sequence which aligned with LpMIP 
protein sequence. Two antiparallel α-helices are formed in the N-terminus by amino 
acids 50-67 (α1) and 79-90 (α2). A long, exposed helix composed of amino acids 98-
139 links the N and C-terminal domains. Like in LpMIP, the C-terminal domain 
consists of 6 β-strands, which form an antiparallel β-sheet and a α-helix (aa 203-211) 
lying across the sheet. The amino acids involved in dimerisation in N-terminal helices 
and in interaction with FK506 are highlighted. An example of the structure of the 
NmMIP dimer is shown in Figure 6.16B. 
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Figure 6.16 3-D model of the predicted structure of NmMIP protein from MC58. 
NmMIP monomer (A) and dimer representations (B) are shown. Secondary structures 
in A are coloured in sequence succession from dark blue to red. The monomeric forms 
of the dimer are coloured green and blue. The position of important residues for 
NmMIP structure and function are highlighted in A. 
 
  
6.9 Discussion 
The vaccine potential of 4 proteins identified from proteomic analysis of the 
meningococcal surface and OMV proteome was assessed in immunological assays 
using protein-specific antibodies raised in mice. Meningococcal macrophage 
infectivity potentiator (NmMIP), tfp biogenesis assembly proteins PilP and PilO and 
putative adhesin complex protein encoded by NMB2095 had not previously been 
characterised as potential vaccine candidates despite their putative functional roles in 
meningococcal pathogenesis. 
A B 
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Recombinant forms of all four proteins were purified from soluble fractions of 
E. coli protein lysates and there was no evidence of formation of inclusion bodies 
during protein production. Inclusion bodies constitute aggregates of partially folded or 
misfolded proteins which in the case of recombinant protein production are 
considered to be the result of the bacterial stress response mechanisms to cope with 
the large amounts of accumulated protein product (Villaverde and Carrió, 2003). The 
solubility of the meningococcal proteins accumulated in the E. coli cytoplasm 
suggests the proteins were in their folded state although their exact conformation 
might be different to the one obtained in their natural location. It also suggests 
proteins did not undergo any degradation often observed in inclusion body-forming 
proteins. Only exception was PilP which exhibited a second truncated version 
appearing at a lower MW in SDS-PAGE of E. coli crude extracts (Figures 6.5 and 
6.6). However, this PilP fragment must be the result of treatment with BugBuster 
since it was only present in SDS-PAGE of BugBuster-lysed cells. 
The murine polyclonal antibodies were shown to specifically recognise the 
protein they were raised against and enabled evaluation of individual proteins in 
immunological assays. The assays performed assessed 2 different mechanisms of 
protection involved in immunity against meningococcal disease. Complement 
deposition and serum bactericidal assays test the attachment of certain components of 
the complement pathway and the complement-dependent killing of meningococci, 
respectively. Opsonophagocytosis assays assess ingestion of meningococci by 
phagocytic cell lines in the presence of complement source. Serum bactericidal assays 
have been shown to correlate with efficacy of serogroup B OMV vaccines and a titer 
of ≥ 4 (or ≥ 4-fold rise from pre to post immunisation) has been proposed as a suitable 
correlate of protection (Holst et al., 2003). Opsonophagocytosis has also been 
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suggested to contribute independently to the observed protection especially in cases 
where SBA activity is absent (Plested and Granoff, 2008). 
NmMIP was the only protein tested whose antibodies provided positive results 
in one or more assays. This can, in part, be explained by the differences in surface 
exposure observed for the 4 proteins in whole-cell ELISA. The extent of a protein’s 
exposure can affect the accessibility of antibodies on the bacterial surface and the 
subsequent attraction of complement factors for formation of the attack complex. 
NmMIP was shown to be sufficiently exposed on the meningococcal surface to bind 
to NmMIP immune sera in whole-cell ELISA. In contrast, only weak binding was 
observed for PilP and NMB2095 sera and no binding for PilO sera. 
Antibodies against NmMIP induced deposition of complement factors on the 
bacterial surface but failed to kill meningococci in a complement-mediated manner. 
Differences in bacterial treatment between the 2 assays might have contributed to this 
apparent paradox. Bacteria were inactivated by treatment with azide/PMSF prior to 
complement deposition assay whilst live untreated bacteria were used in SBAs. 
Inactivation of bacteria by heat or ethanol has previously been accused for modulation 
of the bacterial outer membrane facilitating the accessibility of antibodies to protein 
epitopes that were otherwise buried in untreated bacteria (Kolberg et al., 2008). A 
possible exposure of additional NmMIP epitopes on azide-treated meningococci used 
in CDA could have enhanced antibody binding to the bacterial surface leading to the 
observed attraction of complement factors. In contrast, absence of antibody binding in 
live bacteria would not support attachment of complement and hence induction of 
bactericidal killing in SBA. 
Another parameter that could have potentially affected the SBA result is 
relevant to the folding properties of purified protein injected into mice. Acquisition of 
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a conformation different to that of the native protein can impact on the formation of 
the epitopic regions and hence, the generation of antibodies which can efficiently bind 
to the protein on the meningococcal surface and activate the complement cascade. 
During writing of this thesis, Hung et al. showed that incorporation of a similar 
recombinant NmMIP preparation into liposomes or Zwittergent 3-14 micelles 
followed by injection into mice in the presence of MPL adjuvant produced 
bactericidal antibodies with a titer of 1,024 (Hung et al., 2011). Liposomes and 
micelles form a lipid bilayer mimicking the bacterial cell wall thus allowing the 
protein to obtain a near native conformation. Liposomes have been previously used 
for administration of meningococcal protein vaccine candidates in mice for 
subsequent evaluation of resulting antibodies in SBAs (Delgado et al., 2007; Wright 
et al., 2002). 
The opsonic activity of NmMIP antisera suggests that NmMIP antibodies 
might offer protection against meningococcal disease by an alternative mechanism to 
complement-mediated bacterial lysis. Vaccine-induced opsonophagocytic activity of 
antibodies present in human sera against subcapsular antigens has been observed 
following immunisation with OMVs derived from H44/76 strain (Findlow et al., 
2006). Whether OPA can provide immunity in humans independently of SBA activity 
has not been experimentally demonstrated. Yet, subcapsular antigens may involve a 
more direct role for cell-mediated immunity compared to the capsular polysaccharide 
which is the main effector of vaccine-induced protection in menC (Gomez-Lus et al., 
2003). 
An important observation was the limited sequence variation of NmMIP. 
Antigenic variation is the result of positive immunoselective pressure and provides a 
method for meningococcal immune evasion. Sequence variation is common across 
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meningococcal immunogenic proteins including immunodominant PorA as well as 
minor antigens fHbp and FadL-like protein coded by NMB0088 (Brehony et al., 
2009; Derrick et al., 1999; Yero et al., 2010). Interestingly, this variation occurs in the 
exposed epitopic regions of meningococcal antigens, which are the targets for 
functional antibodies. Unlike these immunogens, NmMIP exhibited a highly 
conserved sequence with only a small number of substitutions scattered across the 
sequence precluding the presence of regions under strong positive selective pressure. 
Although following a structuring similar to other meningococcal antigens (Brehony et 
al., 2009; Urwin et al., 2004), the limited sequence diversity could suggest that 
NmMIP might have evolved to evade immunity and thus represent a weak antigen. In 
a different scenario, immune selection might have recently been introduced in the 
evolution of NmMIP sequence hence the limited variation observed. The limited 
reassortment observed between different allele types as a result of recombination 
events might provide support to this argument.  
Sequence similarities between NmMIP and orthologues from other bacteria 
supports NmMIP functional role as a prolylisomerase. The structural model presented 
in this study confirmed the different conformation observed for N- and C- terminal 
domains with N-terminal helices being fully exposed and C-terminal strands 
containing the enzymatic centre (Riboldi-Tunnicliffe et al., 2001). However, 
structural and topological data did not conclude on the exact orientation of NmMIP on 
the meningococcal outer membrane. Results from whole-cell ELISA support a 
possible surface exposure which however could also be attributed to the heat 
inactivation of bacteria used in the assay. Additional methods would be needed to 
assess surface exposure of NmMIP under physiological conditions including flow 
cytometry and immunogold labelling using anti-NmMIP immune sera.  
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A study on the MIP orthologue from the related species N. gonorrhoeae by 
Leuzzi et al. supported a role for gonorrhoeal MIP in bacterial persistence in 
macrophages (Leuzzi et al., 2005). This is in line with observations from intracellular 
bacterial pathogens which exploit MIP proteins to initiate infection of host 
macrophages (Cianciotto et al., 1992). In a study of Legionella pneumophila MIP, the 
N- and C-terminal domains were assessed for contribution to virulence and both were 
found to be necessary for infection in animal models whilst only the dimer was 
essential for virulence against monocellular systems (Köhler et al., 2003). Respective 
studies on N. meningitidis would greatly improve our understanding into the role of 
NmMIP in meningococcal pathogenesis. 
 
6.10 Concluding remarks 
Of the 4 proteins evaluated in immunological assays, NmMIP provided 
evidence for its potential to induce functional antibodies. The ability of anti-NmMIP 
antibodies to attract complement components on the meningococcal surface in 
combination with their opsonic and bactericidal activity in mice observed in this and 
other studies supports a role in vaccine-induced protective immune response against 
meningococcal disease. On the other hand, the absence of variable regions in the 
NmMIP sequence as a result of negative immune selection might have implications in 
the induction of a similar response in humans and hence the suitability of NmMIP as a 
vaccine candidate. 
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7. General Discussion 
7.1 Bacterial surface proteomics for the discovery of protein vaccine candidates 
7.1.1 Bacterial treatment with proteases 
Characterisation of the repertoire of protein antigens on the surface of bacteria 
for identification of potential vaccine candidates has been the objective of various 
proteomic strategies. A common feature of these strategies is the direct chemical 
treatment of whole bacteria to facilitate downstream isolation and analysis of surface-
exposed proteins. Certain methods involve chemical agents to introduce a 
modification, such as biotin or fluorophores, on accessible amino acid residues of 
surface-exposed proteins (Ge et al., 2007a; Ge et al., 2007b; Mayrhofer et al., 2006). 
Modified surface proteins can be separated from the total proteome by detection of 
fluorescence or purification using affinity interactions to pull down chemically-tagged 
proteins. However, non-uniform modification of proteins, cell-permeable chemicals 
and downstream purification steps might introduce variability and reduce specificity 
of these methods. In this study, treatment of whole bacteria with proteases was used 
for detection and characterisation of protein antigens on the surface of meningococci. 
This method provides a physical way to identify surface antigens through direct 
digestion of their exposed, epitopic domains (Bledi et al., 2003; Rodriguez-Ortega et 
al., 2006). Unlike other methods, the specificity of protease treatment is more 
dependent upon the extent of protein exposure on the bacterial surface, and less upon 
the success of chemical modification and purification steps. 
The potential of protein treatment with proteases for discovery of putative 
antigens has been demonstrated in studies with Gram-positive bacteria, such as 
streptococci (Doro et al., 2009; Rodriguez-Ortega et al., 2006). These studies also 
highlighted certain limitations in the specificity of the method related with the direct 
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MS analysis of supernatant samples containing the protease-digested surface-exposed 
peptides. Contamination of supernatant samples with non-surface proteins was 
observed in most studies which varied depending on the organism and conditions of 
treatment (Dreisbach et al., 2010; Tjalsma et al., 2008; Walters et al., 2009). Analysis 
of meningococcal supernatants following treatment with trypsin identified proteins, 
the majority of which were not unequivocally shown to be expressed at the bacterial 
surface. Gram-negative bacteria could be suggested to be more vulnerable to 
contamination phenomena as a result of the absence of physical barriers to protect the 
outer membrane. On the contrary, the membrane of Gram-positive organisms is 
surrounded by a thick peptidoglycan layer that could potentially offer better resistance 
to proteases. Comparative studies on bacteria of different Gram stain will be required 
to establish possible differences in their cell wall resistance to protease treatment.  
An additional limitation to the analysis of supernatants is the need for more 
specific proteases like trypsin to facilitate downstream MS analysis. Specific 
proteases hydrolyse peptide bonds after certain residues. The number of protease 
cleavage sites across the exposed domains of surface proteins determines the number 
of peptides released in the supernatant. For a protein requiring 2 peptides to be 
identified by MS, 3 cleavage sites are needed. This, in turn, suggests that proteins 
containing less than 3 cleavage sites digested by the respective specific protease will 
fail to be identified. Direct MS analysis also produces inconsistencies in the number 
of peptides matched to each protein which can be the result of differences in the 
proteins abundance. Such inconsistencies further confuse interpretation of data and 
correct assignment of surface proteins. Based on these limitations, it is arguable 
whether the analysis of peptides released in the supernatant can reliably characterise 
the bacterial surface. 
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Comparative analysis of the total protein content before and after treatment 
with proteases poses as an attractive alternative strategy to identify the proteins 
digested by proteases in whole bacteria. This type of analysis avoids contamination 
phenomena related to the analysis of supernatants and therefore does not require 
exhaustive optimisation of treatment conditions. By uncoupling treatment from direct 
MS analysis, it also allows the use of less specific proteases, such as proteinase K, to 
enhance digestion efficiency. Before this report, this strategy had only been used for 
identification of Helicobacter pylori surface proteins (Sabarth et al., 2005). When 
applied to meningococci, it provided a more realistic picture of antigens on the 
meningococcal surface compared to the analysis of supernatants. Major antigens 
PorA, OpcA, Omp85 and fHbp, potential antigens fadL-like NMB0088, NMB1468 
and NMB1946 as well as other known and novel immunogens were part of the 
proteins identified. The specificity of analysis was also improved and only a few 
cytoplasmic proteins were identified mainly due to their co-detection in the same spot 
with proteins of the surface. Although not yet applied to Gram-positive bacteria, this 
approach could potentially find application across bacterial species regardless of their 
cell wall composition. 
Quantitative DIGE analysis applied in this study also provided a way to obtain 
additional information on the individual proteins found on the bacterial surface. 
Quantitative results on the decrease in abundance of a protein spot upon treatment 
with protease are indicators of the extent of protein digestion which, in turn, can be 
associated with the protein’s exposure and accessibility on the bacterial surface. In 
other words, completely digested proteins would be expected to be more accessible on 
the bacterial surface as opposed to partially digested proteins. In the context of 
vaccine development, this information could prove useful when choosing candidates 
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to be prioritised in immunological evaluation studies. Completely digested, highly 
accessible surface proteins are more likely strong immunogens with variable exposed 
epitopes due to positive immune selection. On the other hand, partially digested 
proteins would be expected to be more conserved and exhibit modest antigenic 
properties influenced by their weak accessibility to antibodies on the surface of 
individual isolates. For bacterial species with little previous knowledge of the 
antigenic protein content, this analysis can highlight and narrow down subsequent 
studies to proteins with the greatest potential as protective immunogens. For 
organisms like meningococci where major antigens are well studied, this approach 
can identify additional minor candidates which, proven protective, could complement 
vaccine formulations. 
The nature of protease treatment and 2D-PAGE analysis can impose potential 
limitations to the application of this approach to certain protein groups. One such 
group includes proteins with inherent resistance to proteases. By resisting digestion 
these proteins will fail to be identified even when present on the surface. Outer 
membrane protein PorB is an example of a meningococcal protein with resistance to 
various proteases under native conditions (Minetti et al., 1998). PorB was not found 
among the proteins affected by proteinase K although it is known to expose several 
loops on the meningococcal surface.  
Another protein category that could be missed from this type of analysis 
includes highly hydrophobic members of the outer membrane. These proteins are 
difficult to solubilise in the mild detergents used during 2D-PAGE and might be 
under-represented in 2-D gels. Considering their association with the bacterial 
membrane, absence of these proteins from 2-D analysis could suggest a considerable 
loss of many potentially surface-exposed proteins. Identification of several OMPs on 
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the meningococcal 2-D gels prepared in this study suggests that the representation of 
membrane proteins on 2D gels can be enhanced by the use of certain conditions. 
Other strategies might also be implemented to overcome the issues related to 2D-
PAGE. An attractive alternative would be the use of conventional SDS-PAGE 
coupled to chemical isotopic labelling for comparative analysis of protease treated and 
untreated bacteria (Soufi et al., 2010). Proteins from different samples are first 
modified to contain different isotopic tags (e.g. SILAC, ICPL). They are subsequently 
solubilised in SDS-containing buffers, mixed and separated by SDS-PAGE. The use 
of SDS during sample preparation improves solubilisation and representation of 
membrane proteins. Several gel bands are then excised and proteins digested into 
peptides and analysed by MS. Differential analysis occurs in MS by comparing the 
peak intensity of each peptide in the different samples. The difference in mass 
introduced by isotopic labelling allows for differentiation between peptides from 
different samples. Considering a gel band contains tens of proteins, this type of 
analysis has the capacity to screen the entire proteome for potential surface proteins.  
 
7.1.2 Immunoproteomics 
Immunoproteomics is another proteome-wide analysis that can assist in the 
search for protein candidates to be qualified for further immunological evaluation of 
their vaccine potential. Blotting with immune sera from animals or humans is a 
common strategy to detect proteins that evoke an immune response. Conventional 
SDS-PAGE immunoblots have been used during the evaluation of OMV vaccines to 
assess consistency in IgG responses against major OMPs across different batches 
(Frasch et al., 2001; Fredriksen et al., 1991). However, the low resolution of proteins 
in SDS-PAGE does not allow for accurate identification of other minor immunogenic 
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proteins. Through combination of 2D-PAGE and MS analysis, immunoproteomics 
offers a strategy to not only detect but also identify the proteins involved in immune 
responses. Using this approach, a 2-D map was constructed containing the proteins 
identified to react to immune sera from mice immunised with whole meningococci or 
OMV vaccine preparations. Identification of immunogens not previously reported in 
the literature demonstrated the potential of immunoproteomics to support the 
discovery of novel potential antigens.  
Similar to the surface proteome analysis, there are limitations to the 
information that can be inferred from immunoblots. Reactivity of a protein to 
antibodies present in immune sera does not necessarily mean that these antibodies are 
functional and able to offer protection. Bactericidal killing and opsonophagocytosis 
assays are necessary for the assessment of the functional activity of protein specific 
antibodies and for immunoreactive proteins to be considered as potential antigens. 
Additionally, antibody binding on immunoblots does not represent the true conditions 
of antibody recognition on the bacterial surface. The denaturing conditions used 
during protein separation on gels alter the conformation acquired by protein epitopes 
when presented to the immune system. Immunogenic proteins for which interaction 
with antibodies is based on conformational epitopes are therefore missed by 
immunoproteomic analysis. Similarly, denaturation may reveal otherwise hidden 
epitopes and give a positive result on immunoblots when the native protein would not 
normally react.  
The use of animals as a source of immune sera is another possible cause of 
unrealistic results. Especially in the case of meningococci where the human is the 
only host, immune responses raised in mice and other animals can vary greatly and 
should be treated with some scepticism. This also highlights the importance of 
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studying sequence variation as a more relevant way to assess human immune 
responses. From all of the above, immunoblots are essentially not expected to be the 
protagonists but instead play a supportive role in the screening of bacterial proteomes 
for identification of potential antigens. 
 
7.1.3 Integrated 2-D proteome maps 
 Proteomic methods often generate a great amount of data that require further 
organisation and processing if comprehensive conclusions are to be drawn. The 
methods described for the analysis of bacterial surface antigens potentially provides a 
variety of datasets that need to be compared and integrated into a single data file. The 
use of 2D-PAGE and the generation of 2-D proteome maps provide the starting 
platform where integration of results from different experiments can be achieved. A 
schematic example of an integrated proteome map is presented in Figure 7.1. The map 
incorporates results from the two proteomic experiments performed in this study to 
provide a picture of the meningococcal antigenic proteome. Surface proteins digested 
by proteases are highlighted using dark and light green circles corresponding to 
complete and partial digestion, respectively. Proteins reacting with sera from 
immunised mice are demonstrated by red dots. The resulting map can be 
supplemented with information from comparative studies on protein expression levels 
between different isolates, like the one presented in Chapter 3 between wild-type and 
∆-siaD MC58 strains. Additionally, the size of each spot on 2-D gels can be used to 
provide information on the relative expression levels of the corresponding proteins in 
the bacterial proteome. 
Integrated maps can form the basis for the generation of more comprehensive, 
publicly available “antigen-ome” databases, i.e. databases that incorporate results 
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from application of the described methods to more isolates and more bacterial species 
and link them to information from antigenic variation and immunological studies. 
Construction of such databases are feasible using packages like the Make2D-DB II 
(Mostaguir et al., 2003) which have been used for the design of existing 2-D 
databases such as SWISS-2DPAGE and World-2DPAGE Repository. The 
contribution of “antigen-ome” databases to vaccine discovery will be marked 
considering that the researcher will have simultaneous access to information on the 
coverage, level of expression, surface exposure and immunological responses of 
protein vaccine candidates, prior to any clinical testing. 
 
7.2 The future of proteomics in meningococcal disease 
The advances seen in the field of whole genome sequencing have enabled the 
generation of genome-wide sequence data from an increasing number of 
meningococcal isolates which can be used in comparative genomics and 
transcriptomics studies. There are various reports from studies comparing the 
genomes of invasive and carrier isolates in an attempt to identify virulent genes 
associated with the invasive meningococcal phenotype (Hotopp et al., 2006; Joseph et 
al., 2010; Schoen et al., 2008). Available genome sequences have also facilitated 
construction of microarrays which have been used to screen for differences in the 
gene content of isolates from various serogroups and of different disease phenotype 
(Stabler et al., 2005). Microarray technology was also used in transcriptomics studies 
assessing changes in gene expression upon interaction with human epithelial cells or 
exposure to human serum for identification of genes involved in meningococcal 
pathogenesis (Dietrich et al., 2003; Grifantini et al., 2002a; Kurz et al., 2003).  
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Figure 7.1 Integrated 2-D map of the antigenic proteome of N. meningitidis 
MC58. Proteins on the meningococcal surface digested by proteinase K are indicated 
by green rings, dark and light colours corresponding to complete and partial digestion, 
respectively. Rings filled with red colour highlight those proteins binding to 
antibodies from murine immune sera in immunoproteomic analysis. 
 
So far, meningococcal genomes have been sequenced using Sanger 
technology, which is based on electrophoretic separation of dNTPs with single-base 
resolution. Next generation sequencing-by-synthesis methods, such as pyrosequencing 
and single molecule sequencing, with a yield of gigabases per run are able to sequence 
megabase-long microbial genomes in just a few days (Shendure et al., 2004). The first 
example of application of high-throughput genome sequence analysis in 
meningococcal research was recently demonstrated by whole-genome analysis of 105 
meningococcal reference isolates (Bratcher et al., 2011). Information on gene 
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presence and sequence diversity that would once require years to collect is now 
immediately available for hundreds of proteins across a wide panel of isolates. 
Understanding the impact of differences in genome sequence and expression 
profiles on the protein level is essential to elucidate the processes underlying 
meningococcal pathogenesis. Proteome-wide analysis has been used in cases to 
characterise sub-proteomes or compare pairs of samples subjected to different 
treatment conditions (Marzoa et al., 2009; Mignogna et al., 2005; Schauder et al., 
2005; Vipond et al., 2006). Similar to the methods reported here, these studies used 
2D-PAGE and DIGE for protein separation and differential analysis, respectively. 
Given its robust but labour-intensive character, 2-D gel-based analysis is more likely 
to continue its application to small scale projects with a restricted number of samples. 
Where there is need for high throughput proteome analysis, gel-free MS-based 
methods will come into play. 
Following advances in LC for protein separation and instrumentation for mass 
spectrometry, MS-based proteomics promise large-scale analysis of several proteomes 
in relatively short experimental times. It is now possible to separate whole proteomes 
using 2 steps of high performance liquid chromatography in an automated way 
(Wolters et al., 2001). Each fraction collected from the first separation step is directly 
applied to the second chromatographic column, which is interfaced to the mass 
spectrometer for immediate analysis. The use of 2 chromatographic steps offers the 
advantage of increasing peak capacity and hence improving resolution of separated 
peptides. The automation in the whole process is an added benefit when processing 
large numbers of samples. The evolution of hybrid mass spectrometers has also 
enabled faster and more accurate acquisition of mass spectra. By combining 2 or more 
analysers into hybrid systems, scan times have decreased substantially meaning more 
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mass spectra can be acquired in less time (Frese et al., 2011). Following a typical 
shotgun proteomics workflow where proteins are subjected to trypsin digestion 
followed by LC separation and MS analysis of peptides, a complete MS analysis of a 
bacterial proteome would require a day to complete.  
 Given the availability of sequencing data and hence protein databases, 
characterisation of the total protein content from a large panel of isolates would be 
one possible application of MS-based analysis. Relative protein expression levels 
could also be inferred based on comparison of ion intensities across spectra from the 
different isolates (Neilson et al., 2011). Peptide ion intensities are indicators of the 
relative abundance of proteins in the samples. This method of comparative 
proteomics, also known as label-free quantitation, has no limitations to the number of 
samples to be compared. This is a considerable advantage over isotope labelling 
methods for comparative analysis where the number of compared samples is restricted 
by the number of available isotope tags. Label-free quantitation could be useful in 
many hypothesis-driven studies to identify which proteins are solely or over-
expressed in invasive meningococcal strains as opposed to carriers. It could also be 
used to assess the changes in meningococcal proteome upon interaction with host 
epithelial cells or cells of the host’s innate immune system. Results from such studies 
can highlight single virulent factors or whole protein networks involved in 
meningococcal colonisation and survival in humans. Assessment of the relative 
expression levels of protein vaccine candidates across a wide panel of hypervirulent 
strains will also be possible with label-free approaches. Combined with sequencing 
data on the antigenic diversity of proteins across the same meningococcal population 
this information will provide strong evidence on the potential coverage and efficacy 
of protein candidates and guide plans for their consideration in clinical trials.  
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 Further to their application in whole-proteome comparative studies, MS-based 
methods can offer additional opportunities in the manufacturing evaluation of novel 
menB vaccines. Given the presence of different proteins or variants of the same 
protein in some vaccine preparations, an analytical method to accurately quantify the 
different components in the same batch or across different batches will be essential. 
Protein variants comprise different amino acid sequences, which upon fragmentation 
inside the mass spectrometer will generate unique MS/MS spectra. Based on the 
knowledge of protein variant sequences the MS/MS spectra and hence the peptides 
that belong to each variant will be inferred. Assessing the consistency in protein levels 
across batches can then be possible by comparing peptide ion intensities in a label-
free manner. Alternatively, the abundance of each variant in the same sample can be 
quantified in absolute numbers using absolute quantitation (AQUA) technology 
(Gerber et al., 2003). In AQUA, a known amount of a synthetic peptide incorporating 
a stable isotope-labelled amino acid is spiked in the sample to be analysed. The spiked 
peptide is selected to have the exact same sequence as a tryptic peptide unique to the 
protein variant to be quantified. During MS analysis, the synthetic peptide ion will 
generate a peak in MS spectrum with a mass difference from that of the native peptide 
owing to the isotope-labeled amino acid. The quantity of the native protein is 
subsequently calculated by comparing the ion intensity ratio between the 2 peptides. 
 
7.3 MIP as a potential vaccine candidate 
Screening of the meningococcal proteome identified NmMIP as a novel 
immunoreactive protein expressed at relatively high levels on the bacterial surface. 
Subsequent evaluation of the antigenic and sequence properties of NmMIP offered 
contradicting results as to the potential of NmMIP as a target antigen for use in 
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vaccines. On one hand, results from opsonophagocytosis and complement deposition 
assays in combination with the bactericidal activity observed by Hung et al. (Hung et 
al., 2011) suggest the potential of anti-NmMIP antibodies to confer protection against 
menB strains. In contrast, the absence of positive selection over NmMIP sequence 
raises concerns over the potential involvement of NmMIP in acquired immunity and 
hence its ability to induce a strong response in humans. 
 During the writing of this thesis, Echenique-Rivera et al. reported up-
regulation of the gene fkpA coding for NmMIP in a model of human blood infection 
(Echenique-Rivera et al., 2011). Expression of NmMIP was also shown to be required 
for meningococcal survival in human blood. It is not yet clear whether this is 
associated with the putative role of NmMIP in facilitating persistence in macrophages. 
However, these observations suggest that NmMIP is an important virulent factor 
expressed in the host during meningococcal infection. Testing of human blood from 
infected patients for presence of anti-NmMIP antibodies would provide further 
evidence on this expression as well as the potential contribution of NmMIP to 
protective immune responses in humans. Following experiments should also include 
analysis of surface exposure and expression levels of NmMIP from a wide panel of 
isolates. The information gathered from such analysis combined with the results 
reported here should form the basis of possible clinical evaluation of NmMIP. 
 
7.4 Prospects for meningococcal vaccines 
The idea of a meningococcal vaccine able to protect against all major invasive 
serogroups remains elusive primarily due to the difficulties encountered in the 
development of a vaccine protecting against menB disease. Instead, various 
serogroup-specific vaccine formulations have been developed over the years against 
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the other invasive serogroups. Development of serogroup-specific vaccines has to 
some extent been supported by the different distribution of strains and hence the 
different needs for vaccine formulations in every continent.  
Currently, conjugate polysaccharide vaccines against serogroups A, C, W-135 
and Y are licensed and distributed across the globe. The first conjugate vaccine was a 
monovalent group C formulation introduced into schedules of routine infant 
immunisations in the UK in 1999 (Richmond et al., 1999b). The vaccine achieved 
considerable decline in menC disease owing to the induction of herd immunity 
(Maiden et al., 2008). Following the success of menC vaccine, an initiative has been 
introduced for massive immunisations across countries of the African Meningitis belt 
where the major disease burden resides. The introduced vaccine, termed MenAfriVac, 
is a monovalent formulation against serogroup A, the most prevalent serogroup in that 
area (Bishai et al., 2011). Although the circulation of serogroup W-135 strains in 
Africa remains a concern, this initiative is the first encouraging step towards 
availability of vaccines to those suffering the most. The emergence of serogroup Y 
disease in the United States and European countries is also being treated with 
licensure of tetravalent A, C, W-135 and Y vaccines. The most recent formulation, 
MenVeo from Novartis Vaccines, was recently approved for administration to all ages 
from 2 to 55 years old whilst promising protection to infants under the age of 2 
(www.novartis.com, 2011b; Cooper et al., 2011). Long-term epidemiological studies 
following their use will be essential to assess whether tetravalent vaccines can be as 
successful as their monovalent counterparts. The eventual establishment of tetravalent 
conjugate vaccines as the sole polysaccharide-based formulation might also be 
considered on the basis that their global and cost effective distribution can be 
guaranteed. Any future alterations to the existing immunisation schedules including 
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replacements, additions or withdrawals of vaccines should also follow 
epidemiological data and surveillance studies.  
With OMV vaccines able to protect against only a limited group of serogroup 
B isolates of the same serosubtype, the development of a broadly protective menB 
vaccine has been the main focus of meningococcal vaccine research for the past 
decade. The slow progress seen in the development of such vaccine is mainly 
attributable to the nature of meningococcal candidate antigens. On one side, highly 
immunogenic proteins exhibit high sequence variability which confines the breadth of 
protection to variant specific isolates. On the other side, proteins with more conserved 
epitopes are not immunodominant and often do not guarantee good levels of 
protection.  
To overcome the limitations imposed by either group of protein antigens, 2 
strategies have been suggested. One strategy involves the combination of the most 
common variants of an immunodominant protein in a single formulation. For antigens 
PorA, FetA, Opa and fHbp, the number of variants required for broad protection has 
been calculated and found to be conveniently small owing to the antigenic structuring 
of these proteins. A vaccine containing two fHbp variants developed by Pfizer 
(formerly Wyeth) was shown to elicit protective bactericidal titres in a high 
proportion of adults and adolescents in phase II clinical trials (Richmond et al., 2010). 
Alternatively, vaccines combining variable and conserved proteins in the same 
formulation have been developed and tested. The Novartis multicomponent 4CMenB 
is an example of such vaccine preparation which has now completed clinical trials and 
awaits regulatory review from European authorities under the brand name Bexsero 
(www.novartis.com, 2010). 4CmenB comprises recombinant forms of variant 1 of 
fHbp which is found in approximately 70% of circulating menB isolates, the more 
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conserved NadA and HBPA and OMVs from the New Zealand 98/254 strain 
(www.novartis.com, 2011a). Based on results from clinical trials in infants following 
a three-dose immunisation schedule, 4CmenB claims coverage of 79% or greater 
against the strains tested (www.novartis.com, 2011a). 
While the licensure of the first menB vaccine seems to be a matter of time, 
menB vaccine research should remain active in various directions. Judging by the first 
reports on the efficacy of the protein-based vaccines under trials, there is still room for 
improvement in the current combinations of meningococcal proteins and protein 
variants. It is thus important that the screening of different combinations of existing 
potential antigens for improved vaccine coverage continues. Formulations based on 
multiple variants from immunodominant proteins like PorA, Opa and FetA, carefully 
selected to represent the hypervirulent strains, could possibly offer the desired breadth 
of coverage without compromising efficacy. The effectiveness of such formulations in 
clinical trials remains to be tested together with the ease and cost effectiveness of their 
manufacturing. Alternatively, conserved minor antigens could be combined and act 
synergistically to confer broad protection. In one such example, 4 proteins of 
relatively low expression in meningococci, namely TbpA, NspA, Omp85 and Hsf, 
were over-expressed in a strain where expression of PorA was abolished. Outer 
membrane vesicles derived from this strain were shown to induce bactericidal killing 
of unrelated strains, which was the result of an additive effect of the antigens 
expressed (Weynants et al., 2007). This example also highlights the importance of 
studies for the discovery of novel potential antigens like NmMIP to feed such protein 
combinations.  
Investigation of vaccine preparations based on OMVs and/or non-protein 
meningococcal surface structures could offer an attractive alternative and should also 
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be pursued. The use of naturally-released OMVs containing detoxified 
lipooligosaccharide presents a promising approach for production of a cross-
protective vaccine. By combining the antigenic properties of LOS and OMPs from 
native OMVs, these formulations were recently shown to induce good bactericidal 
response against homologous and heterologous strains in mice (Weynants et al., 
2009). Reproducing this response in humans has so far been difficult and additional 
trials will be required. Other strategies could involve the use of peptide mimics of the 
serogroup B capsular polysaccharide (Moe et al., 1999b) or live bacteria from strains 
with an avirulent, attenuated phenotype (Li et al., 2004; Newcombe et al., 2004; Tang 
et al., 1999). 
Upon administration of the developed menB vaccines, constant monitoring of 
their impact would also be essential. One particular concern involves the possible 
emergence of protein variants not covered by the introduced vaccines as a result of 
meningococcal immune evasion. Constant surveillance will be required to assess this 
possibility and modify the formulations used accordingly. Attention should also be 
focussed on the efficacy of the vaccines and the generation of immunity especially in 
infants which constitute the most vulnerable group. Parameters including formulation 
and adjuvant used could potentially affect vaccines efficacy and should be carefully 
chosen (Sanders and Feavers, 2011).  
Protein-based vaccines will also need to be assessed for induction of herd 
immunity. Herd immunity can occur as a result of the disruption of transmission of 
invasive strains following vaccination. Herd immunity has been considered to be 
responsible for the long-term protection of infants in the absence of protective 
antibody levels following introduction of the serogroup C conjugate vaccine in the 
UK (Borrow and Miller, 2006). So far, the same herd effect has not been reported for 
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OMV vaccines. If herd immunity would be induced by protein-based vaccines, 
sufficient levels of protection could be achieved using fewer vaccine doses in infants 
or even by directing routine immunisations to teenagers and young adults, who exhibit 
the highest rates of carriage and are mostly responsible for transmission.  
Finally, the cost of multicomponent vaccines needs to be addressed. The more 
complex the vaccine, the more complicated and expensive its manufacturing becomes. 
Based on preliminary probabilistic studies, the introduction of the current multi-
component vaccines into routine infant immunisations schedules in the UK may not 
prove to be cost effective (Christensen et al., 2010). The efficacy and breadth of 
coverage of the final formulations will also influence the financial viability of the 
vaccine by determining the immunisation schedule (i.e. number of doses, age groups 
to be immunised). Eventually, a single meningococcal vaccine protecting against the 
major invasive serogroups might pose as the most likely formula to sustain affordable 
routine immunisations without compromising population protection. 
 
7.5 Conclusion 
 This study presented a refined version of the analysis of the bacterial surface 
proteome following cell treatment with proteases. Two-dimensional DIGE of the 
proteomes from protease-treated and untreated bacteria was shown to specifically 
detect surface proteins with antigenic properties. Given the implication of these 
proteins in immune responses, this approach can aid the identification of protein 
antigens from various other bacterial pathogens. Quantitative data on the extent of 
protease cleavage can also be exploited during selection of proteins for preclinical 
assessment. Combination of this information with genomic studies of antigenic 
diversity could eventually lead to a more integrated strategy for the selection of 
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candidates for clinical evaluation. The N. meningitidis macrophage infectivity 
potentiator, which was identified from proteomic analysis of the meningococcal 
surface proteome, was suggested to be a novel immunogen under negative selective 
pressure. Providing it is sufficiently accessible on the surface of invasive strains to 
induce bactericidal antibodies in humans, NmMIP could pose as a promising vaccine 
candidate. While the discovery of novel antigens is vital for improving current 
formulations, the assessment of the quality, efficacy and cost effectiveness of 
forthcoming vaccines should be the future aim of meningococcal vaccine research.  
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Appendix 
Table A1. Meningococcal isolates used in phylogenetic analysis of the gene 
coding for NmMIP. Information on the isolates was derived from the Neisseria 
MLST database (https://pubmlst.org/neisseria/) (Jolley et al., 2010) 
 
id isolate 
sero-
group 
sequence 
type 
clonal complex 
serosubtype NmMIP 
deletion
a
 VR1 VR2 
1 A4/M1027 A 4 ST-4 complex/subgroup IV 5-2 10 n 
2 120M A 1 ST-1 complex/subgroup I/II 5-2 10 n 
7 7891 A 5 ST-5 complex/subgroup III 20 9 d 
10 6748 A 1 ST-1 complex/subgroup I/II 18-1 3 n 
11 129E A 1 ST-1 complex/subgroup I/II 5-2 10 n 
13 139M A 1 ST-1 complex/subgroup I/II    
19 S3131 A 4 ST-4 complex/subgroup IV 7 13-1 n 
24 S4355 A 5 ST-5 complex/subgroup III 5-1 9 d 
31 10 A 4 ST-4 complex/subgroup IV 7 13-1 n 
34 20 A 1 ST-1 complex/subgroup I/II 5-2 10 n 
35 26 A 4 ST-4 complex/subgroup IV 7 13 n 
46 255 A 4 ST-4 complex/subgroup IV 7-2 13-1 n 
52 243 A 4 ST-4 complex/subgroup IV 7 13 n 
61 393 A 1 ST-1 complex/subgroup I/II 5-2 10 n 
64 254 A 1 ST-1 complex/subgroup I/II 5-2 10 n 
67 S5611 A 1 ST-1 complex/subgroup I/II 5-2 10 n 
82 11-004 A 5 ST-5 complex/subgroup III 20 9 d 
84 IAL2229 A 5 ST-5 complex/subgroup III 20 9 d 
90 CN100 A 21  5-2 10 n 
120 F4698 A 5 ST-5 complex/subgroup III 20 9 d 
128 F6124 A 5 ST-5 complex/subgroup III 20 9 d 
160 1014 A 4 ST-4 complex/subgroup IV 7 13-1 n 
210 H1964 A 5 ST-5 complex/subgroup III 20 9 d 
237 44/76 B 32 
ST-32 complex/ET-5 
complex 
7 16 n 
238 153 A 5 ST-5 complex/subgroup III 20 9 d 
239 154 A 6 ST-5 complex/subgroup III 20 9 n 
299 80049 A 5 ST-5 complex/subgroup III 5-2 10 n 
314 D1 C 11 
ST-11 complex/ET-37 
complex 
5 2-1 d 
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id isolate 
sero-
group 
sequence 
type 
clonal complex 
serosubtype NmMIP 
deletion
a
 VR1 VR2 
316 D8 A 4 ST-4 complex/subgroup IV 7 13-1 n 
340 196/87 C 32 
ST-32 complex/ET-5 
complex 
7-2 16-12 n 
343 500 C 11 
ST-11 complex/ET-37 
complex 
5 2 d 
344 F1576 C 11 
ST-11 complex/ET-37 
complex 
5 2 d 
349 38VI B 11 
ST-11 complex/ET-37 
complex 
5 2 d 
369 M597 C 11 
ST-11 complex/ET-37 
complex 
5 2-1  
387 2059001 A 4 ST-4 complex/subgroup IV 7 13 n 
391 90/18311 C 11 
ST-11 complex/ET-37 
complex 
5 2-1 d 
398 BZ 10 B 8 ST-8 complex/Cluster A4 5-1 2-2 n 
400 BZ 83 B 34 
ST-32 complex/ET-5 
complex 
5-2 10 n 
401 BZ 133 B 1 ST-1 complex/subgroup I/II 7 16 n 
403 BZ 147 B 48 
ST-41/44 complex/Lineage 
3 
18-2 1-2 n 
407 BZ 163 B 9 ST-8 complex/Cluster A4 21 16 n 
408 BZ 169 B 32 
ST-32 complex/ET-5 
complex 
5-2 16 n 
409 BZ198 B 41 
ST-41/44 complex/Lineage 
3 
7-2 4 n 
410 BZ 232 B 38 ST-37 complex 5-2 2-2 d 
411 DK 24 B 16  
delete
d 
delete
d 
n 
412 DK 353 B 37 ST-37 complex 5-2 2-2 d 
413 EG 328 B 18 ST-18 complex 22 14 n 
414 EG 327 B 19 ST-18 complex 7 14-1 n 
415 EG 329 B 32 
ST-32 complex/ET-5 
complex 
7-1 16 n 
416 EG 011 B 36  18-1 3 d 
417 NG 3/88 B 12  7-1 1 n 
418 NG 4/88 B 30  18 25-7 n 
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id isolate 
sero-
group 
sequence 
type 
clonal complex 
serosubtype NmMIP 
deletion
a
 VR1 VR2 
419 NG 6/88 B 13 ST-269 complex 7-1 1 n 
420 NG F26 B 13 ST-269 complex 31 16 n 
421 NG H15 B 43 
ST-41/44 complex/Lineage 
3 
19 15-2 n 
422 NG H41 B 27  5-2 10 d 
423 NG H38 B 36  18-1 3 d 
424 NG E31 B 15 ST-364 complex 12-1 13-1 d 
425 NG G40 B 25  19 15-1 n 
426 NG E28 B 26  22-1 14-1 d 
427 NG E30 B 44 
ST-41/44 complex/Lineage 
3 
21 16 n 
428 NG H36 B 47 
ST-41/44 complex/Lineage 
3 
5-1 2-2 n 
430 NG 080 B 32 
ST-32 complex/ET-5 
complex 
7 16 n 
431 NG144/82 B 32 
ST-32 complex/ET-5 
complex 
7 16 n 
434 NG PB24 B 32 
ST-32 complex/ET-5 
complex 
7-2 16-7 n 
436 NG P20 B 11 
ST-11 complex/ET-37 
complex 
5 2 d 
441 8680 B 32 
ST-32 complex/ET-5 
complex 
7-2 3 n 
442 297-0 B   19 15-1 n 
443 3906 B 17  12-1 16-8 n 
444 SWZ107 B 35 ST-35 complex 22-1 14-1 n 
445 528 B 18 ST-18 complex 22 14 n 
446 1000 B 20 ST-18 complex 5-1 10-4 n 
451 14/1455 A 5 ST-5 complex/subgroup III 20 9 d 
466 371 A 1 ST-1 complex/subgroup I/II 5-2 10 n 
467 690 A 4 ST-4 complex/subgroup IV 7 13-1 n 
468 BRAZ10 C 11 
ST-11 complex/ET-37 
complex 
5-1 10-1 n 
488 106 A 1 ST-1 complex/subgroup I/II 5-2 10 n 
492 79128 A 3 ST-1 complex/subgroup I/II 7-1 10 n 
493 322/85 A 2 ST-1 complex/subgroup I/II 5-2 10 n 
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id isolate 
sero-
group 
sequence 
type 
clonal complex 
serosubtype NmMIP 
deletion
a
 VR1 VR2 
494 79126 A 3 ST-1 complex/subgroup I/II 7-3 10-5 n 
507 MA-5756 C 11 
ST-11 complex/ET-37 
complex 
5 2-1 d 
597 92001 A 7 ST-5 complex/subgroup III 20 9 d 
613 Z2491 A 4 ST-4 complex/subgroup IV 7 13-1 n 
638 G2136 B 8 ST-8 complex/Cluster A4 5-2 10-1 n 
639 B6116/77 B 10 ST-8 complex/Cluster A4 5-1 2-2 n 
640 SB25 C 8 ST-8 complex/Cluster A4 18-1 3 n 
641 94/155 C 66 ST-8 complex/Cluster A4 5 2 n 
642 312 901 C 8 ST-8 complex/Cluster A4 5 2 n 
643 AK22 B 153 ST-8 complex/Cluster A4 5-2 10 n 
644 L93/4286 C 11 
ST-11 complex/ET-37 
complex 
5-1 10-4 d 
645 204/92 B 33 
ST-32 complex/ET-5 
complex 
19 15 n 
646 400 B 40 
ST-41/44 complex/Lineage 
3 
7-2 13-2 n 
647 AK50 B 41 
ST-41/44 complex/Lineage 
3 
7-2 4 n 
648 M-101/93 B 41 
ST-41/44 complex/Lineage 
3 
7-2 4 n 
649 50/94 B 45 
ST-41/44 complex/Lineage 
3 
7-2 4 n 
650 M40/94 B 41 
ST-41/44 complex/Lineage 
3 
7-2 4 n 
651 931905 B 41 
ST-41/44 complex/Lineage 
3 
7-2 4 n 
652 N45/96 B 41 
ST-41/44 complex/Lineage 
3 
7-2 4 n 
653 91/40 B 42 
ST-41/44 complex/Lineage 
3 
7-2 4 n 
654 88/03415 B 46 
ST-41/44 complex/Lineage 
3 
7-2 4 n 
655 E32 Z 31 ST-334 complex 5-2 10-9 d 
656 E26 X 39 ST-198 complex 18 25-1 n 
657 860060 X 24 ST-750 complex 12-1 13-5 n 
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id isolate 
sero-
group 
sequence 
type 
clonal complex 
serosubtype NmMIP 
deletion
a
 VR1 VR2 
658 890326 Z 28 ST-103 complex 5-4 2-2 n 
659 A22 W-135 22 ST-22 complex 18-1 3 d 
660 71/94 Y 23 ST-23 complex/Cluster A3 5-1 2-2 n 
661 860800 Y 29 ST-167 complex 5-1 10-4 d 
a It refers to the four amino acid deletion and its prevalence across strains. n: strains without deletion, d: 
strains with deletion. 
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ATGAACACCATTTTCAAAATCAGCGCACTGACCCTTTCCGCCGCTTTGGCACTTTCCGCCTGCGGCAAA
AAAGAAGCCGCCCCCGCATCTGCATCCGAACCTGCCGCCGCTTCTTCCGCGCAGGGCGACACCTCTTCG
ATCGGCAGCACGATGCAGCAGGCAAGCTATGCGATGGGCGTGGACATCGGACGCTCCCTGAAGCAAATG
AAGGAACAGGGCGCGGAAATCGATTTGAAAGTCTTTACCGAAGCCATGCAGGCAGTGTATGACGGCAAA
GAAATCAAAATGACCGAAGAGCAGGCTCAGGAAGTCATGATGAAATTCCTTCAGGAACAACAGGCTAAA
GCCGTAGAAAAACACAAGGCGGACGCGAAGGCCAATAAAGAAAAAGGCGAAGCCTTTCTGAAAGAAAAT
GCCGCCAAAGACGGCGTGAAGACCACTGCTTCCGGCCTGCAATACAAAATCACCAAACAGGGCGAAGGC
AAACAGCCGACCAAAGACGACATCGTTACCGTGGAATACGAAGGCCGCCTGATTGACGGTACGGTATTC
GACAGCAGCAAAGCCAACGGCGGCCCGGTCACCTTCCCTTTGAGCCAAGTGATTCCGGGTTGGACCGAA
GGCGTACAGCTTCTGAAAGAAGGCGGCGAAGCCACGTTCTACATCCCGTCCAACCTTGCCTACCGCGAA
CAGGGTGCGGGCGACAAAATCGGTCCGAACGCCACTTTGGTATTTGATGTGAAACTGGTCAAAATCGGC
GCACCCGAAAACGCGCCCGCCAAGCAGCCGGCTCAAGTCGACATCAAAAAAGTAAATTAAGTCCGAATC
CATGCCCGAAACAGGTTTTCGGGCATTTTTACGGCA 
 
 
 
ATGAAACACTATGCCTTACTCATCAGCTTTCTGGCTCTCTCCGCGTGTTCCCAAGGTTCTGAGGACCTA
AACGAATGGATGGCACAAACGCGACGCGAAGCCAAAGCAGAAATCATACCTTTCCAAGCACCTACCCTG
CCGGTTGCGCCGGTATACAGCCCGCCGCAGCTTACAGGGCCGAACGCATTCGACTTCCGCCGCATGGAA
ACCGACAAAAAAGGGGAAAATGCCCCCGACACCAAGCGTATTAAAGAAACGCTGGAAAAATTCAGTTTG
GAAAATATGCGTTATGTCGGCATTTTGAAGTCCGGACAGAAAGTCTCCGGCTTCATCGAGGCTGAAGGT
TATGTCTACACTGTCGGTGTCGGCAACTATTTGGGACAAAACTACGGTAGAATCGAAAGCATTACCGAC
GACAGCATCGTCCTGAACGAGCTAATAGAAGACAGCACGGGCAACTGGGTTTCCCGTAAAGCAGAACTG
CTGTTGAATTCTTCCGACAAAAACACCGAACAAGCGGCAGCACCTGCCGCAGAACAAAATTAA 
 
Figure A1. Amplified nucleotide sequence and primer annealing position 
(continues in the next page). 
NMB1567 (NmMIP) 
NMB1811 (PilP) 
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ATGGCTTCTAAATCATCTAAAACCAACTTGGATCTCAACAACCTTCACCTGCTCAACCTTCCTGCCAGG
CTTTTTATCGCCCTGCTGGCCGTTGCCGCCGTGCTGGGGCTCGGTTATGCCGGATTGTTCAAAAGCCAG
ATGGAATCCCTTGAGGAATACGAAGCAAAAGAAACCGAACTGAAAAACACCTACAAACAGAAAAGTATC
GACGCGGCCAGCCTGAACAACCTGAGGGACGAACTTGCCTCAATCCGCTCTGCCTTCGATATCATGTTG
AAACAGCTGCCGACAGATGCAGAAATTCCCAATCTGGTTCAAGAGCTTCATCAGGCAGGTTCGAGCAAC
GGTCTGCGCTTGGACAGCGTTATGCCCCAACCTCCCGTAGATGACGGCCCCATCAAAAGATTACCCTAT
TCCATTTCCATTACCGGAAATTACGAACAGATCAGCCAATTTACCCGCGATGTCGGCAGCCTCTCCCGA
ATCATTACCCTTGAGTCGCTGAAAATCGCCCAATCTCCGGAAAACGGCGGCAATCCTGACGGCAAGAGC
AGCATCCTGAACCTCAGCGCCATTGCCACCACCTACCAAGCAAAATCCGTAGAAGAGCTTGCCGCAGAA
GCGGCACAAAATGCCGAGCAAAAATAA 
 
 
 
ATGAAACTTCTGACCACCGCAATCCTGTCTTCCGCAATCGCGCTCAGCAGTATGGCTGCCGCCGCTGGC
ACGGACAACCCCACTGTTGCAAAAAAAACCGTCAGCTACGTCTGCCAGCAAGGTAAAAAAGTCAAAGTA
ACCTACGGCTTCAACAAACAGGGTCTGACCACATACGCTTCCGCCGTCATCAACGGCAAACGCGTGCAA
ATGCCTGTCAATTTGGACAAATCCGACAATGTGGAAACATTCTACGGCAAAGAAGGCGGTTATGTTTTG
GGTACCGGCGTGATGGATGGCAAATCCTACCGCAAACAGCCCATTATGATTACCGCACCTGACAACCAA
ATCGTCTTCAAAGACTGTTCCCCACGTTAA 
 
Figure A1. Amplified nucleotide sequence and primer annealing position. The 
length of primer and position of annealing to the nucleotide sequence is presented by 
thick horizontal arrows. Short vertical arrows represent the cleavage site of the signal 
peptide. The sequence to be amplified by the pair of primers is highlighted in blue. 
The red-coloured sequence corresponds to the ORF downstream of NMB1567. 
 
 
 
 
NMB1810 (PilO) 
NMB2095 (adhesion complex protein) 
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Table A2. Analysis of meningococcal proteins with intrinsic fluorescent 
properties. Protein lysates were extracted from MC58 ∆-siaD strain and subjected to 
SDS-PAGE and 2D-PAGE following the methods described in sections 2.6. No pre-
labelling with fluorescent dyes was performed. Gels were directly scanned in the Cy3 
and Cy5 channel of the Typhoon 4100. Images from 2-D gels were imported into 
DeCyder v.6.5 and matched to 2-D images of total-protein profiles of the same sample 
from previous experiments. The position of the gel spot corresponding to 
autofluorescent protein 2 (AF2) was identified in preparative gels which were 
subsequently used for spot picking. The AF2 protein spot picked was digested with 
trypsin and identified by LC MS/MS as cytochrome c5 (UniProtKB accession number 
Q9JYA2 – NMB1677) (7 peptides matched, sequence coverage of 38%). The 
meningococcal cytochrome c5 is a predicted inner membrane-associated protein 
involved in electron transfer during nitrite respiration (Deeudom et al., 2008). The 
sizes (in kDa) of protein marker bands are shown on the left. M: Pre-stained wide 
range MW protein marker. 
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Figure A2 Abundance profiles of proteinase K-affected protein spots. The mean 
standardised abundance for each spot was calculated using DeCyder differential 
analysis software and plotted against the proteinase K concentration used for 
treatment of meningococci.  
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NmMIP amino acid sequence alignment 
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PilP amino acid sequence alignment 
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PilO amino acid sequence alignment 
Adhesin complex protein amino acid sequence alignment 
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Figure A3. Amino acid sequence alignments for NmMIP, PilP, PilO and adhesin 
complex protein across strains with annotated genomes. Proteins are represented 
by the locus number of the corresponding gene from each meningococcal strain. The 
gene tag used for each strain is as follows: NMB for MC58, NMA for Z2491, NMC 
for FAM18, NMV for 8013, NMCC for 053442, NMAA for WUE2594, NMO for 
alpha14, NME for alpha153, NMW for alpha275 and NMBB for alpha710. The 
sequence marked “majority” corresponds to the consensus. Residues that differ from 
the consensus are highlighted with dark blue. Colour marking on top of the consensus 
sequence describes the extent of disagreement across the aligned sequences for 
dissimilar residues, with increasing degree of disagreement from red to dark blue. 
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Figure A4 Distribution of sequence polymorphisms in the different allele types of 
the gene coding for NmMIP. The NmMIP nucleotide sequences of a representative 
isolate from each allele type were aligned using the MegAlign tool of the DNASTAR 
Lasergene software v.8. Isolates are presented on the left and numbered according to 
Table A1 (Appendix). Identity to nucleotide sequence of isolate 2 is represented by a 
dot and base pair deletion by a hyphen. 
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Supplementary Material 
Supplementary information is provided in the electronic copy that 
accompanies this thesis and includes: 
• A copy of the publications related to this thesis (Tsolakos et al., 2009; 
Tsolakos et al., 2010). 
• The nucleotide and amino acid sequences of NmMIP from the 106 
meningococcal isolates of the MLST database aligned using DNASTAR 
Lasergene software v.8. 
